var title_f30_22_31072="Forearm bowing fracture";
var content_f30_22_31072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Forearm bowing fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 237px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bowing fracture with approximately 15 degrees of apex dorsal bowing of the radius and ulna.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mehlman CT, Wall EJ. Injuries to the shafts of the radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31072=[""].join("\n");
var outline_f30_22_31072=null;
var title_f30_22_31073="PSC of gallbladder US";
var content_f30_22_31073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Primary sclerosing cholangitis of gallbladder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound of the right upper quadrant in a patient with primary sclerosing cholangitis shows marked thickening of the gallbladder wall (black arrows) with numerous septations in the gallbladder lumen (white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31073=[""].join("\n");
var outline_f30_22_31073=null;
var title_f30_22_31074="Planar xanthoma";
var content_f30_22_31074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Planar xanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 269px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Planar xanthoma in the antecubital fossa of a patient with homozygous familial hypercholesterolemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Durrington P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31074=[""].join("\n");
var outline_f30_22_31074=null;
var title_f30_22_31075="Chagas heart disease ECG";
var content_f30_22_31075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Chagas' heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 236px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADsAgUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6H0PSLK60uGa4hMkrlizF25+Y+9X/AOwdN/59v/Ijf40eGf8AkCW3/Av/AEI1p0Ac5e6PYpq2nRLCRHJ5m9fMbnC8d60P7B03/n2/8iN/jRqH/Ib0r/tr/wCgitOgDM/sHTf+fb/yI3+NZ+gaPYz6TBLNCXkbdljI3PzH3qna+JdTl+I0/ht7CzW1htfthuRcMXMZJVRs2Y3bsZGcY5yelbnhn/kCW3/Av/QjW1ahOi0p9Un8mTGalewf2Dpv/Pt/5Eb/ABrP/sex/t/yfJPlfZd+3zGxnfjPWujrM/5mf/tz/wDZ6xKD+wdN/wCfb/yI3+NV9R0TT49PuXSAq6xMQRI3Bwfetuq2qf8AIMvP+uL/APoJoAzdO0TT5NPtneAs7RKSTI3JwPerH9g6b/z7f+RG/wAataX/AMgyz/64p/6CKs0Ac5/Y9j/b/k+SfK+y79vmNjO/GetaH9g6b/z7f+RG/wAaP+Zn/wC3P/2etOgDE1HRNPj0+5dICrrExBEjcHB96NO0TT5NPtneAs7RKSTI3JwPetLVP+QZef8AXF//AEE0aX/yDLP/AK4p/wCgigCr/YOm/wDPt/5Eb/Gs/wDsex/t/wAnyT5X2Xft8xsZ34z1ro6zP+Zn/wC3P/2egA/sHTf+fb/yI3+NZ+v6PYwaTPLDCUkXbhhI3HzD3rI8d/EKHwjf+TLYm7hSFJp2inHmRqzFfuYJ7A5JUHOATzXO+K/HGoWZ8S6Bei2Grre28Wl/KQssUzAqWGedoVtxH6V6NHKsTVipRWj1WvS6Tfyur+WphLEQi7M9J/sHTf8An2/8iN/jR/YOm/8APt/5Eb/GvL7T4ia5J8QP7DSSxm/4nDWH2U2roxt1GXmEu7buUfwYyfxr2OssZgauDcVU+0rr0Kp1Y1L8vQ5yy0exfVtRiaEmOPy9i+Y3GV571of2Dpv/AD7f+RG/xo0//kN6r/2y/wDQTWnXGanOa/o9jBpM8sMJSRduGEjcfMPetD+wdN/59v8AyI3+NHib/kCXP/Af/QhWnQBmf2Dpv/Pt/wCRG/xrPstHsX1bUYmhJjj8vYvmNxlee9dHWZp//Ib1X/tl/wCgmgA/sHTf+fb/AMiN/jWfr+j2MGkzywwlJF24YSNx8w966OszxN/yBLn/AID/AOhCgA/sHTf+fb/yI3+NH9g6b/z7f+RG/wAa06KAOc0jR7Gb7b5kJbZdOi5kbgDGB1rQ/sHTf+fb/wAiN/jWTfTajb+HPEU+iCNtShlmkgWRSyuygHbgY64x+NYvhbxve+LNRhXQo7R7aLSVurnzCQBdyZCQlhnaBtYk4Jx2rrpYOpWpOtG3Kt/Ltf12XmZyqxjJRe7Og1fR7GH7F5cJXfdIjYkbkHOR1rQ/sHTf+fb/AMiN/jXI+Dtfv/Enhy0vdWW3S6TV2gK24IQBGIGM8n616DWNejKhUlSnunYqElOKkupmf2Dpv/Pt/wCRG/xrP0jR7Gb7b5kJbZdOi5kbgDGB1ro6zNC/5iH/AF+Sf0rIoP7B03/n2/8AIjf41n6vo9jD9i8uErvukRsSNyDnI610dZmu/wDMP/6/I/60AH9g6b/z7f8AkRv8aP7B03/n2/8AIjf41p0UAc5pGj2M323zIS2y6dFzI3AGMDrWh/YOm/8APt/5Eb/GjQv+Yh/1+Sf0rToA4vxJplrbatoEUEbJHPdFJFEjfONvQ810P9g6b/z7f+RG/wAay/Fv/Ib8M/8AX4f/AEGunoAzP7B03/n2/wDIjf41n6Bo9jPpMEs0JeRt2WMjc/Mfeujrz/W/EF74Z0Hw9qEQhOlNei31AupzHG7kCQHtg4z65rWhRlXqKnDd7f159CZyUFzM63+wdN/59v8AyI3+NZ97o9imradEsJEcnmb18xucLx3ritU+JV1aeGdS1VTYg3d7PbaKJW2I8UQIaV2J5GVbAHJO0DrXTeEtabxDpXhTVJZIJJ7iB2m8k/Ksmwbl6nGDkY7V04jLq+Hp+1qLS9vn/wADVeqZEK8Jy5V6m/8A2Dpv/Pt/5Eb/ABo/sHTf+fb/AMiN/jWnRXCanOaBo9jPpMEs0JeRt2WMjc/MfetD+wdN/wCfb/yI3+NHhn/kCW3/AAL/ANCNadAHOXuj2Katp0SwkRyeZvXzG5wvHetD+wdN/wCfb/yI3+NGof8AIb0r/tr/AOgitOgDM/sHTf8An2/8iN/jWfoGj2M+kwSzQl5G3ZYyNz8x966Oszwz/wAgS2/4F/6EaAD+wdN/59v/ACI3+NZ/9j2P9v8Ak+SfK+y79vmNjO/GetdHWZ/zM/8A25/+z0AH9g6b/wA+3/kRv8ar6jomnx6fcukBV1iYgiRuDg+9bdVtU/5Bl5/1xf8A9BNAGbp2iafJp9s7wFnaJSSZG5OB71Y/sHTf+fb/AMiN/jVrS/8AkGWf/XFP/QRVmgDifENvHp2oKllviVogSA7cnLe9FS+Mf+QnF/1xH/oTUUAXtBtb99KhaLUfLjJbCeQpx8x71ofYtS/6Cv8A5LLR4Z/5Alt/wL/0I1p0Ac1fWmoDWNMB1PLHzcN9nXj5a0vsWpf9BX/yWWjUP+Q3pX/bX/0EVp0AcZD4KuYvF0niIeIL03skXkMhhj8sx9QuMZwCc9c5q94etNQbR7cpqexfmwvkKcfMa6Wszwz/AMgS2/4F/wChGtKtadWzm72VvkiYxUdg+xal/wBBX/yWWs37JqH/AAkW3+0/n+y53fZ16b+mK6Wsz/mZ/wDtz/8AZ6zKD7FqX/QV/wDJZaralZ6iNOui2qbgInyPs6jPBrZikSWMPE6uh6MpyDUOqf8AIMvP+uL/APoJo2AzNNs9ROnWpXVNoMSYH2dTjgVZ+xal/wBBX/yWWrWl/wDIMs/+uKf+girNAHNfZNQ/4SLb/afz/Zc7vs69N/TFaX2LUv8AoK/+Sy0yGWObxEJIXWSM2fDKcg/P61rUAYepWeojTrotqm4CJ8j7OozwaNNs9ROnWpXVNoMSYH2dTjgVYbULTVNAubvT547i2eKQLIhyCQCCPwIIq3pf/IMs/wDrin/oIpyi4tqSsxJ31RV+xal/0Ff/ACWWs37JqH/CRbf7T+f7Lnd9nXpv6YrpazP+Zn/7c/8A2ekM5rxB8PLHxBdy3OrTNNNLEsMpQNEJFU5AYI4DYPQnkVF4t8H291dx6/eypPqlmgjhmMWCqlumAcH7x6g4zXe1meJv+QJc/wDAf/QhW/1qvZR53ZJrd7PRr0fUj2cd7HNXHw7sLiSSSSX9697/AGiZFVlcXHTeGDZXoOBgcdK6X7FqX/QV/wDJZayPCfip9XupLbULVbOaXfNZYfctxArFSQcD51I+Ze25TyDXVVWK9vGXs67bt3d/uFT5GrwOasbTUDrGpganhh5WW+zrz8taX2LUv+gr/wCSy0af/wAhvVf+2X/oJrTrmNDmvENpqC6PcF9T3r8uV8hRn5hWl9i1L/oK/wDkstHib/kCXP8AwH/0IVp0AZn2LUv+gr/5LLWbY2moHWNTA1PDDyst9nXn5araD4ukv9QhF5ZfZNM1HP8AZdyz5+0beoYfwlh8yjuoPcYrb0//AJDeq/8AbL/0E1tWoToS5ZrX+v8Ahn5kxmpq6D7FqX/QV/8AJZazfENpqC6PcF9T3r8uV8hRn5hXS1meJv8AkCXP/Af/AEIViUH2LUv+gr/5LLR9i1L/AKCv/kstadFAHMaPb3pkvY11UI5uZDt8hSWxtyf1H51V0bwNbaLY6haaTcfZIL9me4EUZDMWGDht2V46bSMdsVzFr4vtNK+JurQ6lJJHZri0iYIWBmd9zdOwUJk9sV6xXZWpV8LGKbaU0n5PqvW34GUZRqN+RwFl4Mh8LxwR6RdyxR3F5Gzq5eQbvm+YB2ODyc4xnv0FdZ9i1L/oK/8AkstGu/8AMP8A+vyP+tadc1SpOrJzqNtvq9WaRioqyRmfYtS/6Cv/AJLLWbo1pqDfbtmp7cXUgP7hTk8c10tZmhf8xD/r8k/pUDD7FqX/AEFf/JZazdZtNQX7Dv1Pdm6jA/cKMHnmr/iTXrLw7YpdaiZRG7lAIkLtwrOTgc4CozH0ANGsusiaa8bKyNdxMrKcgjnkVbpyUVNrRium7D/sWpf9BX/yWWj7FqX/AEFf/JZavXU8VrbS3FzIsUESGSSRjgKoGSSfQCsMeM9AIBF+CD0Pkyf/ABNOFGpUV4Rb9EJyjHdkejWmoN9u2antxdSA/uFOTxzWl9i1L/oK/wDkstYGjeLtDT7dvvsbrqRh+6fpx/s1t2niXRLuIyW+rWTKGKkGZVKkdQQTkH2NXLDVoq7g/uYlUi9mYHie2vl1jw8JNQ3s10QjeSo2Hb1966P7FqX/AEFf/JZa5Px74i0+0u9CuYLiK8eK6JWC2kV5JGK4VVAPUkgD610Wl+KNOvA8dzKNPvoiFms7xhHLGx6dThgezKSD2NH1ary8/K7Bzxva5a+xal/0Ff8AyWWsC30B9c8JnT9Qu1lsLhWSSEwjkbyeoII5GciuyHIrlvAev6fqtjLZ2kxNzZu6SxupU43sNy5+8uQRuHGQR2qacai/eQv7vVdO3oOTj8L6ixeE1i0KPRo7mMabHCbdYfs4OEIwRnOc475z3zVe20OXR5tE06wvRFbQJJHCohB2KFHqST+NdhWZqH/Ib0r/ALa/+gilKrOSalJtN3369/Uailsg+xal/wBBX/yWWj7FqX/QV/8AJZa06KzGc14etNQbR7cpqexfmwvkKcfMa0vsWpf9BX/yWWqenalZ6T4Xiu9SuY7a2Tdl5DjnccAepPYDk1Y0TxBp+sPJFaySR3UYDSWtxE0MyA9GKMA2D2OMVoqVRwdRRdl16E8yTtfUo31pqA1jTAdTyx83DfZ14+WtL7FqX/QV/wDJZaNQ/wCQ3pX/AG1/9BFadZlGZ9i1L/oK/wDkstZvh601BtHtymp7F+bC+Qpx8xrpaxdFu7ey8OwTXlxFbwruzJK4RR8x7mmk27INif7FqX/QV/8AJZazfsmof8JFt/tP5/sud32dem/piln8beH1DC01KHUZxwsGnn7TIzf3QEzz9cAd8VmQ+KoYfEX/ABPbG90ib7JgJOgkVvnzlXjLKfcZyK6Pqde1+R/r8luyPaw7nSfYtS/6Cv8A5LLVbUrPURp10W1TcBE+R9nUZ4NR/wDCZaD/AM//AP5Bk/8AiasDVrLVtIv30+bzVSJ1Y7GXB2n1AqJ4erBc0otL0Y1OL0TI9Ns9ROnWpXVNoMSYH2dTjgVZ+xal/wBBX/yWWrWl/wDIMs/+uKf+girNYlHDeJIbiLUUFzc/aGMQwfLCY5b0oqx4x/5CcX/XEf8AoTUUAXtBur9NKhWLTvMjBbD+eoz8x7VofbdS/wCgV/5MrR4Z/wCQJbf8C/8AQjWnQBzV9d6gdY0wnTMMPNwv2heflq3eXOsS20kdtYeRMwwsvnI20+uD1qfUP+Q3pX/bX/0EVp007O4HF/Z/GH/P9/5BhqhoVv4s/sqDyL79382P3MX94+teh1meGf8AkCW3/Av/AEI1v9Zn2X/gMf8AIj2a8/vZz32fxh/z/f8AkGGsy4sfFVxqskL6hKjyWhRmiSJHCFsEq3Y+h7V6PWZ/zM//AG5/+z0LFTWqS/8AAY/5B7Nef3s5Cy0PxDo0r2nhtIdP0VsOLZyszRPjBEZJwFbhiCD82cfeqbULfxd9gufMvvk8tt37mHpg13lVtU/5Bl5/1xf/ANBNOWLqSd5Wb7tJv5trUSpxW35s4rTNE1MabaA3OtyHyky41FF3cDnAXj6VPNoF/PC8U0muPE6lXX+1QMg9RkAH8q67S/8AkGWf/XFP/QRVml9brXvf8h+zj2PNrTw29hq/2bTIdSsbcQM6W1vqAVIwZCSF4OBknj3rUbRNSZSDNrmDx/yFF/8Aia6L/mZ/+3P/ANnrTpvF1m7uWoeziuh5zP4YubC2uF0uO+0zTvs4D2lrdRqjOibA5JUkHaACARnaCeetuw0bUTYWxWbW8GNcY1JQOg7ba7LVP+QZef8AXF//AEE0aX/yDLP/AK4p/wCgih4ytLVy/ISpRWyOQTw7cRStLbJrUMkgAkYawzmQjPJ35557Y/QVU/sbUP7dx52tb/s2cf2kucbvXb09q9DrM/5mf/tz/wDZ6TxdZ7yH7OPY57+xdS/57a5/4M1/+JrL8TaNrC6Jcta3WrRTrtKNPfJLHu3DAZdvI9a9IrM8Tf8AIEuf+A/+hCmsXVTvf8EHs4nNw6BMfDWk6VdaXIZNPSMxXMV2ElSVRgurDkE859QSDST6T4ghQS6Xdail2h3ILu7SeF/9l0wDg+oII7Gu4oo+t1b3bv111Wu+4eziedWf/CaXGsagzmxsyBHvS2USEnHB3OemOwH41oDSddl+a9vtYmf0juoIVH0CRg/mTXRaf/yG9V/7Zf8AoJrTpfWpr4Ul8l+drh7NdTzzXNG1BdLnLza0F+XO7UlYfeHbbV19D1F0ZGl1wqwwR/ai9P8Avmuj8Tf8gS5/4D/6EK06PrVXv+Qezj2OWutMNz4fj0WbQ82EUaRRqLpQ0YQDYVYchhgEEcgisO30fVf7R1EWt3rMVwvlkP8Abo32nHG4MpDD2Ir0WszT/wDkN6r/ANsv/QTSjiasdE/Pv+YOEX0OYhsPFl5IW1q5kCoNkUemyLbK3+25O4lj6AhR6Gq2uaNqC6XOXm1oL8ud2pKw+8O22vQ6zPE3/IEuf+A/+hCqeLq9Gl6JL9A9nE57+xdS/wCe2uf+DNf/AImo5fDckyHz7fWJbjqk7a1JujPYqAdoP/Aee+RXcUUli6y2lYPZx7Hlmg+FJ5NWu73VrL+1mC3Fq5uHjG8yOC5KgBegA4Hc1sv4f1C3iYaMdVsHGDGp1Lz4kI/2JM/L6qCOOmOtdPoX/MQ/6/JP6Vp1csdXk7uXy6fdt+AlSgtked69J4s1CDSLW8sYLAC5Q3NxaXYLOR0EWR8gPcnOOnPWtD+xdS/57a5/4M1/+Jrodd/5h/8A1+R/1rTqXip7QSivJf53D2a66nF/2LqX/PbXP/Bmv/xNUNK0bUGF7tm1r/j5cHbqSjnj/Z6+9eh1maF/zEP+vyT+lL61V7/kP2cexhaZoEGnSRS2/h8vPGhQSzXvmscjBJLE5JGcn3NZGr+GbeGKxFho82mSLcIIpbS92snXAUcqPoQR7V6PWZrv/MP/AOvyP+tH1uve/O/vYezhtY5Q6T4l1F1tvEZS+0uIgiCErC1yeo88gkMB/dUKp7jHFdX9t1L/AKBX/kytadFRVrSq25tl2SS+5DjFR2Oa0a71Bft2zTN2bqQn9+oweOKmuYHuZTLc+HLWaQ9XkeNifxIq5oX/ADEP+vyT+ladZxk46p2G0nuefa9beRrfh6SLQra2lW6JXyygLnb0yBxXR3kUt6Qbzw9bXBA2gyyRvx6ciq3i3/kN+Gf+vw/+g109V7Sd731DlWxxP/COGHI0zT7/AEyMjBistS8uL8I+VX/gIFVtH0K3uNB0uGXw+k62cTQwSm5CuE3cjI57D8Rmu/rM8M/8gS2/4F/6Ea1eKrP7b+8n2cexz3/CM2f/AELf/k8f8aoXnhuzGq6ev/CP7c+Z8v20nd8vrnivQ6zNQ/5Delf9tf8A0EUfW6/87+9h7OHZHFeI9MXRbGHVLLRmtJLO6t5WkF4W/d+aocEZ6FS1SxxS+JvEeqXd3pLXFlZhLGFPte1RKpZpWGCM8uq59UIrttb0+PVtGvtOmOI7uB4GPoGUjP603QNLh0XR7TT7dmdIE2l2+9I3Vnb3ZiWPuTXQsY/Y3cn7Ta/ZOz3+VvmyPZ+9tocj4V0W2tLa0vLfw7C9zHu8ud5wzJljkruztPbIrZ1exOr+V/aXh6KdoiTG7XChkz1ww5Ge+DWj4Z/5Alt/wL/0I1p1yOvVclNyd11vqackbWseeXnhuzGq6ev/AAj+3PmfL9tJ3fL654q//wAIzZ/9C3/5PH/Guh1D/kN6V/21/wDQRWnV/W6/87+9i9nDsjzfxHpi6LYw6pZaM1pJZ3VvK0gvC37vzVDgjPQqWpnhmLUtclttQvdMjm0qxeWOxtzKMNKHZXmcHqRhlX0BJ7jHe65p8eraNf6dMcR3cDwMfTcpGf1qh4GtRY+E9MtAxcQReXvPVsEjJ9zW/wBb/c6tud2rv+Vr+vk2R7P3vL9Swt1qCKFTSAqjgAXCgCs/7XqH/CRbv7M+f7Ljb9oXpv65rpazP+Zn/wC3P/2euA2D7bqX/QK/8mVqtqV5qJ066DaXtBifJ+0KccGtyq2qf8gy8/64v/6CaAMzTbzURp1qF0vcBEmD9oUZ4FWftupf9Ar/AMmVq1pf/IMs/wDrin/oIqzQBw3iSa4l1FDc232dhEMDzA+eW9KKseMf+QnF/wBcR/6E1FAF7QNZsINKhiln2yKWBGxjj5j7Vof29pv/AD8/+Q2/wo8M/wDIEtv+Bf8AoRrToA5q+1vT21jTHFxlV83J2NxlfpWl/b2m/wDPz/5Db/CjUP8AkN6V/wBtf/QRWnQBmf29pv8Az8/+Q2/wrN8Pa3p8Wj26PcYYbsjY394+1QP4wk/4S678PQ6Hfy3dvbNdb1lhCPHg7SMuD8zAKM4wTk4HNP8Ah3q51jQBILKe2jikaNWlZD5hDHONpJGDxziuiphatOPNJaWT3Wz26kKpGTsjW/t7Tf8An5/8ht/hWb/bWn/8JF5n2j5Psu3Oxuu/6V0tZn/Mz/8Abn/7PXOWH9vab/z8/wDkNv8ACq2pa5pz6ddKtxkmJwPkb0PtW5VbVP8AkGXn/XF//QTQBmabrmnJp1qrXGCIkB+RvQe1Wf7e03/n5/8AIbf4Va0v/kGWf/XFP/QRVmgDmv7a0/8A4SLzPtHyfZdudjdd/wBK0v7e03/n5/8AIbf4Uf8AMz/9uf8A7PWnQBh6lrmnPp10q3GSYnA+RvQ+1Gm65pyadaq1xgiJAfkb0HtWnqn/ACDLz/ri/wD6CaNL/wCQZZ/9cU/9BFAFX+3tN/5+f/Ibf4Vm/wBtaf8A8JF5n2j5Psu3Oxuu/wCldLWZ/wAzP/25/wDs9AB/b2m/8/P/AJDb/Cs3xDreny6PcIlxljtwNjf3h7VH4t8caX4UuootXju0jdVczpGDGoLEcnOSRjkAHAx61g6z41L2/ibS7y0WHUrC8htreEScXKykGJskcZAJPXGK644HESh7RR03/FL82r9rmbrQT5b6naf29pv/AD8/+Q2/wo/t7Tf+fn/yG3+FYPhnxLquqeMte0S9sLGGPSBF5k0Vw7lzKu5MKUH8IOeeD0z1rsayr0J0Jck97J730auvwZUJqaujmrHW9PXWNTc3GFbysHY3OF+laX9vab/z8/8AkNv8KNP/AOQ3qv8A2y/9BNadYlHNeIdb0+XR7hEuMsduBsb+8PatL+3tN/5+f/Ibf4UeJv8AkCXP/Af/AEIVp0AZn9vab/z8/wDkNv8ACs2x1vT11jU3NxhW8rB2NzhfpXS1maf/AMhvVf8Atl/6CaAD+3tN/wCfn/yG3+FZviHW9Pl0e4RLjLHbgbG/vD2rpazPE3/IEuf+A/8AoQoAP7e03/n5/wDIbf4Uf29pv/Pz/wCQ2/wrTooA5rRtb0+P7dvuMbrqRh8jdOPatL+3tN/5+f8AyG3+FZN9NqNv4c8RT6II21KGWaSBZFLK7KAduBjrjH41h+GfGl94vvo49Ba0jt00hbm5lkQuIruTISM4I4XaxPqB2rro4OpWpOtG3Kt/L19dl5mcqqjLle7Og1nW9Pk+w7LjO26jY/I3Tn2rS/t7Tf8An5/8ht/hXEeFNa1bVri9i1G5ttRsbPVIYbTUreHykuTtPmALkjCtgZBIPNelVliKEsPUdOTu1bbzV/6T1WzHCanHmRmf29pv/Pz/AOQ2/wAKzdG1vT4/t2+4xuupGHyN049q6WszQv8AmIf9fkn9KxLD+3tN/wCfn/yG3+FZus63p8n2HZcZ23UbH5G6c+1dLWZrv/MP/wCvyP8ArQAf29pv/Pz/AOQ2/wAKP7e03/n5/wDIbf4Vp0UAc1o2t6fH9u33GN11Iw+RunHtWl/b2m/8/P8A5Db/AAo0L/mIf9fkn9K06AOJ8T6vYzax4eeOfKx3RZzsbgbfpXR/29pv/Pz/AOQ2/wAKy/Fv/Ib8M/8AX4f/AEGunoAzP7e03/n5/wDIbf4Vm+Htb0+LR7dHuMMN2Rsb+8faulrz/W/EF74Z0Hw9qEQhOlNei31AupzHG7kCQHtg4z65rWhRlXqKnDd7f159CZyUFzM63+3tN/5+f/Ibf4Vm32t6e2saY4uMqvm5OxuMr9K4+88XeLL/AEiTVPDlnHcWcuqyW8BjtjO32SMFTLgMNxLqcDI9K6Twtq/9vaf4Z1P7VHd/aEnJmjhMKsRkEbCSRgjHU8iunEZfVw9P2k2t7adH59tn9xEK0ZuyN7+3tN/5+f8AyG3+FH9vab/z8/8AkNv8K06K4TU5rw9renxaPbo9xhhuyNjf3j7Vpf29pv8Az8/+Q2/wo8M/8gS2/wCBf+hGtOgDmr7W9PbWNMcXGVXzcnY3GV+laX9vab/z8/8AkNv8KNQ/5Delf9tf/QRWnQBmf29pv/Pz/wCQ2/wrN8Pa3p8Wj26PcYYbsjY394+1dLWZ4Z/5Alt/wL/0I0AH9vab/wA/P/kNv8Kzf7a0/wD4SLzPtHyfZdudjdd/0rpazP8AmZ/+3P8A9noAP7e03/n5/wDIbf4VW1LXNOfTrpVuMkxOB8jeh9q3Krap/wAgy8/64v8A+gmgDM03XNOTTrVWuMERID8jeg9qs/29pv8Az8/+Q2/wq1pf/IMs/wDrin/oIqzQBw3iS9t73UUa2k3hYgCdpHdvWirHjH/kJxf9cR/6E1FAG94Z/wCQJbf8C/8AQjWnXOaBo1hPpUMssG6RixJ3sM/MfetD+wdN/wCfb/yI3+NABqH/ACG9K/7a/wDoIrTrmr7RNPXWNMQW+Fbzcje3OF+taX9g6b/z7f8AkRv8aAOfbwpqq+Ob3xHb61bI09mbNIGsC2xeShLeYMkOQTwMgY4zmp/hrpVzpHh7ybi8juY3leSMLB5ZTLHcCdx3c89sVs/2Dpv/AD7f+RG/xrN8PaJp8uj27vb5Y7sne394+9dNTF1aseWbVrJbLZbdCI04xd0dLWZ/zM//AG5/+z0f2Dpv/Pt/5Eb/ABrN/sXT/wDhIvL+z/J9l3Y3t13/AFrmLOlqtqn/ACDLz/ri/wD6Caq/2Dpv/Pt/5Eb/ABqtqWh6cmnXTLb4Iicj529D70Aael/8gyz/AOuKf+girNYem6Hpz6das1vkmJCfnb0HvVn+wdN/59v/ACI3+NAB/wAzP/25/wDs9adc1/Yun/8ACReX9n+T7Luxvbrv+taX9g6b/wA+3/kRv8aALWqf8gy8/wCuL/8AoJo0v/kGWf8A1xT/ANBFZmpaHpyaddMtvgiJyPnb0PvRpuh6c+nWrNb5JiQn529B70AblZn/ADM//bn/AOz0f2Dpv/Pt/wCRG/xrN/sXT/8AhIvL+z/J9l3Y3t13/WgDP8XfDnSvFF/dXd5d6hbvdQJbTLbugDqrbl+8jEHPoQDUPjfwTpOoaxD4nn+0DULNERUVwInwx2swxkkbjg5Hauo/sHTf+fb/AMiN/jWb4h0TT4tHuHS3ww24O9v7w9661j8QoqKm7JNfJqzX3JfcZ+xhe9g0TwjDpHifVdci1PUp7nUtv2iKdozGdowmAqAjaOBz065610tZn9g6b/z7f+RG/wAaP7B03/n2/wDIjf41hVrTrS5pu7sl8lovuRUYqKsg0/8A5Deq/wDbL/0E1p1zVjomntrGpobfKr5WBvbjK/WtL+wdN/59v/Ijf41mUHib/kCXP/Af/QhWnXNeIdE0+LR7h0t8MNuDvb+8PetL+wdN/wCfb/yI3+NAGnWZp/8AyG9V/wC2X/oJo/sHTf8An2/8iN/jWbY6Jp7axqaG3yq+Vgb24yv1oA6WszxN/wAgS5/4D/6EKP7B03/n2/8AIjf41m+IdE0+LR7h0t8MNuDvb+8PegDpaKzP7B03/n2/8iN/jR/YOm/8+3/kRv8AGgA0L/mIf9fkn9Ko6d4M0DTdL1LTrDT1gs9RZmukSRx5m4YPzZyox2BAHbFR6Nomnyfbt9vnbdSKPnbpx71pf2Dpv/Pt/wCRG/xrSFWpTTUJNJ22fbb7uhLinujBtfCejeGFs10S2lt0kuolKtcyyqAN2MB2IHU9MV2Nc1rOiafH9h2W+N11Gp+dunPvWl/YOm/8+3/kRv8AGlUqzqyc6km2+r1Y4xUVaKsadZmhf8xD/r8k/pR/YOm/8+3/AJEb/Gs3RtE0+T7dvt87bqRR87dOPeoGdLWZrv8AzD/+vyP+tH9g6b/z7f8AkRv8azdZ0TT4/sOy3xuuo1Pzt0596AOlorM/sHTf+fb/AMiN/jR/YOm/8+3/AJEb/GgA0L/mIf8AX5J/StOua0bRNPk+3b7fO26kUfO3Tj3rS/sHTf8An2/8iN/jQBl+Lf8AkN+Gf+vw/wDoNdPXE+J9IsYdY8PJHBhZLoq43tyNv1ro/wCwdN/59v8AyI3+NAGnXPWel2WteEP7O1SBbiyuFZZYySNw3k9QQRyByKvf2Dpv/Pt/5Eb/ABrN8PaJp8uj27vb5Y7sne394+9VGTg1KLs0JpNWY+98F6BeaLZaVNYkWFkuyCOOeSMoMYI3KwY575Jz3qSLT7TSrvQ7HTreO3tIFlSOJBgKNv8Anmrf9g6b/wA+3/kRv8azb7RNPXWNMQW+Fbzcje3OF+tXOvVnHknJtXva/Xv6iUIp3SOlorM/sHTf+fb/AMiN/jR/YOm/8+3/AJEb/Gsig8M/8gS2/wCBf+hGtOua8PaJp8uj27vb5Y7sne394+9aX9g6b/z7f+RG/wAaADUP+Q3pX/bX/wBBFadc1faJp66xpiC3wrebkb25wv1rS/sHTf8An2/8iN/jQBp1meGf+QJbf8C/9CNH9g6b/wA+3/kRv8azfD2iafLo9u72+WO7J3t/ePvQB0tZn/Mz/wDbn/7PR/YOm/8APt/5Eb/Gs3+xdP8A+Ei8v7P8n2Xdje3Xf9aAOlrP167trXS7k3VxDCHicL5jhcnaeBmmf2Dpv/Pt/wCRG/xrk/GXh/SpNV0iOWyjkjMd021yWGRFkHk1rQpqpO0trN/cmyZtpXR1Wh6lY3NlaQ295bSy+SvyJKrNwo7A1q153ceGNFsLvwldWunW8DT3PkzNGNpZWtpTyQf76rXY/wBg6b/z7f8AkRv8aqtTjFRlDZr9Wv0FFt3TMHxj/wAhOL/riP8A0JqKr+JLK3stRRbaPYGiBI3E929aKwLOm8M/8gS2/wCBf+hGtOuc0G1v30qFotR8uMlsJ5CnHzHvWh9i1L/oK/8AkstABqH/ACG9K/7a/wDoIrQmljgiaSaRI41GWZ2wB9TXO31pqA1jTAdTyx83DfZ14+Wr02m308TRzakskbDDI9qhBHuDTVr6gaVtcwXUXmW00c0ZON8bBhn6iqPhn/kCW3/Av/QjXNHw14h0u/upfDep6dDbXZWSWCe1wqyAbdyBeBlQufdc1U0O08btpcBt9T0VIvm2q1u5I+Y10SoRbvCat56MzU31R6HWTI6x+I2eRlVFs8lmOABvrB+xePf+gtof/gM9cp43svGX2DVHutU0weRp7XMht4GDNHG28oM8ZO3H41dHCe0qRg5pXaW4pVOVN2Z6/VDXLiG20i7e4mjiQxMA0jBRnaeMmsHWr/VLK4srPT7z7fqN4GeKERoiiNR80jtzhclRnByWAFZl74b1zVN174nvbBks4pGt7SCESoGZSCzMyrk44GFGMmohQ056rtH8X6L167FOeto6s7XSSG0uzIIIMKEEf7oq3Xn2ieHPEukWFvb+H9ctF0x0WRIby2MjQEjJVCGHyegPTtxgVrR6Z4xbHm+JNMTnkJpRPH1M39KJUKd9Kit53v8AckxKb6o2P+Zn/wC3P/2etOuKGmeIv7fIPiKHz/suQ409duN/Tbv/AFzVDxboni660G9huPEdkbTyzJI9vYmCXC/NhTvYAnbj8TVU8NCc1H2i1/xf5BKbSvyv8Du9U/5Bl5/1xf8A9BNN01lTSbVnYKogUkk4AG0VxOs6hr50rTLaxvLea+1Gze4czxhEjjVFLtgAljl1AAxyeoqeLwfe6rY2R1jxBdXtsI0b7GYI0tzwMBkXlx7MWFT9XUdasrL729bafPu0HPfSKO5RldVZGDKwyCDkEVm/8zP/ANuf/s9YVn4Sv9KaX+wtdayhk5+ytarJbofVEyNn0Uge2azpLLxoviDZFrGjyy/Zs+Y1m8Y27+m3c3P40OjB/BNfO6f+X4j5mt0eg1meJv8AkCXP/Af/AEIVz32Lx7/0FtD/APAZ6zfEdj44fRbpZ9W0fy2UKTHA6sMkYIPrSWH/AL6+8OfyZ0XgXxJ/wkWmytPH5N9bSGKaP1GTscf7LDn6hh2NdJXBx+CtS0+30+bRdZW31KytxbhpId0c6ZyVk5y3JZgeoJPqQZjb+PozkXehXI/u/PD+ux/5VtXpUqk3Kg0k+j0t9+lu2vkTCUoq00dHp/8AyG9V/wC2X/oJrTrzuyn8X/2pqCiyh8/93vIuI9n3eOSuf0rQLeOG4S300H1kvMD9ISf0rH6tPuv/AAKP+ZXtF5/czofE3/IEuf8AgP8A6EK06881xPHB0uf7QNFSIbd226dyfmGP+WC/zq99l8et/wAxDQ4v+2byZ/8AHVxR9Wl1kvvX6Bzrs/uF8PatPN8RvE9hMT9mCwm29zHGnm/rLGK6HT/+Q3qv/bL/ANBNcgng7V9IsNPudJ1CKfVrN3d1aIItx5pXzhuJJGdoIz3Rc1FD/wAJwNQ1GWBNM8xPLMkPnbnkGOikxqoOPXjPU9x04mnCtJSotWslq0tVpez7qz+bM4ScVaS/pno9Znib/kCXP/Af/QhXJW2qeKNaumTQW+zwQLiebVbMxYl/55qo5Yju2dvTBPZmuWnjddLnNxqeivF8u5Vt3BPzCueWFlDSbSfa5aqJ7HodFcX9i8e/9BbQ/wDwGej7F49/6C2h/wDgM9L6v/eX3j5/JlXwxrl1cfEfW9J27bC3WR1Yfxy7oy/5K6D8/Wu+rxtk8QaPrmmtDdQ3Ws3tzfWoKwYhVneB2J7hQkZPr8nvXWyHxvYjzbo2WoQDllsFCzL9Ekwrf99A+xrrxOGjLklSas13SvZtN623tczp1GrqR0mu/wDMP/6/I/61p15reapq+tXunQ6XLex2qXiC4u7uwEIjbacIqPhmbOMnG0c8k10kmleKOfK8TWo9PM0sN+eJBn9K5XhuTSpJRfZ3v87J2/MtVL/CrnTVmaF/zEP+vyT+lYr6b40U/J4i0lx6nS2X/wBqmsnSbTxuftnkanoq4uXD7rd+W4yRzwKXsE9pr8f1Q+fyZ6HWZrv/ADD/APr8j/rXn+sW/jDRNWg1m4vk1C5ul/s2O0s4cRqSC0bMG6fOMM3YN7VoataeOFFn52paKxNygTbA4w3OCfatJ4PlUZKaafn96+RKqXurM9DorzWBvEHiq4Gj373Onpa4fVD5IVWYEFI4nGN6NjcSMfLgHBYga3/CAWf/AD3/APHD/wDFUp4eFLSrKz7JJ/jdb7+ln1GpuWsVodDoX/MQ/wCvyT+ladeeaT4Fs5ftn73Gy5dPunnGP9qrx8CeWc2OtajYt620zoD9V3FT+IqOWh/M/wDwFf8AyQ7z7fj/AMAveLf+Q34Z/wCvw/8AoNdPXlfiPw7rWnatoL2XiW6urp7krGNQQSRKdvXAwc/jXQXPhPWdSAOseKrtgVCtBYxfZomGckHDFjnofm6U/Y0t3UVvR3+7b8Rc0v5TtKzPDP8AyBLb/gX/AKEa52w8O+KLKP7DB4pjGnRrthklshLchfQuzYOOxIPbOazfD3gm4GlxS2fiXWbXzMmRUmLB23HLEMSAT3xgU3RpR/5eX9E/x2t8rgpSf2T0eszUP+Q3pX/bX/0EVz3/AAhmpf8AQ465/wB9L/hVVvDOq2Wuaa0XirUpXYSgfaUSVQNvoR1qfZUn9v8AB/8ABHzS7HczTxQbPOkVN7hF3HGWPQCpa898c6NqyaRDqV1r7yrpVzFfhFtkQHYw3E46gIW4rQlTXNQ8RXum23iB7WC0t4ZHlitIi5kkaT5fmBHCoD0/iFa/VIuCnGatrd62VreV+q6E+0d7NG/4Z/5Alt/wL/0I1p155ovg66u9MhkufEusujbv3SztEo5I/wCWZWtKy8H3mm3Jl0rxDe2yv9+Fl86Jz/e2uThvcEZ75rL2dHbn19NP8/wK5pdv6/rzN7UP+Q3pX/bX/wBBFadcbfaZrg1jTAfEOWPm4b7EnHy/WtL+yte/6GP/AMkY/wDGj2MP+fi/8m/+RDmf8r/D/M6Cszwz/wAgS2/4F/6Ea5Dx1o2sHQJZ7jxJctHAyP5UMCwiQ71A3leSBnpnB75pluNYvzZaJpmrPbKYjc3dxHEu6CIuwRV/2nZW57BW74rT6qmlKM0073etla3f17eQvaatNHotZn/Mz/8Abn/7PXNt4ElnP+n+ItXvUHRJpmCD32oyg/jmqK+CZV1z7OPEWtiMW+4AXkoIG/7u7fux+NZ8lD+d/d/wR3n2/E9FrlfF/wDyGtH/AOuN5/6KqoPAFtkmS+uZmP8AFPJJKfzZyahfwQunvJf22qXYaCGULCzM8Q3Lg4RmIU49MVpTdCm21J7NbLqmv5mJ870t+P8AwDQ8R/u/DWi3A/5YXlgx9g0qIT+Tk11dcw2iXWqaDBa3GpsIHjjbCwKCNuGGD7ECtT7FqX/QV/8AJZawlNOnGPVN/dp/wSkrSbMHxj/yE4v+uI/9Caiq/iSG4i1FBc3P2hjEMHywmOW9KKyKOm8M/wDIEtv+Bf8AoRrTrnNBur9NKhWLTvMjBbD+eoz8x7VofbdS/wCgV/5MrQAah/yG9K/7a/8AoIrTrmr671A6xphOmYYebhftC8/LWl9t1L/oFf8AkytAGnWZ4Z/5Alt/wL/0I0fbdS/6BX/kytZvh671BdHtwmmb1+bDeeoz8xoA6Wua8SxiaTVY2Xcr6TKpHrnNaX23Uv8AoFf+TK1m/a9Q/wCEi3f2Z8/2XG37QvTf1zVQlySUuwmrqxS8KzC+1+CeNxIkGi2qvIDkM0hLAfkoP/AhXU6p/wAgy8/64v8A+gmuY8KaTc+G4L6Gz0xmjubprgBrlf3akALGP9lQoAHpWpqV5qJ066DaXtBifJ+0KccGt8XUhOq3T+Hp/XqRTTUfe3NPS/8AkGWf/XFP/QRVmsPTbzURp1qF0vcBEmD9oUZ4FWftupf9Ar/yZWuY0D/mZ/8Atz/9nqfWYXudIvoIRmSWCRFHqSpArG+16h/wkW7+zPn+y42/aF6b+ua0vtupf9Ar/wAmVpxlytNdBNX0OO8PXKatKbuA5gsfD8UKkjBDzDe6+xAijyPeu70v/kGWf/XFP/QRXI6VpVzoGm66sGmHZfXE14xNwp2blA2j2GOBW3pt5qI061C6XuAiTB+0KM8CunGVIVKrdP4en9etyKUXGPvbm5WZ/wAzP/25/wDs9H23Uv8AoFf+TK1m/a9Q/wCEi3f2Z8/2XG37QvTf1zXKaHS1meJv+QJc/wDAf/QhR9t1L/oFf+TK1m+IbvUG0e4D6ZsX5ct56nHzCgDpaKzPtupf9Ar/AMmVo+26l/0Cv/JlaADT/wDkN6r/ANsv/QTWnXNWN3qA1jUyNMyx8rK/aF4+WtL7bqX/AECv/JlaADxN/wAgS5/4D/6EK065rxDd6g2j3AfTNi/LlvPU4+YVpfbdS/6BX/kytAGnWZp//Ib1X/tl/wCgmj7bqX/QK/8AJlazbG71AaxqZGmZY+VlftC8fLQB0tZnib/kCXP/AAH/ANCFH23Uv+gV/wCTK1m+IbvUG0e4D6ZsX5ct56nHzCgDpaKzPtupf9Ar/wAmVo+26l/0Cv8AyZWgCLRYInnvJnjVpYruYI5HK525x9cCtiua0a71Bft2zTN2bqQn9+oweOK0vtupf9Ar/wAmVp3YBrv/ADD/APr8j/rWnXNazd6g32Hfpm3F1GR+/U5PPFaX23Uv+gV/5MrSA06zNC/5iH/X5J/Sj7bqX/QK/wDJlazdGu9QX7ds0zdm6kJ/fqMHjigDpazNd/5h/wD1+R/1o+26l/0Cv/JlazdZu9Qb7Dv0zbi6jI/fqcnnigDpaKzPtupf9Ar/AMmVo+26l/0Cv/JlaADQv+Yh/wBfkn9K065rRrvUF+3bNM3ZupCf36jB44rS+26l/wBAr/yZWgDL8W/8hvwz/wBfh/8AQa6euJ8T3N82seHjJp+xluiUXzlO87entXR/bdS/6BX/AJMrQBp1meGf+QJbf8C/9CNH23Uv+gV/5MrWb4eu9QXR7cJpm9fmw3nqM/MaAOlrM1D/AJDelf8AbX/0EUfbdS/6BX/kytZt9d6gdY0wnTMMPNwv2hefloA2dYsU1PSb2wlOI7qB4GOM4DKVPH41V8NaFbaBYGCB5J55G8y4upjuluJMYLsf0A6AAAU/7bqX/QK/8mVo+26l/wBAr/yZWtFVmoOmno9bE8qvzdQ8M/8AIEtv+Bf+hGtOua8PXeoLo9uE0zevzYbz1GfmNaX23Uv+gV/5MrWZQah/yG9K/wC2v/oIrTrmr671A6xphOmYYebhftC8/LWl9t1L/oFf+TK0AWdVsLfVNNurG8TfbXMbRSL7EY49D71znw10V9K0AS3d3Je39y2ZrhxjIUlVUDsAB+JLHvW19t1L/oFf+TK1m+HrvUF0e3CaZvX5sN56jPzGtVWnGm6Sej/r/h+9l2RLim+bqdLWZ/zM/wD25/8As9H23Uv+gV/5MrWb9r1D/hIt39mfP9lxt+0L039c1kUdLVbVP+QZef8AXF//AEE1V+26l/0Cv/JlaraleaidOug2l7QYnyftCnHBoA09L/5Bln/1xT/0EVZrD0281EadahdL3ARJg/aFGeBVn7bqX/QK/wDJlaAMHxj/AMhOL/riP/Qmoqv4kmuJdRQ3Nt9nYRDA8wPnlvSigDpvDP8AyBLb/gX/AKEa065zQNZsINKhiln2yKWBGxjj5j7Vof29pv8Az8/+Q2/woANQ/wCQ3pX/AG1/9BFadc1fa3p7axpji4yq+bk7G4yv0rS/t7Tf+fn/AMht/hQBWm8W+H4NQnsJtZsEvYA7SwtModAilmJHbCgk+wrJ0Pxj4ctdBge51vT4lV2jYvOowxJbH1xzXNrqlzb/ABW1HWl0q5l05tM+xxyrJEPMdCXGAWBAY4UZA5POBzXL3x1G7+Fz6Jb6RcPdtfiYHzogpQS+ZnlvbH19ua9qngcNKcIynZNRu+aOl9/u7bnK6tRJtLv0Z7zaXEN3aw3NrIstvMgkjkQ5V1IyCD3BBqj/AMzP/wBuf/s9Q2viKwmtYZZme3ldAzROpLRkjlSVyCR04JFU/wC2tP8A+Ei8z7R8n2XbnY3Xf9K8aSs2dKOlqtqn/IMvP+uL/wDoJqr/AG9pv/Pz/wCQ2/wqtqWuac+nXSrcZJicD5G9D7Uhmnpf/IMs/wDrin/oIqzWHpuuacmnWqtcYIiQH5G9B7VZ/t7Tf+fn/wAht/hQAf8AMz/9uf8A7PWnXNf21p//AAkXmfaPk+y7c7G67/pWl/b2m/8APz/5Db/CgC1qn/IMvP8Ari//AKCaNL/5Bln/ANcU/wDQRWZqWuac+nXSrcZJicD5G9D7UabrmnJp1qrXGCIkB+RvQe1AG5WZ/wAzP/25/wDs9H9vab/z8/8AkNv8Kzf7a0//AISLzPtHyfZdudjdd/0oA6Wue13VtPufD+qSW95BIlpJ5NwyuCInVl3K3oR6V5f8W4dU1vWZZtEgaTy7WMWl1byiN1kDksG3sNvB4KjnueMA8X2F5H4zu5NHaJvDmqy293qBbjbJFuyu08nf8hJweetetDAUHSU5Vldpu2mlraPXdpu22qsc7rT5rKOh6rF4t8Py6oNMj1ixbUC/li3Ew8zd6beua3K8l8GaXHZ+LfEGsahqF7apLqks9vbxlDDPGw4ZhtLA+2R0HFej/wBvab/z8/8AkNv8K5cbSo0pqNCXMrK/r93+ZdKUpK81YNP/AOQ3qv8A2y/9BNadc1Y63p66xqbm4wreVg7G5wv0rS/t7Tf+fn/yG3+FcZqHib/kCXP/AAH/ANCFadc14h1vT5dHuES4yx24Gxv7w9q0v7e03/n5/wDIbf4UAadZmn/8hvVf+2X/AKCaP7e03/n5/wDIbf4Vm2Ot6eusam5uMK3lYOxucL9KAOlrM8Tf8gS5/wCA/wDoQo/t7Tf+fn/yG3+FZviHW9Pl0e4RLjLHbgbG/vD2oA6Wisz+3tN/5+f/ACG3+FH9vab/AM/P/kNv8KAKtnfWumWWq3moTx29rFdyF5ZG2qoyByfxq5e65pdiVF5qFtCWha4XfIBmNRln+gyOa5/7TpGqaTrenX02be8lmjYbGPysMZHHWuG+H0WpaVDfal4it4rzUrKyj0rTrcOAJYIySW3cgFvl64Py8134bD0alKU5ztJPa6V77Wv2e/ZGM5yjJJLR/wBf8Mehrr+k+ILayn0W/t72KO+jR2ibO088Edq6evHfBJnsb/VbzVYntUvtSt54luJBNcYVCGMjoNpGcbQORzXp/wDb2m/8/P8A5Db/AArLGUqdGs4UneOnVPouq0dtiqUpSjeS1NOszQv+Yh/1+Sf0o/t7Tf8An5/8ht/hWbo2t6fH9u33GN11Iw+RunHtXKaHS1ma7/zD/wDr8j/rR/b2m/8APz/5Db/Cs3Wdb0+T7DsuM7bqNj8jdOfagDpaKzP7e03/AJ+f/Ibf4Uf29pv/AD8/+Q2/woANC/5iH/X5J/StOua0bW9Pj+3b7jG66kYfI3Tj2rS/t7Tf+fn/AMht/hQBl+Lf+Q34Z/6/D/6DXT1xPifV7GbWPDzxz5WO6LOdjcDb9K6P+3tN/wCfn/yG3+FAGnXMafrthpNlolpfytHLqMrwW52kqz5J2k9AT2z1rU/t7Tf+fn/yG3+FcP4jt7XxD4DisrS9jt9Ut5lurOaRH2xTJISpJCntkd+tb4aNOdWMaztF9e3n8upFRyUW47nTXvjbQ7RL1pLiR2tbtbBkjhZ2kuCMiJABlm56DpVhLwX99otysNxAJPO/d3EZjkXAxyp5HSvNrzwpBL4V0O2a8sLzVbO9e/vFuUkEF3JJu8wEhMj7wAO3oORW/wCC47fw3pHh3TLvURdS2on3uqPtXdkhVyM7RnA+nbpXbiqGDhR5qE7yva3lrqvuT+dujMqc6jlaa0sej0Vmf29pv/Pz/wCQ2/wo/t7Tf+fn/wAht/hXlnQHhn/kCW3/AAL/ANCNadc14e1vT4tHt0e4ww3ZGxv7x9q0v7e03/n5/wDIbf4UAGof8hvSv+2v/oIrTrmr7W9PbWNMcXGVXzcnY3GV+laX9vab/wA/P/kNv8KANOszwz/yBLb/AIF/6EaP7e03/n5/8ht/hWb4e1vT4tHt0e4ww3ZGxv7x9qAOlrM/5mf/ALc//Z6P7e03/n5/8ht/hWb/AG1p/wDwkXmfaPk+y7c7G67/AKUAdLVbVP8AkGXn/XF//QTVX+3tN/5+f/Ibf4VW1LXNOfTrpVuMkxOB8jeh9qANPS/+QZZ/9cU/9BFWaw9N1zTk061VrjBESA/I3oParP8Ab2m/8/P/AJDb/CgDB8Y/8hOL/riP/Qmoqv4kvbe91FGtpN4WIAnaR3b1ooA6bwz/AMgS2/4F/wChGtOszwz/AMgS2/4F/wChGtOgDM1D/kN6V/21/wDQRWnWZqH/ACG9K/7a/wDoIrToAKzPDP8AyBLb/gX/AKEa06zPDP8AyBLb/gX/AKEaANOsz/mZ/wDtz/8AZ606zP8AmZ/+3P8A9noA06rap/yDLz/ri/8A6Cas1U1YhdKvCxAAhcknt8poAdpf/IMs/wDrin/oIqzVTSSG0qzKkEGFCCO/yirdAGZ/zM//AG5/+z1p1mf8zP8A9uf/ALPWnQBW1T/kGXn/AFxf/wBBNGl/8gyz/wCuKf8AoIo1T/kGXn/XF/8A0E0aX/yDLP8A64p/6CKALNZn/Mz/APbn/wCz1p1mf8zP/wBuf/s9AGnWZ4m/5Alz/wAB/wDQhWnWZ4m/5Alz/wAB/wDQhQBp0UUUAZmn/wDIb1X/ALZf+gmtOszT/wDkN6r/ANsv/QTWnQBmeJv+QJc/8B/9CFadZnib/kCXP/Af/QhWnQAVmaf/AMhvVf8Atl/6Ca06zNP/AOQ3qv8A2y/9BNAGnWZ4m/5Alz/wH/0IVp1meJv+QJc/8B/9CFAGnRRRQBmaF/zEP+vyT+ladZmhf8xD/r8k/pWnQBma7/zD/wDr8j/rWnWZrv8AzD/+vyP+tadABWZoX/MQ/wCvyT+ladZmhf8AMQ/6/JP6UAadZmu/8w//AK/I/wCtadZmu/8AMP8A+vyP+tAGnRSOyorM7BVUZJJwAKSN1kRXjZWRhkMpyCKAM7Qv+Yh/1+Sf0rTrM0L/AJiH/X5J/StOgDmPFv8AyG/DP/X4f/Qa6euY8W/8hvwz/wBfh/8AQa6egArM8M/8gS2/4F/6Ea06zPDP/IEtv+Bf+hGgDTrM1D/kN6V/21/9BFadZmof8hvSv+2v/oIoA06KKKAMzwz/AMgS2/4F/wChGtOszwz/AMgS2/4F/wChGtOgDM1D/kN6V/21/wDQRWnWZqH/ACG9K/7a/wDoIrToAKzPDP8AyBLb/gX/AKEa06zPDP8AyBLb/gX/AKEaANOsz/mZ/wDtz/8AZ606zP8AmZ/+3P8A9noA0643xVDPea/9j+33tvbHS5p9lvLsy6uo5454f9K7KuU8SfJ4qsHxw+k6hHx67rdh/wCgt+ddOFdpu3Z/k2RU2+4qWFpPpOp+GRHqWoTw3ivFJFcTb14hLggY7Ff1rtq5TVPlk8EyY4S9AOOuGs51/mR+VdXRiJOcYSe7X6sUFZtf1scd4x/5CcX/AFxH/oTUUeMf+QnF/wBcR/6E1FcxoXtA0awn0qGWWDdIxYk72GfmPvWh/YOm/wDPt/5Eb/Gjwz/yBLb/AIF/6Ea06AOavtE09dY0xBb4VvNyN7c4X61oP4f0xlKtbZUjBHmN/jTtQ/5Delf9tf8A0EVp0bAcLH4cvNFnaG0sxrOmtlohNdGOeA5+4WPDr6E/MOhz1qtoUF4+lQN/wi3mZ3fN/aAGfmPavQ6zPDP/ACBLb/gX/oRrpeIUtZwTffX9GkRyW2Zx5i1C21xZb/w3KujvAUEdrMZ5VmDA7jgjClSR9R71R1wveXFxaaFoepQ39xa+VDJcIUWFmfBlJLdFBJ9yAK9RrM/5mf8A7c//AGeqWJp3UvZq69bfNC5HZrmOVspdMg8H+H7w2Ul5falBbiC3SRg0zvGGPJPAA3MSegBqtqvhm51tZf7SsF0zSYImke3jujLJdvg4ViOFjHUjqx64A5f4E/0jUNFt8fJpGmSxkejNP5S/kLeQfia7rVP+QZef9cX/APQTXRiZLC1Wqa97XXqtXa3Tazva+unQiC9pHV6HBaX4ZudDWP8As2wGqaRPCsiW7XJjltXwMqhJwyHkgEjaeM4PGlh1Pz+C9Wb08q7tj+e6cV1el/8AIMs/+uKf+girNc0sTzvmqQTffW79bNa/n11LULaJnnn2i0GugS+GdajQ22dmwOc7uvyyGnas8lxZtBoHhu+S/kyEmvVaOGEYJLt82Wx2UdTjoMmuu/5mf/tz/wDZ606Ua1OL5vZr73YHGT0ucFPLpUPgjTdSntJp7jULWPykgJZpJHiL8DIHQMfTAqO00jVNWs7aO20+LRLcxLuubiXz524/gjVii/Vmbr901T0T/SdP8N2OMppemXUrD+66D7Mn/jpm+mMV6Jpf/IMs/wDrin/oIroxKhhp2jFN679NWlptsuqZELzV2/6scZD4ev8AQ5DFHav4gsW5R5bgRXURzyrHhHHcH5SOnPWq/mLHrhFx4S1hALYnaksMmfn6jbNnH5fSvRKzP+Zn/wC3P/2eud4iMtZwTfzX5O34GnI1szl5Ir66bzNL8KbLZGGTqF6YZJRnnYi7scc5cr9KoeKrHUp9Au4bXQFsJZAqC6a+D+SCwBYKOpA6D1r0qszxN/yBLn/gP/oQprEQi01Tjp6/52f3C5G95P8AA5TT5dOg8D6FqM1i91fXsVvEkCysGlncDK5Jxx8xJ9FJqS40PUdWK2o01NFt2/110Lrzpdv92MDgMefmPTsCelXwool8R6dYMMjSW1NuR90m4CRH/v2716JXRiuTD1Pdim3d3fTV2022V9U9yKd5rVnm9r4bm0jXL9NJtf7S08eWGtrm7cSxkrnckjE5Geqt9Qe1an2a8/6FP/ypCuh0/wD5Deq/9sv/AEE1p1zPE8+tSKb763+dmjRQts7HmPi211j+yDJZeH4rVYXWWYveea0kY6xoB0ZjgAngVrXF1ZrbyG28La1LOFPlxtGUDNjgFi2AM9+1dL4m/wCQJc/8B/8AQhWnT9vTaSdNadr/AI6sXJL+Y4DRns7bwI+ra7biS7t2njnWFm+eVJnj2IM9SwCge4qmmiazqt5qVslnY6Mj+UGlF09xNEpXnaNoXdjoSSAfWprJftGu2ujEApDrd5fyLjqiASD8pLiI/UV2Wn/8hvVf+2X/AKCa6cS4UJ80Yq8m2uyV9LLb70+hELzVm9tDl7nwO+mL5/h26lkZVGbHUZnlimIHZ8742Prkrn+Gq+uQXiaVMx8LeXjb839oA4+Ydq9DrM8Tf8gS5/4D/wChCuV4lz1qRUn3d7/g1f56l+zt8Lsc99mvP+hT/wDKkKbJZ6i6FIPC0EcrcK8+o/IvuduSR7Cu2ope2h/z7X/k3/yQ+V/zP8P8jzXwJpRHiPxHYavKLySIwzoyho0XeZVIVdxwMx9yT6k1oRXdndSTS6b4Z1DUNOSQxLd288YEhHDMqvIpKg8ZGc4OOKw/EDsniW4so3dH1kmzyjFTsW5iEmCPSOZ+mP8AD1G2gitbeKC3jWKGJQiIgwFUDAAHpXVX5IxjWlFNySstlokm9Lbv5bmcLtuKex55rLi5fTYNK8P3sE8t2gaW/V0iRcMeSGJJJAGB61pHT9SsyftPh21v06hrC9ZH+myUqPx3/lXR67/zD/8Ar8j/AK1p1ze3gtFTVvn+d0acj7nDyXNokLn/AIRPXfPA4hKA5OOBuEhX8c4qjotxbBL0XvhnV1nW6kUpEvmquD0DBsGvRqzNC/5iH/X5J/Sj2tK38P8AFhyy7nP+Eo4NXW/TU9I/s+8tpwptzOzsI2RXQkg4zhiDjjKkVmalqGjTi1fT9J1O5txeCMTwxM0cu0lTsO7kZBwR1xxU3jyO9tvENgtm7w2uv+XpV3PFw8W1mdSvoSjTLu7Hae1dPqVtDZ2uk21rEsVvDcxRxxqMBVAIAHtit60KMIqry/Fsk9raPz328vVERcm+W+xyl9pNr4i1TTbL+yNVtdMDPJeCZTGsoC/KjHJypJ5A649K1Ln4eaIdv9nG90rH8NjcFEP/AAA5T8cV2FFZPFzSUafuxXTo/Xv/AMBFezW8tWedaX4JmmF5GPEGorEty6E+VD5hAx0bZgH/AIDV5PAb25xZ69fmM/w3aJNg+zYU/mTXSaF/zEP+vyT+ladT9aqeX/gMf8h+zX9Nnlut6HNpfibwtHdXovLe7vGhZPJ8vGI2Ycg/7NaMGhp4ovbqa3uZ9P0a1naCA2jESXTpw7l2yNgbcoAHJUkkjAqv8atRk0e10LVIYzLLZXvmqgGSxK7f/Zq7fw1p39keHtN08nLW1ukTN/eYKNx/E5P410ymo0I10lzP3dl01bttezir/qZpXm4dN/6/E5p/AG/bFJ4g1V7XOXX90kjD0EiICB6kc+4rJ8LaLqGn6a9vFo8epWpmd7WeS/aMrGTnY+cklTuAPORivTazPDP/ACBLb/gX/oRrnWLk1yySa7Wt89Lal+zW63/ruc9/Z+qtwnhrS19TLrEo/LbCaoXel6x/aunqdH0WIt5mEGpTyA4Xu3lDH5V6HWZqH/Ib0r/tr/6CKn20elNf+Tf5j5X3f4f5HGeIdO1jT9HnvpE0iCOAB3WFZpmK7hkAlgBwTzg9OlW3v9Hv7tLXwtZW+ty+V50skV6VhhXOFDON3zEhsKBn5TnFd3UccMUbu8caI0hy7KoBY+p9av6xTcbTgrq9ui6b21dvUXJJPRnn+g6RrNxpcD/2fosIO7711PIT8x64VQK0P7B1n/n20P8A7+XH+NdD4Z/5Alt/wL/0I1p1H1hdIL7v+CPk82eeXmiauuq6eht9FBbzMAPPg4XvzV/+wdZ/59tD/wC/lx/jXQ6h/wAhvSv+2v8A6CK06PrH91fcHJ5s4O/0zWLC0ku20vSryOEb3ggmmWR1H3ghY43YzgHqeOKzdBuodYtLK28O6YJ5Shlubm7MsUUAJO1eOWc+g6DJJ6Z9OrM8M/8AIEtv+Bf+hGqVenb3qav9y+a626bed1oLkfRnPf2DrP8Az7aH/wB/Lj/GqH9i6x/bvl/Z9Fz9m3Y3z4+99c5r0Osz/mZ/+3P/ANnqfrH91fcPk82c9/YOs/8APtof/fy4/wAaqXPhW8ku0vtRTTkitbecbbZpdzFl/wBo9AQDXf1W1T/kGXn/AFxf/wBBNH1lq9opbrbvoHJ3ZzkvhWzv7DRnjjEbwSxXDEs3zAKQR175rZ/sHTf+fb/yI3+NWtL/AOQZZ/8AXFP/AEEVZrFzbSi+hSVnc4bxJZW9lqKLbR7A0QJG4nu3rRVjxj/yE4v+uI/9CaipGXtBtb99KhaLUfLjJbCeQpx8x71ofYtS/wCgr/5LLR4Z/wCQJbf8C/8AQjWnQBzV9aagNY0wHU8sfNw32dePlrS+xal/0Ff/ACWWjUP+Q3pX/bX/ANBFadAGZ9i1L/oK/wDkstZvh601BtHtymp7F+bC+Qpx8xrpazPDP/IEtv8AgX/oRoAPsWpf9BX/AMllrN+yah/wkW3+0/n+y53fZ16b+mK6Wsz/AJmf/tz/APZ6AOM+HmjalBd+Jpmv/KLapNEn7hTujDtID7fNLJx2rqtSs9RGnXRbVNwET5H2dRng1sxRRwhhEiqGYu2B1J5JqHVP+QZef9cX/wDQTW+JruvVdR9f8rEU4ckeUzNNs9ROnWpXVNoMSYH2dTjgVZ+xal/0Ff8AyWWrWl/8gyz/AOuKf+girNYFnNfZNQ/4SLb/AGn8/wBlzu+zr039MVpfYtS/6Cv/AJLLR/zM/wD25/8As9adAHlfgvTNSB8Xzy3ZjEF1PZR5hB3xq8k2R6DNww/D2FdxptnqJ061K6ptBiTA+zqccCrd1aw2ul6gIECeYssr4/iZgSTVjS/+QZZ/9cU/9BFdGKr/AFiq6nf/ACIpw5I8pV+xal/0Ff8AyWWs37JqH/CRbf7T+f7Lnd9nXpv6YrpazP8AmZ/+3P8A9nrnLD7FqX/QV/8AJZazfENpqC6PcF9T3r8uV8hRn5hXS1meJv8AkCXP/Af/AEIUAcj4c0DUrbx34qu/7QKrN9m2P5A5+Q7sduuK677FqX/QV/8AJZa0goBJAAJ6n1pa2r1nWkpS7Jfckv0JhFRVkc1Y2moHWNTA1PDDyst9nXn5a0vsWpf9BX/yWWjT/wDkN6r/ANsv/QTWnWJRzXiG01BdHuC+p71+XK+Qoz8wrS+xal/0Ff8AyWWjxN/yBLn/AID/AOhCtOgDz3QdA1OP4g+Jr99QKoywCJ/IUhi0aCTjt/qounpW7Y2moHWNTA1PDDyst9nXn5a6UAAnA61maf8A8hvVf+2X/oJravWdaSk+iS+5JEwioqyD7FqX/QV/8llrN8Q2moLo9wX1Pevy5XyFGfmFdLWZ4m/5Alz/AMB/9CFYlB9i1L/oK/8AkstH2LUv+gr/AOSy1p0UAeejw3e6h4n07UftoP8AZt3dneYV4Loq5x3z+mM11/2LUv8AoK/+Sy0aF/zEP+vyT+ladaTqynGMXtFWX3t/myVFJtrqc1rNpqC/Yd+p7s3UYH7hRg881pfYtS/6Cv8A5LLRrv8AzD/+vyP+tadZlGZ9i1L/AKCv/kstZujWmoN9u2antxdSA/uFOTxzXS1maF/zEP8Ar8k/pQBDc6VeXKoJ9SDhHWRc2y/KynII5qnrNpqC/Yd+p7s3UYH7hRg8810tZmu/8w//AK/I/wCtO7tYA+xal/0Ff/JZaPsWpf8AQV/8llrTopAc1o1pqDfbtmp7cXUgP7hTk8c1pfYtS/6Cv/kstGhf8xD/AK/JP6Vp0AcJ4x024uNR0CC9vFuEkuiAGgUBSBnOO/Suo+xal/0Ff/JZay/Fv/Ib8M/9fh/9Brp6d3awGZ9i1L/oK/8AkstZvh601BtHtymp7F+bC+Qpx8xrpazPDP8AyBLb/gX/AKEaQB9i1L/oK/8AkstZt9aagNY0wHU8sfNw32dePlrpazNQ/wCQ3pX/AG1/9BFAB9i1L/oK/wDkstH2LUv+gr/5LLWnRQBzXh601BtHtymp7F+bC+Qpx8xrS+xal/0Ff/JZaPDP/IEtv+Bf+hGtOgDmr601AaxpgOp5Y+bhvs68fLWl9i1L/oK/+Sy0ah/yG9K/7a/+gitOgDM+xal/0Ff/ACWWs3w9aag2j25TU9i/NhfIU4+Y10tZnhn/AJAlt/wL/wBCNAB9i1L/AKCv/kstZv2TUP8AhItv9p/P9lzu+zr039MV0tZn/Mz/APbn/wCz0AH2LUv+gr/5LLVbUrPURp10W1TcBE+R9nUZ4NblVtU/5Bl5/wBcX/8AQTQBmabZ6idOtSuqbQYkwPs6nHAqz9i1L/oK/wDkstWtL/5Bln/1xT/0EVZoA4bxJDcRaigubn7QxiGD5YTHLelFWPGP/ITi/wCuI/8AQmooAvaDdX6aVCsWneZGC2H89Rn5j2rQ+26l/wBAr/yZWjwz/wAgS2/4F/6Ea06AOavrvUDrGmE6Zhh5uF+0Lz8taX23Uv8AoFf+TK0ah/yG9K/7a/8AoIrToA8Vm1Sx/wCFsatFeXUqoNOkMlmdWkRI5MN5rZDAAiPccDG3G4YIzW58Ir9m0G4FhG9/KLhhMzXpYpydo2sTt+XHTGetenVmeGf+QJbf8C/9CNd9fG+1goWeyW99vkv66sxhS5Xf+vzD7bqX/QK/8mVrN+16h/wkW7+zPn+y42/aF6b+ua6Wsz/mZ/8Atz/9nrgNg+26l/0Cv/JlaraleaidOug2l7QYnyftCnHBrcqtqn/IMvP+uL/+gmgDM0281EadahdL3ARJg/aFGeBVn7bqX/QK/wDJlataX/yDLP8A64p/6CKs0Ac19r1D/hIt39mfP9lxt+0L039c1pfbdS/6BX/kytH/ADM//bn/AOz1p0AYepXmonTroNpe0GJ8n7QpxwaNNvNRGnWoXS9wESYP2hRngVp6p/yDLz/ri/8A6CaNL/5Bln/1xT/0EUAVftupf9Ar/wAmVrN+16h/wkW7+zPn+y42/aF6b+ua6Wsz/mZ/+3P/ANnoAPtupf8AQK/8mVrN8Q3eoNo9wH0zYvy5bz1OPmFdLWZ4m/5Alz/wH/0IUAH23Uv+gV/5MrR9t1L/AKBX/kytadFAHNWN3qA1jUyNMyx8rK/aF4+WtL7bqX/QK/8AJlaNP/5Deq/9sv8A0E1p0Ac14hu9QbR7gPpmxfly3nqcfMK0vtupf9Ar/wAmVo8Tf8gS5/4D/wChCtOgDM+26l/0Cv8AyZWs2xu9QGsamRpmWPlZX7QvHy10tZmn/wDIb1X/ALZf+gmgA+26l/0Cv/JlazfEN3qDaPcB9M2L8uW89Tj5hXS1meJv+QJc/wDAf/QhQAfbdS/6BX/kytH23Uv+gV/5MrWnRQBzWjXeoL9u2aZuzdSE/v1GDxxWl9t1L/oFf+TK0aF/zEP+vyT+ladAHNazd6g32Hfpm3F1GR+/U5PPFaX23Uv+gV/5MrRrv/MP/wCvyP8ArWnQBmfbdS/6BX/kytZujXeoL9u2aZuzdSE/v1GDxxXS1maF/wAxD/r8k/pQAfbdS/6BX/kytZus3eoN9h36ZtxdRkfv1OTzxXS1ma7/AMw//r8j/rQAfbdS/wCgV/5MrR9t1L/oFf8AkytadFAHNaNd6gv27Zpm7N1IT+/UYPHFaX23Uv8AoFf+TK0aF/zEP+vyT+ladAHE+J7m+bWPDxk0/Yy3RKL5ynedvT2ro/tupf8AQK/8mVrL8W/8hvwz/wBfh/8AQa6egDM+26l/0Cv/ACZWs3w9d6guj24TTN6/NhvPUZ+Y10tZnhn/AJAlt/wL/wBCNAB9t1L/AKBX/kytZt9d6gdY0wnTMMPNwv2heflrpazNQ/5Delf9tf8A0EUAH23Uv+gV/wCTK0fbdS/6BX/kytadFAHNeHrvUF0e3CaZvX5sN56jPzGtL7bqX/QK/wDJlaPDP/IEtv8AgX/oRrToA5q+u9QOsaYTpmGHm4X7QvPy1pfbdS/6BX/kytGof8hvSv8Atr/6CK06AMz7bqX/AECv/JlazfD13qC6PbhNM3r82G89Rn5jXS1meGf+QJbf8C/9CNAB9t1L/oFf+TK1m/a9Q/4SLd/Znz/ZcbftC9N/XNdLWZ/zM/8A25/+z0AH23Uv+gV/5MrVbUrzUTp10G0vaDE+T9oU44Nblcr43udRWSxstNuorb7THcGV5IfNyEjzjGRj65rSlT9pLlTtv+CuTKXKrl7TbzURp1qF0vcBEmD9oUZ4FWftupf9Ar/yZWsPR77WrC80Oz1SXTrm1vY2RJLeB4XVlj3gEF2ByAfTpXX06tJ07a3T1Vvu/QIy5jhvEk1xLqKG5tvs7CIYHmB88t6UVY8Y/wDITi/64j/0JqKyKL2gazYQaVDFLPtkUsCNjHHzH2rQ/t7Tf+fn/wAht/hR4Z/5Alt/wL/0I1p0Ac1fa3p7axpji4yq+bk7G4yv0rS/t7Tf+fn/AMht/hRqH/Ib0r/tr/6CK06AMz+3tN/5+f8AyG3+FZvh7W9Pi0e3R7jDDdkbG/vH2rD8Oy6tpJn1V4by+03Ury5kltkQtJanzX8t0XqVZAu5RyDgjqav+HvFulQaRbpc/b7dhuyZtPuEX7x/iKbT+Brsq4KpGTVP3l5fj/XzMo1YtXehv/29pv8Az8/+Q2/wrN/trT/+Ei8z7R8n2XbnY3Xf9Kc/jLRzhbZ7u7lPSK1s5pWP5Lx9TgVk3njCytdWmuJLLVUlSyOyCSwmVpG3ZCg7duSeM5xk1Cwddu3I/uK9rDudN/b2m/8APz/5Db/Cq2pa5pz6ddKtxkmJwPkb0PtVfwdq1xP4Qhv/ABBLDBdRNMl27MFSN45XRuTgAAqR+FUtQ8R3er6fcr4Z09ri2MTbtQu8w2+MH/VjG+TvyAF/2qHhKinKH8rs30+/+ri9pGyfc1dN1zTk061VrjBESA/I3oParP8Ab2m/8/P/AJDb/Cue0678RaPHYyahGmsadPCoP2C28uW1bbkfKXO9COM5yD2weNP/AISu2A/eabriev8AxLJ2x/3ypz+GaHhKm8PeXl/V/vQe0XXQj/trT/8AhIvM+0fJ9l252N13/StL+3tN/wCfn/yG3+FYH/CWaYPEXmPHqka/Zdv73SrpOd/oYxVq98Z6ets409Lq71BvlgtPs0kTSueFGWUYXJ5Y8AZPahYOu3bkf3D9rDuXNS1zTn066VbjJMTgfI3ofajTdc05NOtVa4wREgPyN6D2qhpOqzS+AJr/AF2eBJ44rhbmUfLGGR3U4z/D8vGeeneq9prWs6jodrHoGi3MDyQoqXuobI4kBA+fywxkbA5wVGeOaPqlTnlHSydm72X3v/hxe0Vk+50H9vab/wA/P/kNv8Kzf7a0/wD4SLzPtHyfZdudjdd/0qtDc6n4V8uLWZ59W0lsAah5eZ4HPaVVHzIT0dRx0Ix81R/8Jdof/CReZ9u+T7Ltz5T9d/8Au0SwlTemuZd1d/8ADejBVI9dDf8A7e03/n5/8ht/hWb4h1vT5dHuES4yx24Gxv7w9qg1DxzYxGP+zbS/1TGXn+ywN+4iH3nOQM4zwoyx5wOKg8Q+MNDk0a4VL0ljtOPJk/vD/ZoeCxCSfI/uD2sO50H9vab/AM/P/kNv8KP7e03/AJ+f/Ibf4Vj+A9cutW0vVLzV0+ytFePiOQ4MMRjR0DehCOM++ad/wk91qNrEfD+j3sslyAYZ7uPybdVIyJGOclcc4Aycjp1Dlg6sZuHbd30+8FVi0mSWOt6eusam5uMK3lYOxucL9K0v7e03/n5/8ht/hXKWT6z4c1fUri7ml1uxPltdusYE0BK53xov3ox/c5YDkFuRW9/wmWg/8/8A/wCQZP8A4mk8JUetP3l3V/8Ah18wVRfa0IvEOt6fLo9wiXGWO3A2N/eHtWl/b2m/8/P/AJDb/Cuf8ReLtHl0e4S2nmuJW2hY4baRmPzDtt/U8VoJ400MoDJczQP/ABRTW0qOh7gqVyDS+qV/5H9zH7SHc0P7e03/AJ+f/Ibf4Vm2Ot6eusam5uMK3lYOxucL9Km8PeJrfWNKvtQeGWxt7WV0f7SNjBFUPvYH7uVYHB6DrzwMa18VRz6nqbaJp+oalNJ5Ii22zxRElerSOoUL3zzx0Bo+qVuZx5dt+y9XsHtI2vc6X+3tN/5+f/Ibf4Vm+Idb0+XR7hEuMsduBsb+8Paq3keJtKP9pSXS6uX5utOjQRrGv/TsTzkejn5/VTxUOu+MNEn0SYJdursFOx4JFYfMOCCvB9qp4Sb1p++vK7/4P+fQSqL7WnqdD/b2m/8APz/5Db/Cj+3tN/5+f/Ibf4VQfxnogH7u4nnc8COC0mldj7Kqk0kfjPRsEXMl1ZyqcNDc2ksbr+BXke4qfqlf+R/cx+0h3G6Nrenx/bt9xjddSMPkbpx7Vpf29pv/AD8/+Q2/wrnfh54gl1u+8QI9pJawRXCywCVSsjI+cMwPTO08dQOta2reKLOyuZ7O1gvNR1GIc21nA8hDEZAZ8bEyCPvEcEGh4WqqjpW1X9fqCqRa5r6EOs63p8n2HZcZ23UbH5G6c+1aX9vab/z8/wDkNv8ACuR1C18UWcdlqd1dx31zLdo8ukqFWKMc7UhkwDuA6lshj/drei8Z6KUBnmntZejwz28ivGe4YY6/TIPYkc1UsJP/AJd+/wCmv9euz6MSqL7WnqaH9vab/wA/P/kNv8KzdG1vT4/t2+4xuupGHyN049qkPjPQR/y//wDkGT/4msHwJ4vh1C+8QJfGLT4I7sPbpdERSujrncyseM9hgEA880LBV+VzcGku/wB2ncPawulc6z+3tN/5+f8AyG3+FZus63p8n2HZcZ23UbH5G6c+1T2fiO1v/FUmk2U0M6w2YuZXjYMAWfaoyOP4WOPcVY8RSJFHYySuqRrdxlmY4AHPesZ0p02lJWbKUk9UP/t7Tf8An5/8ht/hR/b2m/8APz/5Db/CseTXLjX76K18K3Ki0jLNdan5PmRDHAjiJ+V2JOSQSAAe5FW/7K17/oY//JGP/GtXhuTSpJRfZ3v87J2J9pf4Vci0bW9Pj+3b7jG66kYfI3Tj2rS/t7Tf+fn/AMht/hWBo2ma4wv9niHZi6kB/wBCjOTxz1qxZ6b4n0xfJg1e11SDHD6jEVlU5OfmjwGHIxwMY70KhBrSor/P9UPnf8r/AAKXijWLCXWfDrJcAhLslsqw/hPtzXSf29pv/Pz/AOQ2/wAK4fxKmtjxx4Kl1aWxFv8Aa5Y1jtQ/zMYyckt6BTj6mus1bXLlNRfS9EsPt2oqiyStJII4LdWztMjcnJwSFUE8dhzVSwjTiotO6v5LVrd+n42Eqi1uXP7e03/n5/8AIbf4Vm+Htb0+LR7dHuMMN2Rsb+8faoJ/Ct5qcTS61rt618PmgNkxt4bVxyGVATvI/wCmhbIzwM4qr4Wv/EUGhW0Muix3bpuUzx3aIsuGPzBSMrn07Unh4te5NN9en3Xtf+vUOd9UdH/b2m/8/P8A5Db/AArNvtb09tY0xxcZVfNydjcZX6U6PxNLsAuPD+txTDh0ECyAH2ZWII9xWbe+I7ltd01z4e1hbVfNAkMab2bb2j3bse5H+NT9Uq9vxX+Y/aROi/t7Tf8An5/8ht/hR/b2m/8APz/5Db/Cud1nxNqRvNJSx0y8tLR7yKO7nvIxH8rOqBEGTkktknsFPcitnWvEKabeGzgsL+/vfI88RWsYbgkhcsSAMkEc+lU8HVXLpv59u/YXtY6lbw9renxaPbo9xhhuyNjf3j7Vpf29pv8Az8/+Q2/wrl/DWna1rFpHNqN5PpVjGrJBa2Uw3uSxJeR8fgFHHUnOeNCyvfEOjxm01LTLnWo4m2x31pJEryJ2MkbsuGHQ7cg9QB0oeF0sppvtf9dn8n9+oe07p2Jr7W9PbWNMcXGVXzcnY3GV+laX9vab/wA/P/kNv8KwL3xJu1fTH/sXWl2+b8pteTlR05q5/wAJDq3lfaP+EXv/ALLvx/ro/O27sbvLz+OM5x78UlhKvZfel+o/aRNP+3tN/wCfn/yG3+FZvh7W9Pi0e3R7jDDdkbG/vH2rP1nxNqRu9KWx0y8tLNryGO7uLyMR/K8ioqIMnJLOOfRSOpFW7LXI9N0/TrOO0u76+nSWRLe1CltivgsSzKqjLAZJHWiWEqLl03v17d+3f0EqkXc1/wC3tN/5+f8AyG3+FZv9taf/AMJF5n2j5Psu3Oxuu/6VXutN1fxO4j1gPpOkoQ32S3n/ANInI6b5EOEUHB2qSTjlscVUtz4g0nxE1sYV1qJbXEM7TLDLs39JMjBYdNwxnuAereGVrKa5u1/12b/rXWxz+Wn9dDpf7e03/n5/8ht/hXMeKtZsJdZ0gpPkCK7B+Ru8XHatr+1de/6Fz/yej/wrM1FNX1HULa6vNKWyt7SC5LMblZCS0eAABV0aLptyk1a0vtLs/MUpKWi8uj7lfUdYsFufBrif/V3RSQ7G4U2kw9P7wUV1H9vab/z8/wDkNv8ACqN3YT3tj4ee327rW4hnbJx8vlsrfo1dDWNWScIW6Jr8W/1KirNnDeJL23vdRRraTeFiAJ2kd29aKseMf+QnF/1xH/oTUVgWb3hn/kCW3/Av/QjWnXOaBo1hPpUMssG6RixJ3sM/MfetD+wdN/59v/Ijf40AGof8hvSv+2v/AKCK065q+0TT11jTEFvhW83I3tzhfrWl/YOm/wDPt/5Eb/GgDTrM8M/8gS2/4F/6EaP7B03/AJ9v/Ijf41m+HtE0+XR7d3t8sd2Tvb+8fegDpazP+Zn/AO3P/wBno/sHTf8An2/8iN/jWb/Yun/8JF5f2f5Psu7G9uu/60Ac7An27Ul8OkDyP7Zur24X+9FGyTBcehkniz7Z9a77VP8AkGXn/XF//QTXEaB4Tt08f+KLueA/ZGW3Fuu5uGMY8zn32R/lXSaloenJp10y2+CInI+dvQ+9d+PmpSjGPZN+sld/ovkY0VZNv+rGnpf/ACDLP/rin/oIqzWHpuh6c+nWrNb5JiQn529B71Z/sHTf+fb/AMiN/jXAbB/zM/8A25/+z1p1zX9i6f8A8JF5f2f5Psu7G9uu/wCtaX9g6b/z7f8AkRv8aAOCmjjvNPs9HmRXjGrapdSRkZUxxSzMvHoHkh/KvR9L/wCQZZ/9cU/9BFeeab4TFt4m8VXF1bYsoof9Bbc3zeaC8h69mVR+Ga7DTdD059OtWa3yTEhPzt6D3rvzCalNKLurX+cve/JpP0MaKaWv9W0Nysz/AJmf/tz/APZ6P7B03/n2/wDIjf41m/2Lp/8AwkXl/Z/k+y7sb267/rXAbHS1meJv+QJc/wDAf/QhR/YOm/8APt/5Eb/Gs3xDomnxaPcOlvhhtwd7f3h70Ac7qC/bPFeq+HTu8nU9QiubpQfvWyWsYcfRmjjQj0c+tejgAAADAHauG0rwhZ/8JzrupzW58gwwW0Cl24O3dIevf93/AN81039g6b/z7f8AkRv8a7sbUjLkhHZRX32V/wBF8jKlFq7fdhp//Ib1X/tl/wCgmtOuasdE09tY1NDb5VfKwN7cZX61pf2Dpv8Az7f+RG/xrhNQ8Tf8gS5/4D/6EK065rxDomnxaPcOlvhhtwd7f3h71pf2Dpv/AD7f+RG/xoA4zWU8/XdX0HOE1jU7V5QOph+zgyD6Mtqyn/erstP41vVf+2X/AKDXJyeFLV/ilHdeQfsKaV93c2POErAHP+6zD8vx27HRNPbWNTQ2+VXysDe3GV+td2NmnGnGP8qfzsl+SRjSVnJvudLWZ4m/5Alz/wAB/wDQhR/YOm/8+3/kRv8AGs3xDomnxaPcOlvhhtwd7f3h71wmx0tFZn9g6b/z7f8AkRv8aP7B03/n2/8AIjf40AcQNRl0bxJ4tubWNJLmaK1jt43JCtM080abvYtImcdhXb+HdJTRdLS1WQzTMxluLhhhp5WOXc+5PbsMAcAV59deFluvHWkyww50/wC1XK3YyeBGA8WDn+8f0r0H+wdN/wCfb/yI3+Nd+JmvZQUX8STfy91L8G/mY017zv0/4cNd/wCYf/1+R/1rTrmtZ0TT4/sOy3xuuo1Pzt05960v7B03/n2/8iN/jXAbGnWBpemWF1LqMt1ZWs0hu5BvkiVj27kVc/sHTf8An2/8iN/jWbo2iafJ9u32+dt1Io+dunHvTjJxd07CavuR29raWHjt/s8EFtH/AGXufy0CDiXqcVh2WkWmtWth4g1i0hurrUr1J4ROm8QW5GI0UN0+QKTwMszVH8R/Dqo2mvpNq3mXrtpUxVmzGk2P3vX+DZ/49XRaroWm28enJDbBE+0xpgO2AvPHWvRqVXCjGpGXvSVvNJf56fcYxinJprRfqdKiLGioihUUYCgYAFOrM/sHTf8An2/8iN/jR/YOm/8APt/5Eb/GvNNw0L/mIf8AX5J/StOua0bRNPk+3b7fO26kUfO3Tj3rS/sHTf8An2/8iN/jQBzvj75fEPgtzxt1Q8/WJx/WtD4eoJPDFtqT5a51X/iYTSHq5kAK/gE2KB2CisH4g+GNPv5NGsAjwLc3DIZI3bch25VlJPBBwfwrptL8L6bZabaWnkbvIhSLdvYZ2gDPX2rsdaLwyh9q/wCGr/N7eRlyvnv0N2szwz/yBLb/AIF/6EaP7B03/n2/8iN/jWb4e0TT5dHt3e3yx3ZO9v7x964zU6WszUP+Q3pX/bX/ANBFH9g6b/z7f+RG/wAazb7RNPXWNMQW+Fbzcje3OF+tAEnj35fDhk/543lnP/3xcxPz7fLTdCH2nxb4kveojNvYKf8ArmhlP6zkfUH0qbU/Cuk6jp1zZzW5Ec8bRkh2yMjGRz1HWsrwP4UFj4chj1uISao8kstw6uwDMzsRjB6bdo/Cu6FSKwslfW9retnf5cuvqjJpuon/AF/Wpv8Ahn/kCW3/AAL/ANCNadc14e0TT5dHt3e3yx3ZO9v7x960v7B03/n2/wDIjf41wmoah/yG9K/7a/8AoIrTrmr7RNPXWNMQW+Fbzcje3OF+taX9g6b/AM+3/kRv8aAKHj/5PCtzcH7trLBdsf7oimSQn8AhP4VlfDZVu5tZ1JvmbzxYwse0cYyQPT948n5Cugn8OaVPDJFLaBo5FKspduQRgjrWB8PvCljp/hKxt50M8ymQvKzsC5MjHJwfeuyFWKw0oX96/wCDs393KvvMnFuon0/r/M7asz/mZ/8Atz/9no/sHTf+fb/yI3+NZv8AYun/APCReX9n+T7Luxvbrv8ArXGanS1W1T/kGXn/AFxf/wBBNVf7B03/AJ9v/Ijf41W1LQ9OTTrplt8EROR87eh96ANPS/8AkGWf/XFP/QRVmsPTdD059OtWa3yTEhPzt6D3qz/YOm/8+3/kRv8AGgDB8Y/8hOL/AK4j/wBCaiq/iSyt7LUUW2j2BogSNxPdvWigDpvDP/IEtv8AgX/oRrTrgo9UvbENbW9wRFGzBQUU9z7U7+3tS/5+f/Ia/wCFAHUah/yG9K/7a/8AoIrTrz6XVr6W4gne4PmQ7tnyL3GD2qb+3tS/5+f/ACGv+FAHd1meGf8AkCW3/Av/AEI1y/8Ab2pf8/P/AJDX/CobPVr60tkghuCI1zjKKepz6e9AHoNZn/Mz/wDbn/7PXL/29qX/AD8/+Q1/wqH+1r77Z9q+0HzfL8v7i4xnPpQB6CAATgdarap/yDLz/ri//oJrjf7e1L/n5/8AIa/4UybWtQmhkie5Ox1KnCL0Ix6UAdrpf/IMs/8Arin/AKCKs1wMOtahDDHElydiKFGUXoBj0p/9val/z8/+Q1/woA6j/mZ/+3P/ANnrTrz7+1r77Z9q+0HzfL8v7i4xnPpU39val/z8/wDkNf8ACgDstU/5Bl5/1xf/ANBNGl/8gyz/AOuKf+giuKm1rUJoZInuTsdSpwi9CMelEOtahDDHElydiKFGUXoBj0oA76sz/mZ/+3P/ANnrl/7e1L/n5/8AIa/4VD/a199s+1faD5vl+X9xcYzn0oA9BrM8Tf8AIEuf+A/+hCuX/t7Uv+fn/wAhr/hUN5q19d2zwTXBMbYzhFHQ59PagD0GiuE/t7Uv+fn/AMhr/hR/b2pf8/P/AJDX/CgDqNP/AOQ3qv8A2y/9BNadefRatfRXE86XB8ybbv8AkXsMDtU39val/wA/P/kNf8KAOo8Tf8gS5/4D/wChCtOvPrzVr67tngmuCY2xnCKOhz6e1Tf29qX/AD8/+Q1/woA7vAznHPrWZp//ACG9V/7Zf+gmuX/t7Uv+fn/yGv8AhUMWrX0VxPOlwfMm27/kXsMDtQB6DWZ4m/5Alz/wH/0IVy/9val/z8/+Q1/wqG81a+u7Z4JrgmNsZwijoc+ntQB6DRXCf29qX/Pz/wCQ1/wo/t7Uv+fn/wAhr/hQB1Ghf8xD/r8k/pWnXn1tq19beb5dwf3shkbKL1PXtU39val/z8/+Q1/woA6jXf8AmH/9fkf9a068+udWvrnyvMuD+6kEi4Reo6dqm/t7Uv8An5/8hr/hQB3dZmhf8xD/AK/JP6Vy/wDb2pf8/P8A5DX/AAqG21a+tvN8u4P72QyNlF6nr2oA9AZQ2MgHByMjpWbrv/MP/wCvyP8ArXL/ANval/z8/wDkNf8ACobnVr658rzLg/upBIuEXqOnagD0GiuE/t7Uv+fn/wAhr/hR/b2pf8/P/kNf8KAOo0L/AJiH/X5J/StOvPrbVr6283y7g/vZDI2UXqevapv7e1L/AJ+f/Ia/4UAani3/AJDfhn/r8P8A6DXT15xfXt1e3NnPPcMZLSTzI8Ko5xjnjmrn9val/wA/P/kNf8KAO7rM8M/8gS2/4F/6Ea5f+3tS/wCfn/yGv+FQ2erX1pbJBDcERrnGUU9Tn096APQazNQ/5Delf9tf/QRXL/29qX/Pz/5DX/CoZdWvpbiCd7g+ZDu2fIvcYPagD0GiuE/t7Uv+fn/yGv8AhR/b2pf8/P8A5DX/AAoA6jwz/wAgS2/4F/6Ea068+s9WvrS2SCG4IjXOMop6nPp71N/b2pf8/P8A5DX/AAoA6jUP+Q3pX/bX/wBBFadefS6tfS3EE73B8yHds+Re4we1Tf29qX/Pz/5DX/CgDu6zPDP/ACBLb/gX/oRrl/7e1L/n5/8AIa/4VDZ6tfWlskENwRGucZRT1OfT3oA9BrM/5mf/ALc//Z65f+3tS/5+f/Ia/wCFQ/2tffbPtX2g+b5fl/cXGM59KAPQarap/wAgy8/64v8A+gmuN/t7Uv8An5/8hr/hTJta1CaGSJ7k7HUqcIvQjHpQB2ul/wDIMs/+uKf+girNcDDrWoQwxxJcnYihRlF6AY9Kf/b2pf8APz/5DX/CgC14x/5CcX/XEf8AoTUVViMmrTPLeyuzoqqMBRxk+1FAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram from a patient with chronic Chagas' disease without evidence of heart failure. The 12 lead ECG shows sinus bradycardia, first degree heart block, and the typical combination of right bundle branch block and left anterior hemiblock. Poor R wave progression and abnormal Q wave in V4 suggest the presence of anterior-apical necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31075=[""].join("\n");
var outline_f30_22_31075=null;
var title_f30_22_31076="Lateral neck dissection anatomy";
var content_f30_22_31076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F86365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F86365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Lateral neck dissection anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 520px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31076=[""].join("\n");
var outline_f30_22_31076=null;
var title_f30_22_31077="Appendiceal (ileocecal) mucoceles";
var content_f30_22_31077=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Appendiceal (ileocecal) mucoceles",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31077/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31077/contributors\">",
"     Louis-Michel Wong Kee Song, MD, FRCP(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31077/contributors\">",
"     Norman E Marcon, MD, FRCP(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31077/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31077/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31077/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31077/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/22/31077/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of disorders are associated with lesions in the ileocecal region. Examples frequently encountered in developed countries include colon cancer, Crohn's disease, and less commonly, infection due to Yersinia enterocolitica and Y. pseudotuberculosis. (See related topic reviews.) Many other infectious, neoplastic, and drug-related causes of ileocecal lesions have been described.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of ileocecal mucoceles, which are one of the causes of ileocecal lesions that are frequently considered in specific clinical settings or when more frequent causes have been excluded or are unlikely. The other causes of ileocecal lesions (including tuberculosis, typhlitis, actinomycosis, carcinoid, and lesions due to NSAIDs) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43862?source=see_link\">",
"     \"Tuberculous enteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27125?source=see_link\">",
"     \"Typhlitis (neutropenic enterocolitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38452?source=see_link\">",
"     \"Abdominal actinomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26406?source=see_link\">",
"     \"NSAIDs: Adverse effects on the distal small bowel and colon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appendiceal mucoceles consist of a group of lesions characterized by a distended, mucus-filled appendix. They are rare, accounting for about 0.25 percent of appendectomies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These lesions reportedly show a female predominance and are usually diagnosed in patients in their 50s or 60s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H693912825\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appendiceal mucoceles can be classified into the following four histologic groups, which have relative frequencies of 52, 20, 18, and 10 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. The course and prognosis of appendiceal mucoceles relate to their histologic subtypes.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mucinous cystadenomas, which are morphologically reminiscent of adenomatous colon polyps or villous adenomas.",
"     </li>",
"     <li>",
"      Mucosal hyperplasia, which is histologically similar to a hyperplastic colon polyp.",
"     </li>",
"     <li>",
"      Simple or retention cysts, characterized by degenerative epithelial changes due to obstruction (eg, fecalith) and distention.",
"     </li>",
"     <li>",
"      Mucinous cystadenocarcinomas, which demonstrate glandular invasion into the stroma",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pseudomyxoma peritonei.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An appendiceal mucocele may be discovered as an incidental finding during radiologic, sonographic, or endoscopic evaluation of unrelated complaints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Early diagnosis is rare since the symptoms are nonspecific or absent. The most common symptom is acute or chronic right lower quadrant abdominal pain. An abdominal mass is occasionally palpable. Less common presentations include intermittent colicky pain and gastrointestinal bleeding associated with intussusception of the mucocele, intestinal obstruction from mass effect, acute abdomen from mucocele rupture, sepsis, and genitourinary symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/3,5,9\">",
"     3,5,9",
"    </a>",
"    ]. Early diagnosis and resection are important since some appendiceal mucoceles are malignant and may lead to peritoneal dissemination and the clinical syndrome of pseudomyxoma peritonei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H693912230\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H693912266\">",
"    <span class=\"h2\">",
"     Laboratory data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings are nonspecific but may include anemia and an increased sedimentation rate. Elevated levels of tumor marker (eg, carcinoembryonic antigen (CEA), CA 19-9) have been reported for neoplastic mucoceles. Postoperative monitoring may be useful for the detection of recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Radiologic appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiologic studies, in particular computed tomography (CT) and ultrasound (US), can lead to a presumptive diagnosis of an appendiceal mucocele. However, the findings are nonspecific and the differential diagnosis should include benign appendiceal neoplasms (eg, leiomyoma, fibroma, neuroma, or lipoma), mesenteric or duplication cyst, hydrosalpinx, carcinoid, lymphoma, intussusception, endometriosis, and adenocarcinoma of the appendix, among others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Furthermore, the imaging characteristics cannot distinguish between the histologic subtypes of mucoceles, other than the neoplastic ones (cystadenomas and cystadenocarcinomas), which are generally larger than retention mucoceles. The presence of ascites, hypodense peritoneal implants, and scalloping of the liver surface are predictive of a malignant mucocele with pseudomyxoma peritonei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The typical CT finding is a low attenuation, well encapsulated cystic mass (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86272 \" href=\"mobipreview.htm?13/50/14117\">",
"       image 1",
"      </a>",
"      ). The absence of periappendiceal inflammation or abscess is a key differential point in excluding acute appendicitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. In addition, the presence of curvilinear or punctate wall calcification at the expected site of the appendix strongly suggests an appendiceal mucocele [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/11\">",
"       11",
"      </a>",
"      ]. In one study, CT features suggestive of a coexisting mucocele in patients with acute appendicitis included cystic dilatation of the appendix, mural calcification, and a luminal diameter greater than 1.3 cm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      US is valuable in demonstrating the cystic nature of the lesion. US can also demonstrate variable internal echogenicity depending upon its composition (thin and watery to gelatinous and viscous). The primary differentiation from uncomplicated acute appendicitis is the lack of appendiceal wall thickening of &gt;6 mm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/11\">",
"       11",
"      </a>",
"      ]. Nodular enhancing lesions in the wall of the mucocele may suggest a malignant behavior [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema may demonstrate a smooth cecal filling defect without contrast filling of the appendix or associated ulceration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;At endoscopy, an extrinsic or submucosal lesion may be suspected based upon smooth indentation into the cecal lumen, which may be the only sign of a mucocele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/15\">",
"     15",
"    </a>",
"    ]. When poked with the biopsy forceps, the lesion may be firm in consistency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/6\">",
"     6",
"    </a>",
"    ] or soft with a cushion sign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/8\">",
"     8",
"    </a>",
"    ]. The appearance of the appendiceal orifice in the center of the mound has been labeled as the \"volcano sign\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/6\">",
"     6",
"    </a>",
"    ]. An occasional and highly suggestive endoscopic finding is that of a glossy, rounded, balloon-shaped mass protruding from the appendiceal orifice and moving in and out of the latter with respiration (",
"    <a class=\"graphic graphic_picture graphicRef86273 \" href=\"mobipreview.htm?26/48/27407\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/7\">",
"     7",
"    </a>",
"    ]. An outpouring of inflammatory exudate from the appendiceal orifice may be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/16\">",
"     16",
"    </a>",
"    ]. As a general rule, the overlying mucosa is normal and mucosal biopsies are not usually done. If available, an endosonographic probe can disclose the cystic nature of the mucocele at the time of colonoscopy. Solid lesions such as carcinoids, lipomas, and lymphangiomas can thus be ruled out. Moreover, stromal invasion may perhaps be detected, which would predict the malignant behavior of the mucocele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for any appendiceal mucocele is surgical resection (",
"    <a class=\"graphic graphic_picture graphicRef86274 \" href=\"mobipreview.htm?36/23/37239\">",
"     picture 2",
"    </a>",
"    ), since lesions that appear to be benign on imaging studies may harbor changes of a cystadenocarcinoma. In addition, rupture of a neoplastic mucocele, in particular a cystadenocarcinoma, may result in pseudomyxoma peritonei. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\"",
"    </a>",
"    .) The latter is a morbid and often recurring disease, in which implants of mucinous epithelium on peritoneal surfaces produce mucinous ascites, with adhesions and intestinal obstruction as complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, a preoperative diagnosis of mucocele is helpful to the surgeon to ensure careful handling and resection of the lesion while avoiding peritoneal contamination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival is excellent (91 to 100 percent) after standard appendectomy of retention cysts, mucosal hyperplasia, or cystadenoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/3,4,17\">",
"     3,4,17",
"    </a>",
"    ]. Even in the presence of a cystadenocarcinoma without mesenteric or adjacent organ involvement, standard appendectomy with resection of the appendiceal mesentery appears to be adequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/17\">",
"     17",
"    </a>",
"    ]. A right hemicolectomy is indicated in patients with a complicated mucocele with involvement of the terminal ileum or cecum. If a ruptured mucocele is found intraoperatively, the lesion should be excised and all mucinous peritoneal implants removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]. Pseudomyxoma peritonei should be aggressively treated with surgical debulking to remove all gelatinous masses or involved organs (eg, ovaries) within the abdominal cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/3\">",
"     3",
"    </a>",
"    ]. The use of adjuvant radio- or chemotherapy in this setting is not well defined. Retrospective data from small cohorts of patients with pseudomyxoma peritonei treated using a combination of these approaches demonstrate a 53 to 75 percent five-year survival and a lower 10-year survival of 10 to 32 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association between appendiceal mucoceles and other tumors involving the gastrointestinal tract, ovary, breast, and kidney has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. In particular, colonic adenocarcinoma may be concurrently found in about 20 percent of patients with appendiceal mucoceles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31077/abstract/2,21\">",
"     2,21",
"    </a>",
"    ], and this possibility should be evaluated either preoperatively or intraoperatively. Similarly, careful examination of the ovaries is imperative at the time of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appendiceal mucoceles consist of a rare group of lesions characterized by a distended, mucus-filled appendix. They can be classified into four histologic groups. The course and prognosis of appendiceal mucoceles relate to their histologic subtypes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An appendiceal mucocele may be discovered as an incidental finding during radiologic, sonographic, or endoscopic evaluation of unrelated complaints. Early diagnosis is rare since the symptoms are nonspecific or absent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with an appendiceal mucocele undergo surgical resection, since lesions that appear to be benign on imaging studies may harbor changes of a cystadenocarcinoma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard appendectomy is indicated in patients with retention cysts, mucosal hyperplasia, or cystadenoma. In the presence of a cystadenocarcinoma without mesenteric or adjacent organ involvement, resection of the appendiceal mesentery is also indicated. A right hemicolectomy is indicated in patients with a complicated mucocele with involvement of the terminal ileum or cecum. If a ruptured mucocele is found intraoperatively, the lesion should be excised and all mucinous peritoneal implants removed. Pseudomyxoma peritonei should be aggressively treated with surgical debulking to remove all gelatinous masses or involved organs (eg, ovaries) within the abdominal cavity. The use of adjuvant radio- or chemotherapy in this setting is not well defined. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colonic adenocarcinoma and other tumors involving the gastrointestinal tract, ovary, breast, and kidney may be concurrently found in patients with appendiceal mucoceles. This possibility should be evaluated either preoperatively or intraoperatively. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/1\">",
"      Aho AJ, Heinonen R, Laur&eacute;n P. Benign and malignant mucocele of the appendix. Histological types and prognosis. Acta Chir Scand 1973; 139:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/2\">",
"      Higa E, Rosai J, Pizzimbono CA, Wise L. Mucosal hyperplasia, mucinous cystadenoma, and mucinous cystadenocarcinoma of the appendix. A re-evaluation of appendiceal \"mucocele\". Cancer 1973; 32:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/3\">",
"      Landen S, Bertrand C, Maddern GJ, et al. Appendiceal mucoceles and pseudomyxoma peritonei. Surg Gynecol Obstet 1992; 175:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/4\">",
"      Qizilbash AH. Mucoceles of the appendix. Their relationship to hyperplastic polyps, mucinous cystadenomas, and cystadenocarcinomas. Arch Pathol 1975; 99:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/5\">",
"      Isaacs KL, Warshauer DM. Mucocele of the appendix: computed tomographic, endoscopic, and pathologic correlation. Am J Gastroenterol 1992; 87:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/6\">",
"      Hamilton DL, Stormont JM. The volcano sign of appendiceal mucocele. Gastrointest Endosc 1989; 35:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/7\">",
"      Raijman I, Leong S, Hassaram S, Marcon NE. Appendiceal mucocele: endoscopic appearance. Endoscopy 1994; 26:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/8\">",
"      Mizuma N, Kabemura T, Akahoshi K, et al. Endosonographic features of mucocele of the appendix: report of a case. Gastrointest Endosc 1997; 46:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/9\">",
"      Mourad FH, Hussein M, Bahlawan M, et al. Intestinal obstruction secondary to appendiceal mucocele. Dig Dis Sci 1999; 44:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/10\">",
"      Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 2008; 34:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/11\">",
"      Madwed D, Mindelzun R, Jeffrey RB Jr. Mucocele of the appendix: imaging findings. AJR Am J Roentgenol 1992; 159:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/12\">",
"      Zissin R, Gayer G, Kots E, et al. Imaging of mucocoele of the appendix with emphasis on the CT findings: a report of 10 cases. Clin Radiol 1999; 54:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/13\">",
"      Bennett GL, Tanpitukpongse TP, Macari M, et al. CT diagnosis of mucocele of the appendix in patients with acute appendicitis. AJR Am J Roentgenol 2009; 192:W103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/14\">",
"      Kim SH, Lim HK, Lee WJ, et al. Mucocele of the appendix: ultrasonographic and CT findings. Abdom Imaging 1998; 23:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/15\">",
"      Zanati SA, Martin JA, Baker JP, et al. Colonoscopic diagnosis of mucocele of the appendix. Gastrointest Endosc 2005; 62:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/16\">",
"      Nakagawa T. Colonoscopic diagnosis of mucocele of the appendix. Gastrointest Endosc 1993; 39:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/17\">",
"      Soweid AM, Clarkston WK, Andrus CH, Janney CG. Diagnosis and management of appendiceal mucoceles. Dig Dis 1998; 16:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/18\">",
"      Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994; 219:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/19\">",
"      Smith JW, Kemeny N, Caldwell C, et al. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1992; 70:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/20\">",
"      Fernandez RN, Daly JM. Pseudomyxoma peritonei. Arch Surg 1980; 115:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31077/abstract/21\">",
"      Wolff M, Ahmed N. Epithelial neoplasms of the vermiform appendix (exclusive of carcinoid). II. Cystadenomas, papillary adenomas, and adenomatous polyps of the appendix. Cancer 1976; 37:2511.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2581 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31077=[""].join("\n");
var outline_f30_22_31077=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H693912825\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H693912230\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H693912266\">",
"      Laboratory data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Radiologic appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2581\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2581|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/50/14117\" title=\"diagnostic image 1\">",
"      Contrast-enhanced CT of appendiceal mucocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2581|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/48/27407\" title=\"picture 1\">",
"      Endoscopic view of appendiceal mucocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/23/37239\" title=\"picture 2\">",
"      Appendiceal mucocele",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38452?source=related_link\">",
"      Abdominal actinomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26406?source=related_link\">",
"      NSAIDs: Adverse effects on the distal small bowel and colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43862?source=related_link\">",
"      Tuberculous enteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27125?source=related_link\">",
"      Typhlitis (neutropenic enterocolitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_22_31078="Treatment of adrenal insufficiency in children";
var content_f30_22_31078=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of adrenal insufficiency in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31078/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31078/contributors\">",
"     Patricia A Donohoue, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31078/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31078/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31078/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31078/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/22/31078/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal insufficiency is defined by the impaired synthesis and release of adrenocortical hormones. It is classified based upon the mechanism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary adrenal insufficiency, also known as Addison's disease, results from disease intrinsic to the adrenal cortex (",
"      <a class=\"graphic graphic_table graphicRef81494 \" href=\"mobipreview.htm?3/12/3277\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Central adrenal insufficiency is caused by impaired production or action of adrenocorticotropic hormone (ACTH). It can be caused by several mechanisms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Secondary adrenal insufficiency results from pituitary disease impairing release of adrenocorticotropic hormone (ACTH). In addition, unresponsiveness of end-organs to adrenocortical hormones is classified as secondary adrenal insufficiency because this presents in a similar manner as diseases caused by adrenocorticotropic hormone (ACTH) deficiencies (",
"      <a class=\"graphic graphic_table graphicRef56675 \" href=\"mobipreview.htm?34/51/35643\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tertiary adrenal insufficiency results from the impaired release or effect of corticotropin releasing hormone (CRH) from the hypothalamus (",
"      <a class=\"graphic graphic_table graphicRef54164 \" href=\"mobipreview.htm?41/14/42219\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical findings of children with adrenal insufficiency include fatigue and gastrointestinal complaints of nausea and vomiting. Additional symptoms can be categorized based upon the specific hormones affected (",
"    <a class=\"graphic graphic_table graphicRef66355 \" href=\"mobipreview.htm?6/34/6700\">",
"     table 4",
"    </a>",
"    ). Signs of mineralocorticoid deficiency (hypotension, dehydration, and electrolyte abnormalities) are often observed in patients with primary adrenal insufficiency.",
"   </p>",
"   <p>",
"    The most common cause of adrenal insufficiency in infants is classic congenital adrenal hyperplasia, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/0/31754?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of adrenal insufficiency will be discussed in this topic review. The causes, clinical manifestations, and diagnosis of adrenal insufficiency are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17255?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=see_link\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27238?source=see_link\">",
"     \"Causes and clinical manifestations of central adrenal insufficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with primary adrenal insufficiency, treatment includes physiologic replacement with glucocorticoid and mineralocorticoid. Glucocorticoid dosing must be increased during times of stress. Patients with secondary adrenal insufficiency require only glucocorticoid replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer to use",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    for glucocorticoid replacement for most infants and children because of its short duration of action and lower potency, allowing for fine titration to the optimal dose. Based on the estimates of normal cortisol secretion rate of 7 to 12",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31078/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], using the body surface area which is calculated from a child&rsquo;s height and weight using a nomogram or calculator (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?4/27/4529?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). This dose is adjusted up or down depending on clinical response and growth rate, such that a child with a body-surface area of 1 m",
"    <sup>",
"     2",
"    </sup>",
"    requires a dose of 5 to 16",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of parenteral cortisol equivalent. Because of the short half-life of hydrocortisone (cortisol) given orally, and its partial destruction by gastric acidity, the daily oral replacement dose is 1.5 to 2 times that of the normal daily cortisol secretion rate (ie, 10 to 24",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /24",
"    </span>",
"    h) (",
"    <a class=\"graphic graphic_table graphicRef53011 \" href=\"mobipreview.htm?23/63/24571\">",
"     table 5",
"    </a>",
"    ). The total daily oral hydrocortisone dose is usually divided into three doses and administered every eight hours. &nbsp;",
"   </p>",
"   <p>",
"    Instead of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , one also can use oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    . These synthetic glucocorticoids are about five times more potent than hydrocortisone (daily dose 3 to 5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per 24 hours). In addition, they have a longer half-life than hydrocortisone, which makes it possible to administer doses every 12 hours. Other more potent synthetic glucocorticoid preparations, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , are not often used for replacement therapy except in adults. Their great potency makes it difficult to titrate the appropriate dose for children. Prednisolone, prednisone, and dexamethasone lack significant mineralocorticoid activity (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"mobipreview.htm?41/61/42972\">",
"     table 6",
"    </a>",
"    ). If these glucocorticoids are chosen for treatment of patients with primary adrenal insufficiency, the treatment regimen also must include a mineralocorticoid such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/32/44549?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    (9-alpha-fluorocortisol). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/0/31754?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Mineralocorticoids'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    The data regarding normal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    production rates are helpful in estimating an approximate initial replacement dose of hydrocortisone equivalent, but the dose for long-term replacement must be adjusted to the requirement of individual subjects, as indicated by biochemical and physiologic response to treatment. The glucocorticoid dose will need to be adjusted upwards to keep pace with a child's growth. During infancy, the glucocorticoid requirements, adjusted for body surface area, are higher relative to other age groups.",
"   </p>",
"   <p>",
"    For patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, the doses of glucocorticoid required to suppress the ACTH-stimulated excessive adrenal androgens are usually higher than those required for other causes of adrenal insufficiency; the optimal dose is usually determined by the concentrations of 17-hydroxyprogesterone and androstenedione",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    testosterone in prepubertal children and pubertal females) in plasma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/0/31754?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with primary adrenal failure of other etiologies, the close follow-up of somatic growth (weight, bone age, and height and weight velocities) provides the most important guidelines for dose adjustment. &nbsp;In general, inadequate weight gain or recurrent symptoms of glucocorticoid deficiency (",
"    <a class=\"graphic graphic_table graphicRef66355 \" href=\"mobipreview.htm?6/34/6700\">",
"     table 4",
"    </a>",
"    ) suggest the need for increased dose of glucocorticoid or mineralocorticoid. The need for higher doses of cortisol replacement would be supported by the presence of increasing hyperpigmentation, and a marked elevation of the plasma ACTH level (more than 10 times the upper limit of normal). Signs and symptoms suggesting the need for adjustment of mineralocorticoid replacement are discussed below.",
"   </p>",
"   <p>",
"    Excessive weight gain with decreased height velocity, facial plethora, or other symptoms or signs of Cushing's syndrome indicate excessive glucocorticoid replacement. In patients with adequate replacement therapy, measurements of plasma ACTH are typically above the normal range and we do not find them helpful for routine monitoring.",
"   </p>",
"   <p>",
"    Central (secondary or tertiary) adrenal insufficiency, which is characterized by ACTH deficiency, is treated with glucocorticoid at physiologic replacement doses in the lower end of the expected dose range. The dose must be titrated carefully to prevent overtreatment, which seems to occur at lower doses in children with ACTH deficiency than in those with primary adrenal failure. Mineralocorticoid treatment is generally unnecessary, as these patients have a normal renin-angiotensin-aldosterone axis and hence normal mineralocorticoid secretion. The growth rates in weight and height, and general clinical well-being are the most useful parameters to follow for dose adjustments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mineralocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary adrenal failure require mineralocorticoid replacement with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/32/44549?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    (9-alpha-fluorocortisol). The usual daily dose is 0.1 mg; however, higher doses are occasionally needed in infants, or in patients treated with glucocorticoids having little or no mineralocorticoid activity (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"mobipreview.htm?41/61/42972\">",
"     table 6",
"    </a>",
"    ). The mineralocorticoid dose is not adjusted by age or surface area because the aldosterone secretion rate is nearly constant throughout the lifespan. However, infants younger than 1 year may require sodium chloride supplementation at a dose of approximately 1 gram (17 mEq) daily, due to relatively low dietary sodium intake in formula and breast milk and a relative renal resistance to mineralocorticoids in this age group.",
"   </p>",
"   <p>",
"    Signs and symptoms of inadequate mineralocorticoid replacement include dehydration, poor weight gain, salt-craving, hyponatremia with hyperkalemia, and marked elevation of plasma renin activity (PRA). Routine measurement of PRA is not generally useful in monitoring adequacy of treatment because its levels tend to be variable, based on posture and sodium intake, and are often above the normal range even in patients who are receiving adequate replacement therapy. However, on occasion, measurements of these hormones may be useful in monitoring compliance with therapy, or in response to an unexplained change in clinical status.",
"   </p>",
"   <p>",
"    Children with secondary adrenal insufficiency do not have mineralocorticoid deficiency because ACTH is not an important regulator of aldosterone release. Treatment with mineralocorticoids is not necessary. However, these patients may have deficiencies of other pituitary hormones that may require replacement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17255?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of adrenal insufficiency in children\", section on 'Evaluation for cause'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     STRESS CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary, secondary, or tertiary adrenal insufficiency require additional doses of glucocorticoids when subjected to physiologic stress. In this setting, the primary goal of treatment is to avoid the serious consequence of adrenal crisis. Clinical experience suggests that the treatment regimens described below provide ample glucocorticoid coverage for acute stress, but ongoing monitoring and treatment are required if the physiological stress is prolonged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low-grade fever (sore throat, rhinorrhea, fever up to 38&ordm;C) may not require a change in dose. During conditions of moderate stress (eg, severe upper respiratory infections), the dose should be double the usual glucocorticoid replacement dose. In major stress (eg, temperature above 38&ordm;C",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting), the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    dose should be increased to three to four times the normal replacement.",
"   </p>",
"   <p>",
"    Under stress conditions, infants and children frequently are unable to tolerate oral therapy. In such cases, the parents are advised to administer an intramuscular injection of approximately 50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    sodium succinate (SoluCortef&reg;). Alternatively, a simpler age-based dose regimen can be used:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &lt;3 years: 25 mg",
"     </li>",
"     <li>",
"      3 to 12 years: 50 mg",
"     </li>",
"     <li>",
"      12 years and older: 100 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This treatment will provide up to six hours of coverage, and allow the family time to get medical attention.",
"   </p>",
"   <p>",
"    Every patient should wear a medical identification bracelet or necklace (eg, MedicAlert&reg;) and carry the emergency medical information card that is supplied with it. Both should indicate the diagnosis \"adrenal insufficiency\" and the clinician to call in the event of an emergency. Patients can enroll in MedicAlert&reg; by calling (888) 525-5176 or through the Internet at",
"    <a class=\"external\" href=\"file://www.medicalert.org/\">",
"     www.medicalert.org",
"    </a>",
"    (United States) and",
"    <a class=\"external\" href=\"file://www.medicalert.ca/\">",
"     www.medicalert.ca/",
"    </a>",
"    (Canada).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surgical procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;During general anesthesia, with or without surgery, the cortisol secretion rate in normal subjects increases greatly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31078/abstract/3\">",
"     3",
"    </a>",
"    ]. Similarly, in patients with adrenal insufficiency, the glucocorticoid requirement increases.",
"   </p>",
"   <p>",
"    Although protocols vary, the following protocol from the consensus conference for congenital adrenal hyperplasia is recommended for surgeries that do not last longer than 30 to 45 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31078/abstract/4\">",
"     4",
"    </a>",
"    ]. The initial dose is given as an IV bolus, followed by a continuous IV infusion. The stress doses of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    are tapered rapidly according to the clinical improvement, generally by reducing the dose by 50 percent each day.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 3 years:",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"       Hydrocortisone",
"      </a>",
"      25 mg IV",
"     </li>",
"     <li>",
"      3 years to 12 years:",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"       Hydrocortisone",
"      </a>",
"      50 mg IV",
"     </li>",
"     <li>",
"      12 years and older:",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"       Hydrocortisone",
"      </a>",
"      100 mg IV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial bolus is followed by the same dose at a constant rate over a 24-hour period. For surgeries lasting longer than 30 to 45 minutes, we suggest using a protocol that includes a continuous infusion of glucocorticoid, such as the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31078/abstract/5\">",
"     5",
"    </a>",
"    ]: A rapid injection of 25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    sodium succinate (eg, SoluCortef&reg;) is given IV just prior to anesthesia and is followed by a dose of approximately 50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    as a constant infusion for the period of the surgical procedure. If the patient will not be able to take oral hydrocortisone post-operatively, a third dose of approximately 25 to 50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    hydrocortisone is given as a constant IV infusion for the rest of the first 24 hours of the surgical day. This is followed the next day by three to four times replacement therapy hydrocortisone given by constant IV infusion or orally. If the patient experiences significant hypotension or electrolyte abnormalities, additional hydrocortisone may be needed.",
"   </p>",
"   <p>",
"    These high doses will provide the needed extra glucocorticoid as well as mineralocorticoid coverage, as parenteral preparations with purely mineralocorticoid effects are not available.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     Hydrocortisone",
"    </a>",
"    20 mg has approximately the same mineralocorticoid effect as 0.1 mg of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/32/44549?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    (9-alpha-flurorocortisol). Stress dosing is generally continued until the patient can tolerate oral intake, is afebrile, and is hemodynamically stable. The timing is dictated by the nature of the surgery and expected recovery time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADRENAL CRISIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapid recognition and prompt therapy of a salt-losing crisis are critical to survival. Electrolyte and fluid therapy must be instituted as soon as possible. A rapid overview guiding the recognition and treatment of adrenal crisis is shown in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef61357 \" href=\"mobipreview.htm?22/54/23405\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The predominant manifestations of adrenal crisis are hypotension and shock, usually with hyponatremia and hyperkalemia. Patients often have nonspecific symptoms such as anorexia, nausea, vomiting, abdominal pain, weakness, fatigue, lethargy, fever, confusion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coma (",
"    <a class=\"graphic graphic_table graphicRef78490 \" href=\"mobipreview.htm?3/53/3931\">",
"     table 8",
"    </a>",
"    ). It is precipitated by mineralocorticoid deficiency. Thus, adrenal crisis can occur in patients who are receiving physiologic or even pharmacologic doses of synthetic glucocorticoid if their mineralocorticoid requirements are not met.",
"   </p>",
"   <p>",
"    Adrenal crisis is most likely to occur in primary adrenal insufficiency because of the associated mineralocorticoid deficiency and salt loss. However, patients with central adrenal insufficiency also may present in crisis with hypotension and shock, and require stress steroid coverage to prevent this. Such patients do not have the electrolyte disturbances and severe dehydration that is seen when patients with primary adrenal insufficiency have adrenal crisis. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    In infants presenting with adrenal crisis, the cause may be classic congenital adrenal hyperplasia; the evaluation and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/0/31754?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\"",
"    </a>",
"    .) However, with the availability of newborn screening, most of these infants are diagnosed before adrenal crisis occurs.",
"   </p>",
"   <p>",
"    For infants and children with salt-losing crisis not caused by congenital adrenal hyperplasia, we suggest the following measures be instituted as soon as an adrenal crisis is suspected:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Baseline samples &mdash; Samples should be drawn for urgent testing of electrolytes and glucose. In patients without a diagnosis of adrenal insufficiency, additional blood samples must be obtained for the measurement of serum cortisol and plasma ACTH prior to the administration of glucocorticoid therapy.",
"     </li>",
"     <li>",
"      Fluids and electrolytes &mdash; Give a bolus of 5 percent dextrose with 0.9 percent saline, without potassium (D5 NS), 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      intravenously over one hour. This will improve the hyponatremic dehydration, as well as hypoglycemia if present. The potassium concentration usually remains elevated and the acidosis may persist. It may be necessary to use insulin and glucose or a sodium-potassium exchange resin such as Kayexalate&reg; if the hyperkalemia is associated with EKG changes.",
"     </li>",
"     <li>",
"      Glucocorticoid and mineralocorticoids &mdash; Treatment with a glucocorticoid should be initiated as soon as possible, and is given as an intravenous bolus over several minutes. We use",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      sodium succinate (SoluCortef&reg;) at the following doses:",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infants and toddlers 0 to 3 years old: 25 mg",
"     </li>",
"     <li>",
"      Children 3 to 12 years old: 50 mg",
"     </li>",
"     <li>",
"      Children and adolescents 12 years and older: 100 mg",
"      <br/>",
"      <br/>",
"      The initial bolus is followed by the same dose at a constant rate over a 24-hour period. Throughout the treatment, electrolytes and water balance must be monitored very carefully to prevent water retention and its complications. After the initial crisis is treated, then a maintenance dose of glucocorticoid can be calculated and initiated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/56/19330?source=see_link\">",
"       \"Patient information: Congenital adrenal hyperplasia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with adrenal insufficiency require glucocorticoid replacement. Maintenance doses of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      for patients with primary adrenal insufficiency are approximately 10 to 24",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per 24 hours when given orally (",
"      <a class=\"graphic graphic_table graphicRef53011 \" href=\"mobipreview.htm?23/63/24571\">",
"       table 5",
"      </a>",
"      ), or the equivalent dose of other glucocorticoid preparations (",
"      <a class=\"graphic graphic_table graphicRef64138 \" href=\"mobipreview.htm?41/61/42972\">",
"       table 6",
"      </a>",
"      ). Patients with ACTH deficiency generally require lower daily doses. The total daily oral hydrocortisone dose is divided into three doses and administered every eight hours. The optimal dose depends on the type of adrenal insufficiency and should be titrated to the individual patient's needs depending on the clinical response. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For infants and children with primary adrenal insufficiency we suggest treatment with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      rather than",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The relatively low potency and short duration of action of hydrocortisone allows for fine titration of the dose. Longer-acting synthetic glucocorticoids such as prednisone and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      may be used in older adolescents and adults, but lack mineralocorticoid effects and must be combined with separate mineralocorticoid replacement. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with primary adrenal insufficiency also require mineralocorticoid replacement. The dose of mineralocorticoid depends on the type of glucocorticoid given concurrently, and is further adjusted based on the clinical response. Doses of mineralocorticoid may need to be adjusted to optimize growth in height and weight, prevent salt-craving, and maintain normal electrolytes, especially in infants. In most children and adolescents, the mineralocorticoid dose is close to 0.1",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and does not need frequent adjustment. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mineralocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoid doses must be increased during physiologic stress using doses ranging from two to four times the replacement dose, depending on the stressor. Children who are unable to tolerate oral therapy should be given an intramuscular injection of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      sodium succinate (SoluCortef&reg;) to meet their urgent need, but should then seek medical attention. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Stress conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General anesthesia sharply increases glucocorticoid requirements, in addition to the stress of surgery itself. Typical regimens for corticosteroid replacement during surgery include an intravenous bolus at the beginning of surgery, followed by variable regimens postoperatively depending on the length of the surgery and the degree of surgical stress. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Surgical procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adrenal crisis is generally precipitated by mineralocorticoid deficiency in patients with primary adrenal failure. The predominant clinical finding is hypotension or shock, often with hyponatremia and hyperkalemia (",
"      <a class=\"graphic graphic_table graphicRef78490 \" href=\"mobipreview.htm?3/53/3931\">",
"       table 8",
"      </a>",
"      ). Patients with central adrenal insufficiency may present in crisis with hypotension and shock, without significant electrolyte imbalance or dehydration. Such patients should be urgently treated with fluid boluses and a glucocorticoid, as described in the rapid overview (",
"      <a class=\"graphic graphic_table graphicRef61357 \" href=\"mobipreview.htm?22/54/23405\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Adrenal crisis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31078/abstract/1\">",
"      Kenny FM, Preeyasombat C, Migeon CJ. Cortisol production rate. II. Normal infants, children, and adults. Pediatrics 1966; 37:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31078/abstract/2\">",
"      Linder BL, Esteban NV, Yergey AL, et al. Cortisol production rate in childhood and adolescence. J Pediatr 1990; 117:892.",
"     </a>",
"    </li>",
"    <li>",
"     Oyama T. Influence of general anesthesia and surgical stress on endocrine function. In: Anesthesia and the patient with endocrine disease, Brown BR (Ed), F.A. Davis Company, Philadelphia 1980. p.173.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31078/abstract/4\">",
"      Joint LWPES/ESPE CAH Working Group.. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002; 87:4048.",
"     </a>",
"    </li>",
"    <li>",
"     Donohoue PA. Adrenal disorders. In: Pediatric Practice Endocrinology, Kappy MS, Allen DB, Geffner ME.  (Eds), McGraw Hill Medical, New York 2010. p.132-190.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5825 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31078=[""].join("\n");
var outline_f30_22_31078=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mineralocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      STRESS CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADRENAL CRISIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5825\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5825|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/12/3277\" title=\"table 1\">",
"      Cause prim adrenal insufficienc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/51/35643\" title=\"table 2\">",
"      Causes secondary adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/14/42219\" title=\"table 3\">",
"      Causes of tertiary adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/34/6700\" title=\"table 4\">",
"      Signs adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/63/24571\" title=\"table 5\">",
"      Glucocorticoid replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/61/42972\" title=\"table 6\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/54/23405\" title=\"table 7\">",
"      Rapid overview adrenal crisis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/53/3931\" title=\"table 8\">",
"      Signs of adrenal crisis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?4/27/4529?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body Surface Area (Mosteller, square root method)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27238?source=related_link\">",
"      Causes and clinical manifestations of central adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17255?source=related_link\">",
"      Diagnosis of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/56/19330?source=related_link\">",
"      Patient information: Congenital adrenal hyperplasia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/0/31754?source=related_link\">",
"      Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_22_31079="Diagnosis of juvenile dermatomyositis and polymyositis";
var content_f30_22_31079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of juvenile dermatomyositis and polymyositis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31079/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31079/contributors\">",
"     Clare Hutchinson, MDCM, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31079/contributors\">",
"     Brian M Feldman, MD, MSc, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31079/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31079/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31079/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31079/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31079/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/22/31079/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile dermatomyositis (JDM) and juvenile polymyositis (JPM) are rare autoimmune myopathies affecting children. JDM is characterized primarily as a capillary vasculopathy, whereas JPM involves direct T-cell invasion of muscle fibers similar to that seen in adult polymyositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    JDM is the more common of the two disorders accounting for approximately 85 percent of idiopathic inflammatory myopathies of childhood. JPM accounts for only 3 to 6 percent of cases.",
"   </p>",
"   <p>",
"    The diagnosis of JDM and JPM will be reviewed here. The pathogenesis, clinical manifestations, and treatment of these disorders are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/5/2138?source=see_link\">",
"     \"Treatment and prognosis of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1975, Bohan and Peter proposed a classification schema and diagnostic criteria for the various forms of myositis including JDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/3\">",
"     3",
"    </a>",
"    ]. Their diagnostic criteria for JDM included all of the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symmetrical weakness of the proximal muscles",
"     </li>",
"     <li>",
"      Characteristic cutaneous changes, consisting of heliotrope dermatitis (reddish-purple rash on the upper eyelids with periorbital edema) and Gottron's papules (erythematous, papulosquamous eruption over the dorsal surfaces of the knuckles) (",
"      <a class=\"graphic graphic_picture graphicRef52062 \" href=\"mobipreview.htm?8/3/8243\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Elevation of the serum level of one of the muscle enzymes",
"     </li>",
"     <li>",
"      Electromyography (EMG) demonstrating denervation and myopathy",
"     </li>",
"     <li>",
"      Muscle biopsy displaying necrosis and inflammation, as seen in panel A (",
"      <a class=\"graphic graphic_picture graphicRef63190 \" href=\"mobipreview.htm?0/23/377\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, EMG and muscle biopsy are no longer used as frequently because of their invasive nature, especially in patients with the classical clinical features of JDM (ie, characteristic rash and proximal muscle weakness). In an international survey of pediatric rheumatologists published in 2006, all respondents routinely utilized the clinical features of JDM to make the diagnosis of JDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/4\">",
"     4",
"    </a>",
"    ]. Elevated serum muscle enzymes, muscle biopsy and EMG were used as diagnostic aids in 87, 61, and 55 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, magnetic resonance imaging (MRI) was rated as a very useful tool in the diagnosis of JDM, but for some, access to this modality was limited.",
"   </p>",
"   <p>",
"    The diagnostic criteria for JPM were similar to those described for JDM except that the cutaneous findings are absent in patients with JPM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of JDM is clinically based upon the presence of symmetric, proximal muscle weakness, and characteristic heliotrope rash and Gottron's papules. The diagnosis of JPM is more challenging because of the lack of cutaneous manifestations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the presence of nail capillary changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/5\">",
"     5",
"    </a>",
"    ], elevation of muscle enzymes, and an electromyogram demonstrating denervation and myopathy are supportive of the diagnosis of these disorders. Increasingly, magnetic resonance imaging is being used as a diagnostic tool in childhood inflammatory myopathy. A muscle biopsy may be used to confirm the diagnosis whenever the clinical evaluation and initial laboratory testing are inconclusive. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Our approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the diagnosis of JDM typically is based upon the characteristic findings of symmetric proximal muscle weakness and its distinctive rashes, the physical examination is the key diagnostic component. In addition, careful examination of the nailfolds may detect abnormalities that are supportive of a diagnosis of JDM though not diagnostic for JDM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic diagnostic rashes of JDM include a heliotrope reddish-purple rash on the upper eyelids with periorbital edema and Gottron's papules (erythematous, papulosquamous eruption over the dorsal surfaces of the knuckles), (",
"    <a class=\"graphic graphic_picture graphicRef52062 \" href=\"mobipreview.htm?8/3/8243\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\", section on 'Rash'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Muscle strength",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing of weakness is essential in assessing any child with suspected or confirmed JDM or JPM because symmetrical proximal muscle weakness is a diagnostic requirement.",
"   </p>",
"   <p>",
"    A standardized confrontational muscle strength testing score of eight muscle groups, the MMT8, has been validated for use in assessing strength in JDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Childhood Myositis Assessment Scale (CMAS) is a clinical assessment tool that provides an objective measure of muscle strength. The CMAS tests function and endurance by having a child complete a number of different physical maneuvers that assess primarily axial and proximal muscle groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/7\">",
"     7",
"    </a>",
"    ]. A score is assigned from 0 to 51, with a higher score indicating greater strength. In a validation study of 10 children with JDM or JPM and 12 physicians, the CMAS was found to correlate with the physician global assessment of disease activity, manual muscle testing, and serum CK level, with excellent intra- and inter-rater reliability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CMAS may be used for serial assessments of patients with JDM and JPM to monitor response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nailfold capillaroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nailfold capillaroscopy is easily performed at the bedside or in clinic. A drop of oil or lubricant is placed on the patient's fingernail bed, and a light microscope or ophthalmoscope (set on the highest level of magnification) is used to assess nailfold capillary dilatation, drop out, and the total number of capillaries per millimeter, as shown in panel C (",
"    <a class=\"graphic graphic_picture graphicRef63190 \" href=\"mobipreview.htm?0/23/377\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nailfold capillary changes are highly sensitive in making a diagnosis of JDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities in nailfold capillaroscopy suggest an underlying connective tissue disease, which may be JDM. In one study, nailfold capillary microscopy demonstrated a lower density of capillaries (4.9 versus 6.9 capillaries per millimeter) and increased capillary width in 18 children with connective tissue disease including 8 with JDM compared to 17 healthy control children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study of 84 children with a variety of rheumatologic disorders and 34 healthy controls, nailfold capillaroscopy demonstrated significant drop-out and dilatation of nailfold capillaries in patients with childhood dermatomyositis or scleroderma compared to children with other rheumatologic diseases and controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/10\">",
"     10",
"    </a>",
"    ]. Of the 25 patients with JDM for whom muscle biopsies were available, there was good correlation between the severity and number of vascular abnormalities on biopsy (eg, non-necrotizing vasculitis or significant loss of capillary bed) and an increased likelihood of having nailfold capillaroscopic abnormalities.",
"   </p>",
"   <p>",
"    In patients with JDM, abnormal nailfold capillaroscopy correlated with increased skin involvement, but not muscle weakness in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. However, in one study, loss of nailfold capillary density correlated with both muscle weakness and skin disease activity over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/5\">",
"     5",
"    </a>",
"    ]. The likelihood of nailfold changes increases with the duration of untreated disease. Ongoing assessment of the nailfold for capillary changes may be useful for monitoring disease activity and response to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Muscle enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated serum muscle enzyme levels are markers for muscle damage and when present, support the diagnosis of JDM or JPM. The muscle enzymes routinely tested in the evaluation of myopathy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Creatine kinase (CK)",
"     </li>",
"     <li>",
"      Lactate dehydrogenase (LDH)",
"     </li>",
"     <li>",
"      Aldolase",
"     </li>",
"     <li>",
"      Alanine aminotransferase (ALT)",
"     </li>",
"     <li>",
"      Aspartate aminotransferase (AST)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be remembered that CK, LDH, ALT, and AST may arise from sources other than muscle even in the setting of a patients with muscle weakness.",
"   </p>",
"   <p>",
"    Although the majority of children with JDM and JPM will have serum elevation of one or more of these enzymes, some patients may have normal values despite clinically evident weakness. This was illustrated in a retrospective study of 166 patients with JDM that reported normal serum levels of CK, LDH, and aldolase in 26, 13, and 17 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/12\">",
"     12",
"    </a>",
"    ]. The muscle enzyme levels were more likely to be normal with prolonged disease duration prior to treatment, particularly beyond four months. Thus, elevated serum muscle enzymes aid in the diagnosis of JDM and JPM, but normal enzyme levels do not exclude them.",
"   </p>",
"   <p>",
"    Following muscle enzyme levels is useful in monitoring the disease course and response to treatment. In one study of 16 patients with JDM, elevations of serum LDH and AST were associated with disease flare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/13\">",
"     13",
"    </a>",
"    ]. The risk of disease flare within the next four months increased three-fold following a 20 percent rise in serum AST levels. However, an association with disease flares was not seen with either an elevation of serum ALT or CK.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with JDM and JPM, evidence of increased muscle cell membrane irritability is demonstrated by the following classic triad of electromyogram (EMG) findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/14\">",
"     14",
"    </a>",
"    ], which are characterized as the presence of spikes and waves:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Short, polyphasic, small motor-unit potentials",
"     </li>",
"     <li>",
"      Insertional irritability, spontaneous fibrillations, positive sharp waves",
"     </li>",
"     <li>",
"      High-frequency repetitive discharges",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because EMG is an invasive and uncomfortable test, it should be used only when the diagnosis is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/4\">",
"     4",
"    </a>",
"    ]. It is helpful in distinguishing muscle weakness caused by muscle denervation, which may be due to motor neuron disease and myasthenia gravis, from that caused by inflammatory myopathy (eg, JDM). In some children with myositis, the EMG may be normal (falsely negative test) due to the patchy nature of muscle inflammation.",
"   </p>",
"   <p>",
"    EMG also may be used to detect areas of inflammation to determine an appropriate site for muscle biopsy. However, care should be taken to avoid sampling tissue directly from the area of an EMG needle insertion as this may cause significant artifact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is increasingly used in the diagnosis of childhood inflammatory myopathy to avoid the morbidity of muscle biopsy and EMG, as shown in panel B (",
"    <a class=\"graphic graphic_picture graphicRef63190 \" href=\"mobipreview.htm?0/23/377\">",
"     picture 2",
"    </a>",
"    ). Of 122 children with various stages of JDM evaluated in one study from the United Kingdom and Ireland, 78 of 102 patients (76 percent) who underwent MRI had abnormalities consistent with myositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/15\">",
"     15",
"    </a>",
"    ]. In this cohort, EMG was performed in only 8 percent of patients, and muscle biopsy in 36 percent.",
"   </p>",
"   <p>",
"    Another study of 19 patients with JDM (15 with active and 4 with inactive disease) and 5 healthy controls evaluated the role of MRI in the diagnosis of JDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/16\">",
"     16",
"    </a>",
"    ]. All patients with clinically active disease had abnormal findings on MRI compared to none of the patients with inactive disease or controls. The abnormalities included increased signal intensity (on T2 or STIR images) of the affected muscle, perimuscular edema, enhanced chemical shift artifact, and increased signal intensity in subcutaneous fat. Higher muscle signal intensity on MRI correlated with decreased muscle strength. After therapy, signal intensity in the muscle returned to normal.",
"   </p>",
"   <p>",
"    MR spectroscopy (MRS) is a research tool that is not yet routinely available. It can detect irregularities in muscle function and metabolism in inflammatory myopathy. In a study of 13 children with JDM, MRS identified metabolic abnormalities in the quadriceps muscle of 10 patients with severe clinical weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/17\">",
"     17",
"    </a>",
"    ]. Two patients who had resolution of clinical weakness on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    treatment had normal findings, as did one patient with amyopathic JDM.",
"   </p>",
"   <p>",
"    Whole body MRI may emerge as a method of determining the extent of muscle disease and following patients with JDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle biopsy can confirm the diagnosis of JDM and JPM when the diagnosis remains uncertain.",
"   </p>",
"   <p>",
"    The characteristic histologic findings of JDM include the following, as shown in panel A (",
"    <a class=\"graphic graphic_picture graphicRef63190 \" href=\"mobipreview.htm?0/23/377\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Perifascicular atrophy",
"     </li>",
"     <li>",
"      Degeneration of type I and II muscle fibers",
"     </li>",
"     <li>",
"      Regeneration of muscle fibers with associated basophilia",
"     </li>",
"     <li>",
"      Centralization of nuclei in muscle fibers",
"     </li>",
"     <li>",
"      Perivascular mononuclear infiltrate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In JPM, the muscle biopsy typically shows an inflammatory exudate consisting of mononuclear T cells, which accumulate in the endomysium and surround and invade muscle fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The site chosen for biopsy is generally the quadriceps muscle. The chosen site should have evidence of muscle inflammation demonstrated by physical exam, magnetic resonance imaging, or EMG. Open biopsy of an area that is actively inflamed, but not atrophied, is preferred by many pathologists, but needle biopsy might suffice in the hands of an experienced team.",
"   </p>",
"   <p>",
"    The clinical course and disease severity typically correlates with the histologic findings of the muscle biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. This was illustrated in a review of 72 pretreatment muscle biopsies from patients with confirmed JDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/20\">",
"     20",
"    </a>",
"    ]. Severe muscle necrosis, vasculopathy, and endomysial fibrosis were associated with a chronic course of JDM, in particular with associated ulcerative disease, as shown in panel E (",
"    <a class=\"graphic graphic_picture graphicRef63190 \" href=\"mobipreview.htm?0/23/377\">",
"     picture 2",
"    </a>",
"    ). Another study has devised a classification system for muscle biopsy findings in JDM, including vascular, inflammatory, muscle fiber, and connective tissue changes. This system could potentially be used to test which histologic features are predictive of disease course or outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/21\">",
"     21",
"    </a>",
"    ]. If data from future prospective validation studies identify reliable histologic prognostic markers, it may be possible to use grading of histological findings as a basis for choosing therapeutic regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although other blood tests are often performed in patients suspected of having childhood inflammatory myopathy, these studies are often not directly useful in establishing the diagnosis. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count &mdash; Leukocytosis and anemia are uncommon findings at disease onset with the possible exception of a low hematocrit in a child with significant gastrointestinal bleeding. Lymphopenia may be present in children with JDM and usually resolves after corticosteroid therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inflammatory markers &mdash; Both C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) may be elevated in patients with JDM and JPM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/22\">",
"       22",
"      </a>",
"      ]. However, these often do not correlate with the degree of inflammation detected clinically, and are not useful in making the diagnosis or monitoring disease activity in patients with JDM or JPM.",
"     </li>",
"     <li>",
"      von Willebrand factor &mdash; Although several studies have shown that children with active JDM have increased plasma von Willebrand factor (vWF) levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/13,23\">",
"       13,23",
"      </a>",
"      ], increased vWF levels have not been shown to be more specific for active disease than serum muscle enzyme measurements. Blood vessel injury is thought to cause the release of vWF from platelets and endothelial cells resulting in elevated plasma levels of vWF.",
"     </li>",
"     <li>",
"      Autoantibodies &mdash; Although antinuclear antibodies (ANA) are present in 70 percent of patients with JDM and JPM, a positive ANA is nonspecific and has limited diagnostic value.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myositis-specific antibodies (MSAs), which are associated with specific clinical subgroups of adult patients with dermatomyositis and polymyositis, have only been identified in a small number of children with inflammatory myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/24\">",
"     24",
"    </a>",
"    ]. As a result, MSAs are generally not helpful in making the diagnosis of JDM. MSA testing may be considered for patients with unusual clinical features or an unusual clinical course. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\", section on 'Immunologic mechanisms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use the following approach in making the diagnosis of JDM in our practice.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of JDM is suspected if there is both symmetric, proximal muscle weakness and characteristic cutaneous changes of JDM, which can include heliotrope dermatitis, Gottron's papules, and nailfold capillary abnormalities.",
"     </li>",
"     <li>",
"      Serum muscle enzyme studies often provide evidence of the presence of myositis, but not always.",
"     </li>",
"     <li>",
"      When available, magnetic resonance imaging (MRI) and, usually, EMG electromyography are performed to document evidence of muscle inflammation and confirm a diagnosis of JDM in a patient with typical clinical findings. In cases where the diagnosis remains uncertain a muscle biopsy is performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of JDM is relatively straightforward in the presence of the characteristic rash and symmetric proximal muscle weakness. However, in the absence of its cutaneous manifestations, JDM similar to JPM is often difficult to distinguish from other causes of muscle weakness (eg, other myopathic diseases, or disorders due to denervation or neuropathy).",
"   </p>",
"   <p>",
"    Clinical features, such as the age at onset, the chronicity of the disorder, family history, and the predominant site of muscle involvement are useful in differentiating JDM and JPM from these disorders. In these cases, laboratory evaluation including serum muscle enzyme levels, magnetic resonance imaging, electromyography, and muscle biopsy are helpful in determining the etiology of muscle weakness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Noninflammatory myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of noninflammatory myopathies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscular dystrophy due to genetic causes including Duchenne and Becker muscular dystrophy. There is often a family history of other affected members. Patients with Duchenne and Becker muscular dystrophy are usually male because the locus for the affected gene, dystrophin, is the X chromosome. Duchenne muscular dystrophy typically presents at an earlier age than those with JDM and JPM. Genetic testing is available to confirm the diagnosis of many of these genetic myopathies including Duchenne and Becker muscular dystrophy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/16/1290?source=see_link\">",
"       \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19882?source=see_link\">",
"       \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic myopathies are due to underlying deficiencies of energy production in muscle. These disorders include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency syndromes, defects of fatty acid transport and beta-oxidation enzymes, myoadenylate deaminase deficiency, and mitochondrial defects. Specific biochemical and immunohistochemical testing of muscle tissue is necessary for the diagnosis of these disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/905?source=see_link\">",
"       \"Approach to the metabolic myopathies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21065?source=see_link\">",
"       \"Causes of metabolic myopathies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7370?source=see_link\">",
"       \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other forms of myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myositis may be caused by infection or another rheumatologic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31079/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral infections (eg, influenza, Coxsackie, and Poliomyelitis) may be associated with acute and transient myositis. The history of a recent infection and the short self-resolving clinical course distinguishes infectious myositis from JDM and JPM. Viral myositis is often characterized by calf pain as opposed to the proximal muscle weakness seen in JDM and JPM.",
"     </li>",
"     <li>",
"      Myositis may present as a clinical manifestation of other rheumatologic diseases such as systemic scleroderma, systemic lupus erythematosus, mixed connective tissue disease, and systemic onset juvenile idiopathic arthritis. Differentiation among these disorders, JDM, and JPM is usually not difficult because of the presence of characteristic clinical features of each disease, although overlap syndromes may occur. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39433?source=see_link\">",
"       \"Juvenile systemic sclerosis (scleroderma)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=see_link\">",
"       \"Systemic lupus erythematosus in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=see_link\">",
"       \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3447?source=see_link\">",
"       \"Definition and diagnosis of mixed connective tissue disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Disorders of denervation or neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions of the brain, spinal cord, anterior horn cell, lower motor neuron, and the neuromuscular junction may present with muscle weakness. Laboratory evaluation including magnetic resonance imaging (lack of inflammatory changes), electromyography, and muscle biopsy differentiate these disorders from JDM and JPM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of juvenile dermatomyositis (JDM) is made clinically and is based upon the presence of symmetric, proximal muscle weakness and the characteristic rashes of heliotrope dermatitis and Gottron's papules (",
"      <a class=\"graphic graphic_picture graphicRef52062 \" href=\"mobipreview.htm?8/3/8243\">",
"       picture 1",
"      </a>",
"      ). The diagnosis of juvenile polymyositis (JPM) is more challenging because of the lack of cutaneous manifestations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated serum muscle enzyme levels are supportive of the diagnosis of JDM; however, normal muscle enzyme levels do not exclude these disorders. Nailfold capillary abnormalities also are supportive of the diagnosis of JDM and JPM; however, they may be seen in other connective tissue disorders, as shown in panel C (",
"      <a class=\"graphic graphic_picture graphicRef63190 \" href=\"mobipreview.htm?0/23/377\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Muscle enzymes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Nailfold capillaroscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) may demonstrate inflammation of the characteristically involved muscle groups, as shown in panel B (",
"      <a class=\"graphic graphic_picture graphicRef63190 \" href=\"mobipreview.htm?0/23/377\">",
"       picture 2",
"      </a>",
"      ) and is an important diagnostic tool in confirming a diagnosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electromyography and muscle biopsy, as shown in panel C (",
"      <a class=\"graphic graphic_picture graphicRef63190 \" href=\"mobipreview.htm?0/23/377\">",
"       picture 2",
"      </a>",
"      ), are invasive diagnostic procedures that may best be reserved for cases in which the diagnosis is inconclusive despite thorough physical examination and investigation including serum muscle testing and MRI. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Electromyography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Muscle biopsy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the diagnosis of JDM is straightforward in the presence of the characteristic rash and symmetric proximal muscle weakness, JDM in the absence of its cutaneous manifestation (similar to JPM) is often difficult to distinguish from other causes of muscle weakness. These include muscular dystrophies, metabolic myopathy, infectious myositis, myositis associated with other rheumatic diseases, and disorders of denervation or neuropathy. Clinical features and laboratory evaluation differentiate JDM and JPM from these other disorders that present with muscle weakness. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/1\">",
"      Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/2\">",
"      Banker BQ, Victor M. Dermatomyositis (systemic angiopathy) of childhood. Medicine (Baltimore) 1966; 45:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/3\">",
"      Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/4\">",
"      Brown VE, Pilkington CA, Feldman BM, et al. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford) 2006; 45:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/5\">",
"      Schmeling H, Stephens S, Goia C, et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology (Oxford) 2011; 50:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/6\">",
"      Rider LG, Koziol D, Giannini EH, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010; 62:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/7\">",
"      Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1999; 42:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/8\">",
"      Smith RL, Sundberg J, Shamiyah E, et al. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004; 31:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/9\">",
"      Dolezalova P, Young SP, Bacon PA, Southwood TR. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis 2003; 62:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/10\">",
"      Spencer-Green G, Schlesinger M, Bove KE, et al. Nailfold capillary abnormalities in childhood rheumatic diseases. J Pediatr 1983; 102:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/11\">",
"      Christen-Zaech S, Seshadri R, Sundberg J, et al. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/12\">",
"      Pachman LM, Abbott K, Sinacore JM, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006; 148:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/13\">",
"      Guzm&aacute;n J, Petty RE, Malleson PN. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J Rheumatol 1994; 21:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/14\">",
"      Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/15\">",
"      McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006; 45:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/16\">",
"      Hernandez RJ, Sullivan DB, Chenevert TL, Keim DR. MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR Am J Roentgenol 1993; 161:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/17\">",
"      Park JH, Niermann KJ, Ryder NM, et al. Muscle abnormalities in juvenile dermatomyositis patients: P-31 magnetic resonance spectroscopy studies. Arthritis Rheum 2000; 43:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/18\">",
"      Tzaribachev N, Well C, Schedel J, Horger M. Whole-body MRI: a helpful diagnostic tool for juvenile dermatomyositis case report and review of the literature. Rheumatol Int 2009; 29:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/19\">",
"      Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 1982; 25:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/20\">",
"      Miles L, Bove KE, Lovell D, et al. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum 2007; 57:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/21\">",
"      Wedderburn LR, Varsani H, Li CK, et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007; 57:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/22\">",
"      Haas RH, Dyck RF, Dubowitz V, Pepys MB. C-reactive protein in childhood dermatomyositis. Ann Rheum Dis 1982; 41:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/23\">",
"      Bloom BJ, Tucker LB, Miller LC, Schaller JG. von Willebrand factor in juvenile dermatomyositis. J Rheumatol 1995; 22:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/24\">",
"      Rider LG, Miller FW, Targoff IN, et al. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum 1994; 37:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31079/abstract/25\">",
"      Compeyrot-Lacassagne S, Feldman BM. Inflammatory myopathies in children. Rheum Dis Clin North Am 2007; 33:525.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6409 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-59FAC149C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31079=[""].join("\n");
var outline_f30_22_31079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION AND DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Rash",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Muscle strength",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nailfold capillaroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Muscle enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Noninflammatory myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other forms of myositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Disorders of denervation or neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6409\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6409|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/3/8243\" title=\"picture 1\">",
"      Rash - Juvenile dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/23/377\" title=\"picture 2\">",
"      Physical findings - Juvenile dermatomyositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3447?source=related_link\">",
"      Definition and diagnosis of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39433?source=related_link\">",
"      Juvenile systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/5/2138?source=related_link\">",
"      Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_22_31080="Diagnosis of psychiatric and psychologic disorders in patients with cancer";
var content_f30_22_31080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31080/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31080/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31080/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31080/contributors\">",
"     Jonathan M Silver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31080/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31080/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/22/31080/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cancer have a high rate of psychiatric comorbidity; approximately one-half exhibit emotional difficulties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The psychological complications generally take the form of adjustment disorder, depressed mood, anxiety, impoverished life satisfaction, or loss of self-esteem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Patients most at risk for depression and other psychiatric illness have advanced disease, a prior psychiatric history, poorly controlled pain, and other life stressors or losses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to these psychiatric conditions, non-specific distress is very common in cancer patients, with a reported incidence varying from 15 to 42 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/8\">",
"     8",
"    </a>",
"    ]. Distress is the summation of multiple psychological, social, and spiritual factors. If severe enough, distress can interfere with the patient's ability to deal effectively with the illness, its symptoms, and the complications of treatment. The National Comprehensive Cancer Network has recommended routine screening of all cancer patients for psychological distress and simple instruments are available to measure distress in cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Making psychiatric diagnoses and rapidly identifying patients who need help are difficult for many reasons. One problem is that psychiatric symptomatology may be mimicked by treatment side effects or symptoms of the cancer. Time factors and patient reluctance to discuss psychosocial problems can also act as barriers to the recognition of psychosocial problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific issues regarding the diagnosis of psychiatric disorders in patients with cancer are reviewed here. The management of cancer patients with these problems is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=see_link\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    .) Further information on specific psychiatric disorders is available in separate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADJUSTMENT DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjustment disorder is the most prevalent psychiatric problem associated with cancer. It is evident in 20 to 30 percent of all such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/1,13,14\">",
"     1,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adjustment disorder is characterized by a variety of clinically significant behavioral or emotional symptoms occurring as a result of a triggering event or stressor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/15\">",
"     15",
"    </a>",
"    ]. It may be associated with the following subtypes: depressed mood; anxiety; or disturbance of conduct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The onset of adjustment disorder must occur within three months of the triggering event and by definition does not endure past six months of the termination of the stressor or its consequences. However, the disorder may become chronic (lasting more than six months) when there is a chronic stressor or when the consequences of the stressor have long-term impact (as is often the case for people with cancer). Adjustment disorder can only be diagnosed if the disturbance is unique and does not meet the criteria for other disorders such as major depression or generalized anxiety disorder, and if the symptoms are not the result of bereavement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The identification and diagnosis of adjustment disorder is not straightforward. One of the difficulties is that the disorder lacks precise features; it is a function rather than symptom-based diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, there are no set criteria for quantifying the stressors that lead to adjustment disorder in a given individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/18\">",
"     18",
"    </a>",
"    ]. Finally, it is often difficult to define what constitutes \"maladaptive behavior\" in response to catastrophic levels of stress, and the severity of symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decrement in social function vary widely within a given individual over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, making the diagnosis of adjustment disorder is important since these patients generally benefit from some form of counseling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=see_link\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    .) Rapid identification of adjustment disorder can prompt early psychological intervention that enhances the patient's quality of life or, at the very least, prevents further erosion of his or her ability to function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of depression in patients with cancer is discussed here. Particular aspects applicable to patients receiving palliative care are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=see_link&amp;anchor=H15#H15\">",
"     \"Assessment and management of depression in palliative care\", section on 'Assessment and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The accurate diagnosis of depression is required to avoid a negative impact on quality of life. Furthermore, depression may contribute to shortened survival in those diagnosed with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/20\">",
"     20",
"    </a>",
"    ], as well as increasing the risk of developing cancer in some people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/21\">",
"     21",
"    </a>",
"    ]. Although the physiologic basis for the increased mortality is not understood, this effect may be mediated by an alteration in the cellular immune response and a decrease in natural killer cell activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/20,22\">",
"     20,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported prevalence of major depression in individuals with cancer varies widely, with reports ranging from 0 to 38 percent, and lesser degrees of symptomatology are present in additional patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/23\">",
"     23",
"    </a>",
"    ]. This wide variability is explained by the lack of agreement as to appropriate diagnostic criteria, differences in patient populations (ie, demographics, type and stage of disease, treatment versus no treatment), and variation in assessment methods. In general, rates are higher in populations with advanced cancer, greater levels of disability,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unrelieved pain.",
"   </p>",
"   <p>",
"    Factors that may be associated with an increased risk of depression include young age, a prior history of depression, and the presence of uncontrolled symptoms from the cancer. Certain types of malignancies appear to be associated with an increased incidence of depression, including cancers of the head and neck, pancreas, breast, and lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a common presumption that all people with cancer are and should be depressed. This notion minimizes the degree of suffering that can be associated with comorbid depression and its impact upon a person's quality of life. Health professionals may underestimate the morbidity caused by depression because they believe that they would feel depressed if roles were reversed.",
"   </p>",
"   <p>",
"    This view also promotes the underdiagnosis of depression and in turn, its undertreatment. Low-income and minority patients may be at particular risk, because they are less likely to receive routine screening and support for possible depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depressive states exist on a continuum from sadness to major affective disorders. It is important that physicians differentiate between normal sadness and abnormal levels of distress. Using screening tools and raising awareness about depression is an important step. Several studies have suggested that physicians and nurses do not recognize levels of depressive symptoms; this failure is worse when patients have more severe depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Simple single-question and other abbreviated assessments appear to be as effective as longer instruments in screening for depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. One useful screening method relies upon a \"one question interview\" technique, in which the patient is asked this question: \"Please grade your mood during the past week by assigning it a score from 0 to 100, with a score of 100 representing your usual relaxed mood. A score of 60 is considered the passing grade\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/29\">",
"     29",
"    </a>",
"    ]. In this study of 275 patients with cancer, the sensitivity and specificity rates of this technique for the detection of adjustment disorders and major depression were 84 and 61 percent, respectively. Another single-item screen has been adapted from the Schedule for Affective Disorders and Schizophrenia (SADS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/30\">",
"     30",
"    </a>",
"    ], asking the question \"Have you been depressed most of the time for the past two weeks?\"",
"   </p>",
"   <p>",
"    Another method to open a dialogue with the patient who might otherwise resist discussions of emotional issues is by asking about specific somatic symptoms. The diagnosis of depression in physically healthy patients depends upon the presence of somatic symptoms such as decreased appetite, loss of energy, insomnia, loss of sexual drive, and psychomotor retardation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with cancer these physical symptoms must be carefully evaluated to clarify their etiology. Although neurovegetative symptoms are very compelling when present in the absence of physical illness, they are less reliable as diagnostic criteria for depression in patients with cancer since they can be caused by the cancer itself or its treatment. Loss of appetite due to chemotherapy, fatigue due to cancer or its treatment, and lack of sleep because of unrelieved pain are examples of the problems encountered in differentiating somatic symptoms that are due to depression or other medical causes. If certain physical symptoms are attributable to depression, antidepressants may be chosen to target the physical symptoms that are most distressing to the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain drugs used in the treatment of cancer, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    also cause depressive symptoms that may be confused with adjustment disorder or mood disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/17\">",
"     17",
"    </a>",
"    ]. Such confounding of the diagnosis can lead to improper treatment offered to patients, or may cause depression to be overlooked as a drug side effect.",
"   </p>",
"   <p>",
"    Persistently depressed mood and sadness are appropriate responses for patients with a life-threatening disease. Thus, the diagnosis of depression in cancer patients, especially those who have advanced disease, relies more upon the other psychologic or \"cognitive symptoms.\"",
"   </p>",
"   <p>",
"    Anhedonia, the lack of ability to experience pleasure, is a useful depressive symptom to monitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients who are not depressed may be sad periodically, but maintain the capacity for experiencing pleasure. They react positively to opportunities to engage in the activities that they enjoy, even though the range of activities available to them may be diminished. There is nothing inherent to the disease or treatment process that robs one of the capacity to feel pleasure. Some patients with far advanced disease experience heightened pleasure in intimacies with family or friends knowing that the experiences are among the last they might have; the knowledge that death is near can increase the poignancy and emotion of such contacts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Feelings of hopelessness, worthlessness, excessive guilt, loss of self-esteem, and wishes to die are also among the most diagnostically reliable symptoms of depression in cancer patients. However, interpretation of even these symptoms can be difficult. As an example, feelings of hopelessness in dying patients who have no hope for recovery can be normal. On the other hand, many patients who never have a hope of a cure are able to maintain hope that life can be extended, symptoms can be controlled,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    quality of life can be maintained. Hopelessness that is pervasive and accompanied by a sense of despair or despondency is more likely to represent a symptom of a depressive disorder.",
"   </p>",
"   <p>",
"    Patients often state that they feel they are burdening their families unfairly, causing them great pain and inconvenience. Such beliefs are less likely to represent symptoms of depression than if the patient suffers with guilty recrimination, feels that their life has never had any worth, or that they are being punished for evil things they have done.",
"   </p>",
"   <p>",
"    The perception of being a burden to others can sometimes be altered by counseling and helping the patient to reframe the situation as a necessary component of the mourning process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/33\">",
"     33",
"    </a>",
"    ]. The patient can come to see that allowing him or herself to be cared for is important for their family's sake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100093459\">",
"    <span class=\"h1\">",
"     SUICIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of cancer may precipitate distress such that patients commit suicide; the absolute risk appears to be small but persistent. Evidence for an elevated risk of suicide in patients with cancer comes from observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cohort study using multiple registries examined the risk of suicide in more than 6,000,000 Swedes from 1991 through 2006; compared with cancer-free individuals, patients diagnosed with cancer were [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/38\">",
"       38",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      13 times more likely to commit suicide within one week of receiving the diagnosis (RR 12.6, 95% CI 8.6-17.8)",
"     </li>",
"     <li>",
"      3 times more likely within one year (RR 3.1, 95% CI 2.7-3.5)",
"     </li>",
"     <li>",
"      Risk of suicide was especially high in patients with poor prognosis cancers (eg, lung, esophageal, liver, and pancreatic)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cohort study of over 500,000 Danish cancer patients diagnosed between 1971 and 1999 found that the rate of suicide among male patients was 70 percent greater than that in the general population, and 40 percent greater in female patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depression near the end of life may cause the patient to seek assistance in shortening life, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24778?source=see_link\">",
"     \"Euthanasia and physician assisted suicide\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=see_link\">",
"     \"Assessment and management of depression in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANXIETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cancer may present with a complex mixture of physical and psychological symptoms in the context of their frightening reality. Thus, the recognition of anxiety symptoms requiring treatment can be challenging.",
"   </p>",
"   <p>",
"    Patients with anxiety complain of tension or restlessness, or they exhibit jitteriness, autonomic hyperactivity, vigilance, insomnia, distractibility, shortness of breath, numbness, apprehension, worry or rumination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Often the physical or somatic manifestations of anxiety overshadow the psychological or cognitive ones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/40\">",
"     40",
"    </a>",
"    ]. These symptoms are a cue to further inquiry about the patient's psychological state, which is commonly one of fear, worry, or apprehension.",
"   </p>",
"   <p>",
"    Anxiety can have many etiologies in patients with cancer. It may be encountered as a component of an adjustment disorder, panic disorder, generalized anxiety disorder, phobia, or agitated depression. In the patient with advanced disease, symptoms of anxiety are most likely to arise from a medical complication of the illness or treatment such as organic anxiety disorder, delirium, or other organic mental disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Hypoxia, sepsis, poorly controlled pain, and adverse drug reactions such as akathisia, or withdrawal states often present as anxiety. Benzodiazepine withdrawal also can present first as agitation or anxiety; this diagnosis is often missed in patients with advanced disease, especially the elderly, since physiologic dependence on these medications is often unrecognized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychological factors also often cause anxiety, particularly in patients who are alert and not confused [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients frequently fear isolation, estrangement from others, and may have a general sense of feeling like an outcast. Financial burdens and family role changes are other common stressors.",
"   </p>",
"   <p>",
"    The patient's subjective level of distress is the primary impetus for the initiation of anxiety treatment. Other considerations include problematic patient behavior such as noncompliance, family and staff reactions to the patient's distress, and the balance of the risks and benefits of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DELIRIUM AND DEMENTIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium is an etiologically nonspecific, global, cerebral dysfunction, characterized by concurrent disturbances of level of consciousness, attention, thinking, perception, memory, psychomotor behavior, emotion, and the sleep-wake cycle. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disorientation, fluctuation, or waxing and waning of the above symptoms, as well as the acute or abrupt onset of these disturbances are other critical features. In contrast to dementia, delirium is a reversible process.",
"   </p>",
"   <p>",
"    Delirium is one of the most frequent neuropsychiatric complications in patients with advanced cancer, and it causes moderate to severe distress in both patient and caregivers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/44\">",
"     44",
"    </a>",
"    ]. The incidence ranges from 15 to 75 percent, depending on the clinical setting. For instance, among hospitalized patients with advanced cancer, 15 to 20 percent have organic mental disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Among patients undergoing hematopoietic stem cell transplantation, episodes of delirium were observed in 50 percent, with peak severity at the end of the second week after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/47\">",
"     47",
"    </a>",
"    ]. In a study focusing on the terminally ill, delirium was diagnosed in more than 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delirium can be due either to the direct effects of cancer on the central nervous system (CNS), or to indirect CNS effects of the disease or treatments (eg, medications, electrolyte imbalance, failure of a vital organ or system, infection, vascular complications, and preexisting cognitive impairment or dementia). Most often, it is multifactorial in origin.",
"   </p>",
"   <p>",
"    It is important to identify the cause(s) of delirium in patients with cancer, since rapid and significant cognitive improvement can occur with treatment. In one series of 140 confused patients with cancer, delirium improved with identification and treatment of the underlying cause in 67 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A common error among medical and nursing staff is to conclude that a new psychological symptom is functional without completely ruling out all possible organic etiologies. As an example, given the large numbers of drugs cancer patients require and the fragile state of their physiologic functioning, even routinely ordered hypnotics and opioids can cause an organic mental syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/50-53\">",
"     50-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapeutic agents known to cause delirium include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , BCNU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , asparaginase,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , corticosteroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , and biological response modifiers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]. However, with the exception of corticosteroids and biological response modifiers, most patients who receive these drugs will not develop prominent CNS effects.",
"   </p>",
"   <p>",
"    The spectrum of mental disturbances related to corticosteroids includes minor mood lability, affective disorders (mania or depression), cognitive impairment (reversible dementia), and delirium (steroid psychosis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of these disorders range from 3 to 57 percent in noncancer populations, most commonly occurring at higher doses. Symptoms usually develop within the first two weeks of treatment, although they can occur at any time and on any dose, even during the tapering phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/51\">",
"     51",
"    </a>",
"    ]. Prior psychiatric illness, or prior disturbance on corticosteroids are poor to fair predictors of susceptibility to, or the nature of, mental disturbances during subsequent steroid treatments. These disorders are often rapidly reversible upon dose reduction or discontinuation.",
"   </p>",
"   <p>",
"    Early symptoms of delirium may be misdiagnosed as anxiety, anger, depression, psychosis, or unreasonable or uncooperative attitudes toward rehabilitative efforts or other treatments. The diagnosis should be considered in any patient with the acute onset of agitation, impaired cognitive function, altered attention span, or a fluctuating level of consciousness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/59\">",
"     59",
"    </a>",
"    ]. Instruments are being developed to facilitate the diagnosis of delirium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It can be difficult to differentiate delirium from dementia since they frequently share such common clinical features such as impaired memory, thinking, judgment, and disorientation. Dementia occurs in relatively alert individuals with little or no clouding of consciousness. The temporal onset of symptoms in dementia is more insidious or chronically progressive, and the patient's sleep-wake cycle is generally not impaired. Most prominent in dementia are difficulties in short and long term memory, impaired judgment and abstract thinking, and disturbed higher cortical functions (eg, aphasia, apraxia). Occasionally one will encounter delirium superimposed on an underlying dementia, particularly in the elderly, a patient with AIDS, or one with a paraneoplastic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31080/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnosis of delirium and confusional states\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/57/11155?source=see_link\">",
"       \"Patient information: Delirium (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9220769\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with cancer have a high rate of emotional difficulties and psychiatric comorbidity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjustment disorder occurs in 20 to 30 percent of patients with cancer. In adjustment disorder, a triggering event or stressor leads to depressed mood, anxiety, or disturbance of conduct within three months; the disorder ends six months after the stressor or its consequences have ceased. However, the disorder may last more than six months if the stressor is chronic. Adjustment disorder is not diagnosed if the symptoms meet criteria for other disorders such as major depression or generalized anxiety disorder, or the symptoms are due to bereavement. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Adjustment disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The estimated prevalence of major depression (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"       table 1",
"      </a>",
"      ) in cancer patients varies from 0 to 38 percent. The prevalence may be underestimated because of the notion that cancer patients are and should be depressed. The rate of depression is generally higher in patients with advanced cancer, greater disability,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unrelieved pain. Other risk factors include young age, a prior history of depression, and the presence of uncontrolled cancer symptoms, as well as specific types of malignancies, including head and neck, pancreas, breast, and lung cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of depression in cancer patients, especially those who have advanced disease, relies primarily upon the symptoms of anhedonia (inability to experience pleasure), hopelessness, worthlessness, excessive guilt, and wishes to die. Symptoms such as anorexia, anergia, insomnia, decreased libido, and psychomotor retardation may be caused by cancer rather than major depression. In addition, drugs used to treat cancer (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ) can cause symptoms that are similar to depressive symptoms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of completed suicide in patients with cancer is elevated in both men and women. In addition, depression near the end of life may cause the patient to seek assistance in shortening life. (See",
"      <a class=\"local\" href=\"#H100093459\">",
"       'Suicide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Depression'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24778?source=see_link\">",
"       \"Euthanasia and physician assisted suicide\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=see_link\">",
"       \"Assessment and management of depression in palliative care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cancer patients may have a number of anxiety symptoms (eg, tension, restlessness, jitteriness, autonomic hyperactivity, vigilance, insomnia, distractibility, shortness of breath, numbness, apprehension, worry, and rumination) and anxiety disorders (panic disorder, generalized anxiety disorder, and phobia). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Anxiety'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=see_link&amp;anchor=H191515190#H191515190\">",
"       \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Assessment and diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=see_link\">",
"       \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/24/22921?source=see_link&amp;anchor=H19509096#H19509096\">",
"       \"Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Delirium is characterized by a disturbance of consciousness (reduced awareness of the environment) and impaired attention, and occurs in 15 to 75 percent of patients with advanced cancer (depending upon the clinical setting). The etiology typically involves the direct effects of cancer upon the central nervous system (CNS), the indirect CNS effects of cancer or treatments (eg, medications, electrolyte imbalance, failure of a vital organ, infection, and vascular complications), and preexisting cognitive impairment or dementia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Delirium and dementia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"       \"Diagnosis of delirium and confusional states\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chemotherapeutic agents that can cause delirium include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , BCNU,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , asparaginase,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , corticosteroids, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      . However, with the exception of corticosteroids, most patients who receive these drugs will not develop prominent CNS effects. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Delirium and dementia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We encourage clinicians to print or e-mail the patient education material about delirium. (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/57/11155?source=see_link\">",
"       \"Patient information: Delirium (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/1\">",
"      Derogatis LR, Morrow GR, Fetting J, et al. The prevalence of psychiatric disorders among cancer patients. JAMA 1983; 249:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/2\">",
"      Burgess C, Cornelius V, Love S, et al. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 2005; 330:702.",
"     </a>",
"    </li>",
"    <li>",
"     Sarafino, E. Health psychology: Biopsychosocial interactions, 2nd ed, John Wiley and Sons, New York 1994.",
"    </li>",
"    <li>",
"     Friedenbergs, I, Kaplan, E. Cancer. In: Medical aspects of disability: A handbook for the rehabilitation professional, Eisenberg, M, Glueckauf, R, Zaretsky, H (Eds), Springer Publishing Company, New York 1993. p.105.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/5\">",
"      Molassiotis A, Boughton BJ, Burgoyne T, van den Akker OB. Comparison of the overall quality of life in 50 long-term survivors of autologous and allogeneic bone marrow transplantation. J Adv Nurs 1995; 22:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/6\">",
"      Kathol RG, Mutgi A, Williams J, et al. Diagnosis of major depression in cancer patients according to four sets of criteria. Am J Psychiatry 1990; 147:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/7\">",
"      Chochinov HM. Depression in cancer patients. Lancet Oncol 2001; 2:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/8\">",
"      Strong V, Waters R, Hibberd C, et al. Emotional distress in cancer patients: the Edinburgh Cancer Centre symptom study. Br J Cancer 2007; 96:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/9\">",
"      National Comprehensive Cancer Network. Distress management. Clinical practice guidelines. J Natl Compr Canc Netw 2003; 1:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/10\">",
"      Jacobsen PB, Donovan KA, Trask PC, et al. Screening for psychologic distress in ambulatory cancer patients. Cancer 2005; 103:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/11\">",
"      Loscalzo MJ, Clark KL. Problem-related distress in cancer patients drives requests for help: a prospective study. Oncology (Williston Park) 2007; 21:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/12\">",
"      Vachon ML. Psychosocial needs of patients and families. J Palliat Care 1998; 14:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/13\">",
"      Dugan W, McDonald MV, Passik SD, et al. Use of the Zung Self-Rating Depression Scale in cancer patients: feasibility as a screening tool. Psychooncology 1998; 7:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/14\">",
"      Akechi T, Okuyama T, Sugawara Y, et al. Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. J Clin Oncol 2004; 22:1957.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, American Psychiatric Association, Washington, DC 1994.",
"    </li>",
"    <li>",
"     Strain, J. Adjustment disorders. In: Psycho-oncology, Holland, J (Ed), Oxford University Press, New York 1998. p.509.",
"    </li>",
"    <li>",
"     Massie, M, Holland, J, Lesko, L. Management of common psychiatric syndromes in elderly patients with cancer. In: Cancer and aging: Progress in research and treatment, Zenser, T, Coe, R (Eds), Springer Publishing Company, New York 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/18\">",
"      Zilberg NJ, Weiss DS, Horowitz MJ. Impact of Event Scale: a cross-validation study and some empirical evidence supporting a conceptual model of stress response syndromes. J Consult Clin Psychol 1982; 50:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/19\">",
"      Fabrega H Jr, Mezzich J. Adjustment disorder and psychiatric practice: cultural and historical aspects. Psychiatry 1987; 50:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/20\">",
"      Steel JL, Geller DA, Gamblin TC, et al. Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol 2007; 25:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/21\">",
"      Penninx BW, Guralnik JM, Pahor M, et al. Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 1998; 90:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/22\">",
"      Irwin MR. Depression and risk of cancer progression: an elusive link. J Clin Oncol 2007; 25:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/23\">",
"      Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004; :57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/24\">",
"      Ell K, Sanchez K, Vourlekis B, et al. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J Clin Oncol 2005; 23:3052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/25\">",
"      Moffic HS, Paykel ES. Depression in medical in-patients. Br J Psychiatry 1975; 126:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/26\">",
"      Katon W, Sullivan MD. Depression and chronic medical illness. J Clin Psychiatry 1990; 51 Suppl:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/27\">",
"      McDonald MV, Passik SD, Dugan W, et al. Nurses' recognition of depression in their patients with cancer. Oncol Nurs Forum 1999; 26:593.",
"     </a>",
"    </li>",
"    <li>",
"     Passik, SD, McDonald, MV, Dugan, W, et al. Depression in cancer patients: Recognition and treatment. Medscape 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/29\">",
"      Akizuki N, Akechi T, Nakanishi T, et al. Development of a brief screening interview for adjustment disorders and major depression in patients with cancer. Cancer 2003; 97:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/30\">",
"      Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/31\">",
"      Jefford M, Mileshkin L, Richards K, et al. Rapid screening for depression--validation of the Brief Case-Find for Depression (BCD) in medical oncology and palliative care patients. Br J Cancer 2004; 91:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/32\">",
"      Mitchell AJ. Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders. J Clin Oncol 2007; 25:4670.",
"     </a>",
"    </li>",
"    <li>",
"     Byock, L. Dying well: The prospect for growth at the end of life. Riverhead Books, New York 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/34\">",
"      Miccinesi G, Crocetti E, Benvenuti A, Paci E. Suicide mortality is decreasing among cancer patients in Central Italy. Eur J Cancer 2004; 40:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/35\">",
"      Tanaka H, Tsukuma H, Masaoka T, et al. Suicide risk among cancer patients: experience at one medical center in Japan, 1978-1994. Jpn J Cancer Res 1999; 90:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/36\">",
"      Allebeck P, Bolund C, Ringb&auml;ck G. Increased suicide rate in cancer patients. A cohort study based on the Swedish Cancer-Environment Register. J Clin Epidemiol 1989; 42:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/37\">",
"      Fox BH, Stanek EJ 3rd, Boyd SC, Flannery JT. Suicide rates among cancer patients in Connecticut. J Chronic Dis 1982; 35:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/38\">",
"      Fang F, Fall K, Mittleman MA, et al. Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med 2012; 366:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/39\">",
"      Yousaf U, Christensen ML, Engholm G, Storm HH. Suicides among Danish cancer patients 1971-1999. Br J Cancer 2005; 92:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/40\">",
"      Holland JC. Anxiety and cancer: the patient and the family. J Clin Psychiatry 1989; 50 Suppl:20.",
"     </a>",
"    </li>",
"    <li>",
"     Massie, MJ. Anxiety, panic and phobias. In: Handbook of Psychooncology: Psychological care of the patient with cancer, Holland, JC, Rowland, J (Eds), New York, Oxford University Press 1989. p.300.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/42\">",
"      Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/43\">",
"      Whitcup SM, Miller F. Unrecognized drug dependence in psychiatrically hospitalized elderly patients. J Am Geriatr Soc 1987; 35:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/44\">",
"      Bruera E, Bush SH, Willey J, et al. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer 2009; 115:2004.",
"     </a>",
"    </li>",
"    <li>",
"     Fleishman, SB, Lesko, LM. Delirium and dementia. In: Handbook of Psychooncology: Psychological care of the patient with cancer. Holland, J, Rowland, J (Eds), Oxford University Press, New York.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/46\">",
"      Levine PM, Silberfarb PM, Lipowski ZJ. Mental disorders in cancer patients: a study of 100 psychiatric referrals. Cancer 1978; 42:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/47\">",
"      Fann JR, Alfano CM, Burington BE, et al. Clinical presentation of delirium in patients undergoing hematopoietic stem cell transplantation. Cancer 2005; 103:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/48\">",
"      Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983; 140:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/49\">",
"      Tuma R, DeAngelis LM. Altered mental status in patients with cancer. Arch Neurol 2000; 57:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/50\">",
"      Bruera E, Macmillan K, Pither J, MacDonald RN. Effects of morphine on the dyspnea of terminal cancer patients. J Pain Symptom Manage 1990; 5:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/51\">",
"      Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 1989; 7:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/52\">",
"      Gaudreau JD, Gagnon P, Harel F, et al. Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol 2005; 23:6712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/53\">",
"      Gaudreau JD, Gagnon P, Roy MA, et al. Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer 2007; 109:2365.",
"     </a>",
"    </li>",
"    <li>",
"     Young, DF. Neurological complications of cancer chemotherapy. In: Neurological Complications of Therapy: Selected topics, Silverstein, A (Ed), Futura Publishing, New York 1982. p.57.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/55\">",
"      Holland J, Fasanello S, Onuma T. Psychiatric symptoms associated with L-asparaginase administration. J Psychiatr Res 1974; 10:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/56\">",
"      Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/57\">",
"      Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987; 107:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/58\">",
"      Weddington WW Jr. Delirium and depression associated with amphotericin B. Psychosomatics 1982; 23:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/59\">",
"      Lipowski ZJ. Delirium (acute confusional states). JAMA 1987; 258:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31080/abstract/60\">",
"      Gaudreau JD, Gagnon P, Harel F, et al. Fast, systematic, and continuous delirium assessment in hospitalized patients: the nursing delirium screening scale. J Pain Symptom Manage 2005; 29:368.",
"     </a>",
"    </li>",
"    <li>",
"     Breitbart, W, Passik, SD. Psychiatric aspects of palliative care. In: Oxford Textbook of Palliative Care, Oxford Press 1990.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4858 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31080=[""].join("\n");
var outline_f30_22_31080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9220769\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADJUSTMENT DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100093459\">",
"      SUICIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANXIETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DELIRIUM AND DEMENTIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9220769\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/4858\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/4858|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17756\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=related_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24778?source=related_link\">",
"      Euthanasia and physician assisted suicide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=related_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/57/11155?source=related_link\">",
"      Patient information: Delirium (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/24/22921?source=related_link\">",
"      Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_22_31081="Nodular basal cell carcinoma";
var content_f30_22_31081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65704%7EONC%2F61190%7EONC%2F59407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65704%7EONC%2F61190%7EONC%2F59407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pearly papule with telangiectasias is representative of a nodular basal cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A typical nodular basal cell carcinoma presents as a well-circumscribed nodule with a translucent or pearly appearance and telangiectasias (most evident in the left panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 186px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large basal cell tumors may develop vascular compromise, leading to central ulceration. This appearance has been historically referred to as a \"rodent ulcer.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31081=[""].join("\n");
var outline_f30_22_31081=null;
var title_f30_22_31082="Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure";
var content_f30_22_31082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31082/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31082/contributors\">",
"     Dana Miskulin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31082/contributors\">",
"     Ambreen Gul, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31082/contributors\">",
"     Michael R Rudnick, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31082/contributors\">",
"     Shawn E Cowper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31082/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31082/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/22/31082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/22/31082/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/22/31082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrogenic systemic fibrosis (NSF) is a fibrosing disorder seen only in patients with kidney failure. It is characterized by two primary features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thickening and hardening of the skin overlying the extremities and trunk",
"     </li>",
"     <li>",
"      Marked expansion and fibrosis of the dermis in association with CD34-positive fibrocytes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NSF was originally named nephrogenic fibrosing dermopathy (NFD) because of the characteristic skin findings. However, subsequent studies showed that some patients had fibrosis of deeper structures including muscle, fascia, lungs, and heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1\">",
"     1",
"    </a>",
"    ]. Because of the systemic findings, nephrogenic systemic fibrosis is preferred to nephrogenic fibrosing dermopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Systemic involvement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    NSF has also been called dialysis-associated systemic fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, this term is too narrow since the disease is not limited to patients on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSF occurs exclusively in patients with kidney failure. The first cases were noted between 1997 and 2000 in hemodialysis patients or patients with failed renal allografts who developed severe skin induration that was histologically thought to be scleromyxedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Subsequent reports have mostly involved patients on hemodialysis, but also included patients on peritoneal dialysis, renal transplant recipients (typically with reduced allograft function), patients with advanced chronic kidney disease, and acute renal failure not requiring dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/4,9-17\">",
"     4,9-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of cases has declined dramatically since initial reports, most certainly due to the avoidance of gadolinium-containing agents among at risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/18\">",
"     18",
"    </a>",
"    ]. As of January 2013, over 400 cases of NSF had been reported to the International NSF Registry at Yale University [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/19\">",
"     19",
"    </a>",
"    ]. Almost all cases were in adults, but children were also affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/20\">",
"     20",
"    </a>",
"    ]. By 2010 the number of cases reported to the United States Food and Drug Administration (FDA) Adverse Events Reporting System peaked at over 500 but the overwhelming majority of cases reported in 2010 related to events that occurred much earlier. By 2011, the number of reported cases decreased to approximately 150 (",
"    <a class=\"graphic graphic_figure graphicRef86395 \" href=\"mobipreview.htm?27/6/27757\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/21\">",
"     21",
"    </a>",
"    ]. Due to limitations of the Adverse Events Reporting System, reported cases are not necessarily confirmed cases and duplicate reporting of a single case cannot be excluded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no predilection to NSF by gender, race, or age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/22-25\">",
"     22-25",
"    </a>",
"    ], etiology of kidney disease, or duration of renal failure. However, patients undergoing peritoneal dialysis, compared with hemodialysis, may be at higher risk. As an example, a case control study found that, over a four year period, the attack rate after exposure to gadolinium was higher for peritoneal dialysis (PD) than for hemodialysis patients (4.6 cases per 100 PD patients versus 0.61 cases per 100 hemodialysis patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between time of dialysis initiation to diagnosis of NSF can vary, ranging from 2 months to 15 years in one series of 12 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10\">",
"     10",
"    </a>",
"    ]. Cases have been reported in the United States, Europe, and Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1\">",
"     1",
"    </a>",
"    ]. Clustering of cases suggests that NSF is underdiagnosed by clinicians who are unfamiliar with the condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective analysis of two large tissue repositories failed to identify any cases presenting before 1997 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1\">",
"     1",
"    </a>",
"    ]. These observations suggest that NSF is truly a new disease, which is probably due to exposure of patients with advanced renal failure to a new medication, infectious agent, or toxin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/9\">",
"     9",
"    </a>",
"    ]. Increasing evidence has implicated gadolinium-containing contrast agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gadolinium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gadolinium (Gd) is a non-radioactive, paramagnetic element in the lanthanide series. Gd",
"    <sup>",
"     +3",
"    </sup>",
"    ions closely approximate Ca",
"    <sup>",
"     2+",
"    </sup>",
"    ions in size, and consequently, Gd ions are effective (and toxic) calcium channel blockers. Gd is the active element of several non-tissue-specific, hyperosmolal (650",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    contrast agents that are primarily administered during magnetic resonance (MR) imaging or MR angiography studies. Because of its toxicity, Gd",
"    <sup>",
"     +3",
"    </sup>",
"    is bound to a proprietary ligand (or chelate). The chelates can be ionic or non-ionic and linear or cyclical. Generally, ionic and cyclic chelates bind gadolinium more strongly than non-ionic or linear chelates respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Binding of Gd",
"    <sup>",
"     +3",
"    </sup>",
"    ions reduces their interaction with tissues and facilitates their excretion.",
"   </p>",
"   <p>",
"    The five most commonly used FDA approved gadolinium-chelates differ by biochemical structure and charge. Linear chelates include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24277?source=see_link\">",
"     gadopentetate dimeglumine",
"    </a>",
"    (Magnevist),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/41/39573?source=see_link\">",
"     gadodiamide",
"    </a>",
"    (Omniscan),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/45/25301?source=see_link\">",
"     gadobenate dimeglumine",
"    </a>",
"    (MultiHance) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/55/25461?source=see_link\">",
"     gadoversetamide",
"    </a>",
"    (OptiMARK) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/27\">",
"     27",
"    </a>",
"    ]. Gadopentetate (Magnevist) and gadobenate dimeglumine (MultiHance) are ionic and gadodiamide (Omniscan), gadoversetamide (OptiMARK) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/15/4341?source=see_link\">",
"     gadoteridol",
"    </a>",
"    (ProHance) are nonionic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gadolinium containing contrast agents are excreted unchanged almost exclusively by the kidney. Their half-life is 1.3 hours in healthy volunteers, 10 hours at an estimated glomerular filtration rate (GFR) of 20 to 40",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and 34 hours in patients with end-stage renal disease. For patients with end-stage renal disease, the half-life is reduced dramatically to between 1.9 to 2.6 hours if hemodialysis follows the administration of gadolinium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. A discussion of issues surrounding dialysis after gadolinium exposure is found elsewhere. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'If gadolinium must be given'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    At physiological pH macrocyclic chelates are less likely to dissociate than linear chelates, although NSF has been noted with both types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/27\">",
"     27",
"    </a>",
"    ]. This has led to the hypothesis that excess exposure to free Gd3+ in patients with kidney disease leads to tissue damage. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Role of free gadolinium'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Support for the pathogenic role of gadolinium comes from the demonstration of gadolinium deposition in tissue specimens of some patients with NSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/17,32-35\">",
"     17,32-35",
"    </a>",
"    ]. In one report, for example, gadolinium was noted in 4 of 13 specimens in seven patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/32\">",
"     32",
"    </a>",
"    ]. It was suggested that gadolinium had a tissue residence time of 4 to 11 months.",
"   </p>",
"   <p>",
"    The first report that suggested an association of gadolinium with NSF was published in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/36\">",
"     36",
"    </a>",
"    ]. Between 2006 and 2008 more than 300 cases linking gadolinium with NFD were published.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case series from Austria, NSF developed in five of nine hemodialysis patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/41/39573?source=see_link\">",
"       gadodiamide",
"      </a>",
"      (Omniscan) for MR angiography, a technique that may require up to three times the contrast dose used in routine MR imaging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/36\">",
"       36",
"      </a>",
"      ]. Symptoms appeared two to four weeks after exposure. There was no correlation with age, sex, underlying renal disease, drug therapy, dialysis modality, or comorbid conditions.",
"     </li>",
"     <li>",
"      In a case series from Denmark, 13 patients with end-stage renal disease (seven on hemodialysis, one on peritoneal dialysis, and five not requiring dialysis) developed symptoms of NSF a mean of 25 days (range 2 to 75 days) after exposure to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/41/39573?source=see_link\">",
"       gadodiamide",
"      </a>",
"      (Omniscan) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/13\">",
"       13",
"      </a>",
"      ]. There was no correlation between gadodiamide dose and NSF severity. No other exposure or event could be identified that was common to more than a minority of the patients. Of note, 6 of the 13 patients had been previously exposed to gadolinium without developing NSF.",
"     </li>",
"     <li>",
"      In a detailed review of 75 cases of NSF performed by the United States Food and Drug Administration (FDA), all had received a gadolinium-based contrast agent for an MR study two days to 18 months before disease onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/37\">",
"       37",
"      </a>",
"      ]. Similar findings were noted by the International NSF registry: more than 95 percent of cases reported to the registry had been exposed to gadolinium within two to three months of disease onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective cohort study from Denmark, among 565 patients with renal insufficiency who were exposed to gadolinium-based contrast agents, 17 cases of NSF were identified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/38\">",
"       38",
"      </a>",
"      ]. By contrast, there were no cases of NSF among age and sex matched controls who had renal insufficiency but were not exposed to such agents. The prevalence of NSF was highest among patients with estimated GFR &lt;15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2, including those on dialysis. However three cases involved patients with estimated GFR between 15 and 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NSF has been reported after the administration of the five most commonly used FDA approved gadolinium-chelates in the United States (Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/39\">",
"     39",
"    </a>",
"    ]. The FDA added a boxed warning and new warnings to the product labeling about the risk of NSF with all gadolinium-based agents in 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is strong evidence that the risk of NSF is greater with linear than with macrocyclic preparations. As an example, in the United States among cases in which the type of gadolinium preparation was reported,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/41/39573?source=see_link\">",
"     gadodiamide",
"    </a>",
"    causes greater than 80 percent of cases, with the remainder mostly due to gadopentetate. This cannot be explained by relative market share since gadopentetate has the highest share in the United States.",
"   </p>",
"   <p>",
"    In addition, a retrospective study of the Veterans Affairs Electronic Medical Records found no cases of NSF among 141 patients with 198 single agent exposures to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/15/4341?source=see_link\">",
"     gadoteridol",
"    </a>",
"    (a macrocyclic agent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/28\">",
"     28",
"    </a>",
"    ]. The author also further analyzed MedWatch data reporting that 283, 125, 20, 10, and 9 cases were associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/41/39573?source=see_link\">",
"     gadodiamide",
"    </a>",
"    , gadopentetate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/55/25461?source=see_link\">",
"     gadoversetamide",
"    </a>",
"    , gadobenate, and gadoteridol, respectively. These results may be explained in part by low market share for some formulations, and significantly more exposures with gadopentetate compared with other formulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/40\">",
"     40",
"    </a>",
"    ]. However, there was only one case of NSF due to single agent exposure to gadoteridol. The FDA revised the Black Box warning in 2010, advising practitioners against the use of gadodiamide, gadoversetamide, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24277?source=see_link\">",
"     gadopentetate dimeglumine",
"    </a>",
"    (all linear agents) in patients with acute kidney injury (AKI) or chronic kidney disease with estimated GFR &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the magnitude of the risk after exposure to gadolinium, which varies by level of GFR. Most of the cases have been reported in chronic dialysis patients. The reported risk has ranged between 2.5 and 5 percent in studies of approximately 400 to 500 dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Cases have been reported in patients with acute kidney injury. The risk in individuals with estimated GFR of 15 to 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 remains undefined but cases have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/44\">",
"     44",
"    </a>",
"    ]. The risk is felt to be low among patients with estimated GFR 15 to 29",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    per 1.73m2 (ie, stage 4) and very low in individuals with estimated GFR 30 to 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 (ie, stage 3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/29/5594?source=see_link&amp;anchor=H27259120#H27259120\">",
"     \"Definition and staging of chronic kidney disease\", section on 'GFR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is some evidence that a dose-response relationship exists. This was illustrated in a report of 301 MR imaging studies with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/41/39573?source=see_link\">",
"     gadodiamide",
"    </a>",
"    in dialysis patients: 207 were done with a double dose (0.2",
"    <span class=\"nowrap\">",
"     mmol/kg)",
"    </span>",
"    and 94 with a single dose (0.1",
"    <span class=\"nowrap\">",
"     mmol/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/44\">",
"     44",
"    </a>",
"    ]. All 12 NSF patients (eight chronic dialysis patients and four with acute hepatorenal syndrome) had received a double dose. The odds ratio for the development of NSF after a double versus single dose of gadodiamide was calculated at 22.3 (95% CI 1.3-378).",
"   </p>",
"   <p>",
"    In another study, the cumulative dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/41/39573?source=see_link\">",
"     gadodiamide",
"    </a>",
"    was higher among patients with more severe NSF (lifetime dose 0.5 &plusmn; 0.09 vs. 0.33 &plusmn; 0.04 mmol &frasl;kg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/13\">",
"     13",
"    </a>",
"    ]. The odds ratio for developing NSF after a 0.2 mmol &frasl;kg gadodiamide dose compared with a 0.1 mmol &frasl;kg dose, (the maximum recommended dose), was estimated in another series as 12.1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/3,44\">",
"     3,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many centers have stopped using gadolinium-based contrast agents in patients with estimated GFR &lt;30",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    per 1.73m2 or undergoing dialysis. A study from Johns Hopkins University, reports a decrease in the incidence rate of NSF after increased screening, restricting use, reducing doses and dialyzing immediately post dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/46\">",
"     46",
"    </a>",
"    ]. Similarly, a study from Massachusetts General Hospital also showed no cases of NSF after adopting a restrictive policy for gadolinium use in patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Erythropoietin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    (EPO) therapy or an increase in dose may be associated with NSF, but the true nature of the relationship between EPO and NSF remains incompletely understood. EPO has been implicated because: it has fibrogenic properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/9\">",
"     9",
"    </a>",
"    ]; it stimulates the bone marrow; it is associated with animal models of NSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/49\">",
"     49",
"    </a>",
"    ]; and a large number of bone-marrow derived CD34+ fibroblasts infiltrate the dermis in NSF. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The possible etiologic role of EPO, particularly high-dose EPO, was evaluated in a study that compared 22 hemodialysis patients with biopsy proven NSF to 50 control hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/50\">",
"     50",
"    </a>",
"    ]. Almost one-half of patients in both groups had been exposed to gadolinium prior to the development of NSF. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The skin changes of NSF began after the initiation of EPO therapy in all 22 patients. In 15 patients, NSF developed between two and 16 weeks after the initiation of EPO. In six patients, the weekly EPO dose was increased by a median of 312",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      between one and nine months before symptom onset.",
"     </li>",
"     <li>",
"      The NSF patients received a significantly higher median dose of EPO than controls (427 versus 198",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      per week).",
"     </li>",
"     <li>",
"      NSF improved in some patients who stopped or decreased the dose of EPO. However, it is unclear if this was due to the reduction in therapy or recovery of renal function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since this study was not controlled, a cause-and-effect relationship between EPO and NSF cannot be proven. In addition, the data regarding gadolinium seem compelling since more than 95 percent of cases reported to the NSF registry had been exposed to gadolinium within two to three months of disease onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other possible associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other possible associations with NSF have been described or suggested, all occurring in patients with renal disease, most of whom were dialysis-dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review identified fistula reconstruction or dialysis catheter placement in 90 percent of patients and kidney or liver transplantation in 48 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/24\">",
"       24",
"      </a>",
"      ]. In addition, a thrombotic complication preceded the diagnosis of NSF in 12 percent, many of whom had an unsuspected hypercoagulable state.",
"     </li>",
"     <li>",
"      In a retrospective single center study, the presence of an infection at the time of gadolinium contrast administration markedly increased the risk of NSF in dialysis patients (odds ratio of 25, 95% CI 3.9-264) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/51\">",
"       51",
"      </a>",
"      ]. Further studies are required to verify this association.",
"     </li>",
"     <li>",
"      An association between NSF and liver transplant recipients has been described in combination with advanced renal dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. The patients required dialysis before or after transplantation, although some patients were no longer dialysis-dependent at the onset of NSF. A recent article has refuted this association [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some have proposed that the absence of treatment with ACE inhibitors, which have antifibrogenic properties, may promote the development of NSF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/55\">",
"       55",
"      </a>",
"      ]. However, this has not been a consistent finding in patients with NSF.",
"     </li>",
"     <li>",
"      A case report described two patients without a history of exposure to gadolinium who developed NSF post-kidney transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/56\">",
"       56",
"      </a>",
"      ]; the authors postulated that vascular manipulation or endothelial injury was a possible trigger.",
"     </li>",
"     <li>",
"      Medications considered to have fibrogenic properties, such as selective serotonin reuptake inhibitors and calcineurin inhibitors, have not been associated with NSF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A deep biopsy is needed, since the fibrotic lesions may extend into the subcutaneous tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1\">",
"     1",
"    </a>",
"    ]. Routine light microscopy varies with disease severity, ranging from a subtle proliferation of dermal fibrocytes in early lesions, to marked thickening of the dermis with a florid proliferation of fibrocytes with long dendritic processes in fully developed cases, often associated with histiocytes and stellate factor XIIIa+ dermal dendritic cells (",
"    <a class=\"graphic graphic_picture graphicRef63319 graphicRef75055 \" href=\"mobipreview.htm?24/45/25305\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1,57\">",
"     1,57",
"    </a>",
"    ]. Thick collagen bundles with surrounding clefts are a prominent finding, and a variable increase in dermal mucin and elastic fibers is usually evident with special stains.",
"   </p>",
"   <p>",
"    Immunohistochemical staining reveals abundant CD34+ dermal dendritic cells, with the dendritic processes aligning along elastic fibers and around collagen bundles in a dense network (",
"    <a class=\"graphic graphic_picture graphicRef76644 graphicRef56673 \" href=\"mobipreview.htm?35/17/36121\">",
"     picture 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/57\">",
"     57",
"    </a>",
"    ]. It has been suggested that the CD34+ cells are circulating fibrocytes that have been recruited to the dermis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. There is also an increased number of CD68+ and factor XIII+ dendritic cells, some of which are positive for both markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/4,23\">",
"     4,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, special testing may reveal gadolinium in tissue specimens from some patients who have been exposed to gadolinium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/32,33,35\">",
"     32,33,35",
"    </a>",
"    ]. Identification of gadolinium in patient tissue is not, by itself, diagnostic of NSF. The absence of gadolinium in patient tissues does not exclude a diagnosis of NSF if the clinical and pathological criteria are fulfilled (see consensus scoring system below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of NSF is not fully understood. The resemblance of NSF to a tissue injury reaction and the presence of myofibroblasts in the tissue specimens suggest that fibrogenic cytokines may be important, possibly resulting in a cascade of events similar to wound healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/3,11\">",
"     3,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two proposed contributors to the exaggerated tissue fibrosis are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation of the transforming growth factor (TGF)-beta-1 pathway",
"     </li>",
"     <li>",
"      An increase in circulating fibrocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/4,10,24\">",
"       4,10,24",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     TGF-beta-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to TGF-beta-1, in situ hybridization studies have showed a marked increase in TGF-beta-1 mRNA levels in the skin and fascia of affected patients in association with large numbers of",
"    <span class=\"nowrap\">",
"     CD68+/factor",
"    </span>",
"    XIIIa+ dendritic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/4,57\">",
"     4,57",
"    </a>",
"    ]. According to one theory, a noxious stimulus activates",
"    <span class=\"nowrap\">",
"     CD68+/factor",
"    </span>",
"    XIIIa+ dendritic cells in tissue, which produce TGF-beta-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10\">",
"     10",
"    </a>",
"    ]. A vicious cycle ensues as TGF-beta-1 regulates dendritic cell maturation and antigen presentation. This leads to further recruitment and activation of dendritic cells and more TGF-beta-1 production resulting in generation of tissue fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Increased circulating fibrocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second theory is that a putative toxin directly stimulates the bone marrow to produce CD34+ circulating fibrocytes, which accumulate in the affected tissue and produce collagen in the absence of tissue injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10\">",
"     10",
"    </a>",
"    ]. There is evidence that the tissue fibrosis in NSF is caused by circulating fibrocytes recruited from the circulation, rather than by proliferation of resident dendritic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Proinflammatory/profibrotic cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSF affected tissues, compared to normal tissues, contain increased numbers of macrophages and fibroblasts. TGF-beta expression is also increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/4\">",
"     4",
"    </a>",
"    ]. This prompted researchers to examine the effect of gadolinium chelates on the expression and production of a panel of profibrotic and proinflammatory cytokines and growth factors by normal human peripheral blood monocytes in vitro. In response to the gadolinium chelates, a marked increase in expression was noted for IL-13, IL-4, IL-6, and IL-13. There was also increased expression of TGF-beta, and VEGF. In contrast, the expression levels of two other cytokines examined, CTGF and TNF-alpha, were not affected by exposure to any of the gadolinium containing compounds. This indicated that the upregulation observed for the other cytokines and growth factors was not a non-specific effect but reflected a real monocyte response. This led researchers to hypothesize that secretion of several cytokines and growth factors by peripheral blood monocytes, generally accepted to play important roles in the initiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression of fibrotic processes, are responsible for the pathogenesis of NSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Role of free gadolinium",
"    </span>",
"    &nbsp;&mdash;&nbsp;With either theory, the inciting event may be the tissue deposition of an initiating toxin, such as gadolinium&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/3\">",
"     3",
"    </a>",
"    ]. Free gadolinium (Gd3+) is poorly soluble, highly toxic, and can form precipitates with anions that tend to be elevated in renal failure. To enable its use in humans, free Gd3+ is bound to a large organic molecule (called a chelate), which prevents its dissociation. Free Gd 3+ may dissociate from the chelate with prolonged exposure to gadolinium in those with kidney failure who do not undergo dialysis. Iron mobilization may also induce the dissociation of gadolinium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Free Gd3+ has several deleterious effects in vivo. It precipitates in tissues, disrupts calcium ion passage in nerve and muscle cells, and interferes with intracellular enzymes and cell membranes through a process of transmetallation, wherein Gd3+ swaps places with endogenous metals such as zinc and copper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/60\">",
"     60",
"    </a>",
"    ]. Anions, such as phosphate, which tend to be elevated in renal failure, may be a cofactor in the development of NSF by precipitating with free Gd 3+ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSF is characterized by skin involvement in all patients and systemic involvement in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1\">",
"     1",
"    </a>",
"    ]. Among patients with gadolinium exposure, the latent period between exposure and disease onset is usually two to four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/13,36\">",
"     13,36",
"    </a>",
"    ]. However, the reported range is as short as two days and as long as 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Skin involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin disease in NSF typically presents as symmetrical, bilateral fibrotic indurated papules, plaques, or subcutaneous nodules that may or may not be erythematous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1,57,61\">",
"     1,57,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the majority of cases, the lesions first develop on the ankles, lower legs, feet, and hands and then move proximally to involve the thighs, forearms, and, less often, the trunk or buttocks. Common distribution patterns involve the ankles to below the knees, the mid-thighs, and the skin between the wrists and mid-upper arms, bilaterally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10,23\">",
"     10,23",
"    </a>",
"    ]. Unusual distribution patterns involving the skin overlying the mid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/14\">",
"     14",
"    </a>",
"    ] and lower abdomen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10,23\">",
"     10,23",
"    </a>",
"    ] have been reported. The head is spared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10,62\">",
"     10,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lesions are often preceded by edema and may initially be misdiagnosed as cellulitis. The edema usually resolves and the involved skin retains a thickened and firm texture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1\">",
"     1",
"    </a>",
"    ]. The skin may have a \"cobblestone\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/63\">",
"     63",
"    </a>",
"    ], \"woody\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1,4,10\">",
"     1,4,10",
"    </a>",
"    ], or peau d' orange appearance (orange peel-like) (",
"    <a class=\"graphic graphic_picture graphicRef77008 \" href=\"mobipreview.htm?5/61/6111\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1,62\">",
"     1,62",
"    </a>",
"    ]. The lesions may be pruritic and accompanied by sharp pain or a burning sensation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1,4,22\">",
"     1,4,22",
"    </a>",
"    ]. Movement of the joints may be so limited by the fibrosis that flexibility is lost (",
"    <a class=\"graphic graphic_picture graphicRef69935 graphicRef82710 \" href=\"mobipreview.htm?14/1/14358\">",
"     picture 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There may be sclerodactyly or loss of skin appendages of the dorsum of the hands and lower extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/4\">",
"     4",
"    </a>",
"    ]. Unlike autoimmune sclerosing conditions, livedo reticularis is not a feature of NSF.",
"   </p>",
"   <p>",
"    Late in the disease, hyperpigmentation, hairlessness, and epidermal atrophy have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/64\">",
"     64",
"    </a>",
"    ]. Confluent dermal plaques with thickening and hardening may also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Systemic involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of systemic involvement is unknown, but a number of different organ system manifestations have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle induration may be seen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/5,23,65\">",
"       5,23,65",
"      </a>",
"      ], but strength is normal or only slightly reduced [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/5\">",
"       5",
"      </a>",
"      ]. Joint contractures are common with advanced disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/4,5,10\">",
"       4,5,10",
"      </a>",
"      ]. The limitation in motion appears to be due to periarticular skin thickening, since there is no evidence of synovitis or arthritis. Computed tomography shows fibrosis of the fascia and muscles in the most severely affected patients; muscle fibrosis may also be seen on histologic examination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fibrosis has also been identified in a variety of internal organs, including the lungs (with reduced diffusing capacity for carbon monoxide) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/4\">",
"       4",
"      </a>",
"      ] and diaphragm (with respiratory failure) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/23,66\">",
"       23,66",
"      </a>",
"      ], myocardium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/4,23,67\">",
"       4,23,67",
"      </a>",
"      ], pericardium, pleura [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/23\">",
"       23",
"      </a>",
"      ], and dura mater [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Yellow asymptomatic scleral plaques are common (",
"      <a class=\"graphic graphic_picture graphicRef54337 \" href=\"mobipreview.htm?28/63/29680\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1,24\">",
"       1,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with systemic disease may have marked elevations in erythrocyte sedimentation rate and serum C-reactive protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcification of soft tissue, muscle, vasculature, myocardium and cardiac valves has also been noted in patients with NSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/61\">",
"     61",
"    </a>",
"    ]. However, these findings can also result from the secondary hyperparathyroidism associated with advanced renal failure. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of NSF is based upon histopathologic examination of a biopsy of an involved site. A deep incisional or punch biopsy should be performed since the typical changes can extend into the subcutaneous fat, fascia, and muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/24,61\">",
"     24,61",
"    </a>",
"    ]. Repeat biopsy is warranted if the initial biopsy is nondiagnostic but the clinical picture is strongly suggestive of NSF.",
"   </p>",
"   <p>",
"    The evaluation of possible NSF should also include asking if the patient has had a recent MR imaging procedure that might have involved gadolinium administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no laboratory test that is specific for NSF. Affected patients have findings consistent with chronic inflammation, including elevations in serum C-reactive protein, serum ferritin, and the erythrocyte sedimentation rate and a reduction in serum albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with a thrombotic event may be tested for a hypercoagulable state, particularly if occurring in an unusual location (eg, arterial). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Screening for inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the tests that are normal are the eosinophil count, serum and urine protein electrophoresis, thyroid function tests, serum creatine kinase (which may be below normal), antinuclear antibodies, anticentromere and anti-topoisomerase I (Scl-70) antibodies, and rheumatoid factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. Antiphospholipid antibodies may be elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/68\">",
"     68",
"    </a>",
"    ], but this is not a consistent finding and elevations are common in patients on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is often unclear whether extracutaneous involvement is due to NSF or other comorbid conditions, pulmonary function tests may reveal reductions in total lung capacity and volume and diffusing capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10\">",
"     10",
"    </a>",
"    ]. Two-dimensional echocardiography is suggested to document possible cardiomyopathy. Muscle biopsy may be obtained to determine the extent of systemic involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266305852\">",
"    <span class=\"h2\">",
"     Consensus scoring system",
"    </span>",
"    &nbsp;&mdash;&nbsp;A scoring system was developed using data from the Yale International NSF Registry in order to provide a more standardized method for establishing the diagnosis of NSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/69\">",
"     69",
"    </a>",
"    ]. This system assigns scores to clinical features (obtained from history, physical exam and laboratory evaluation) and histologic features obtained on skin biopsy (",
"    <a class=\"graphic graphic_table graphicRef64487 \" href=\"mobipreview.htm?37/46/38635\">",
"     table 1",
"    </a>",
"    ). Clinical and histologic scores of 0 to 4 are plotted on a reporting grid (",
"    <a class=\"graphic graphic_figure graphicRef55350 \" href=\"mobipreview.htm?16/51/17214\">",
"     figure 2",
"    </a>",
"    ). The utility of this scoring system in establishing the diagnosis has not been validated.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thickening and hardening of the skin overlying the extremities and trunk can simulate a variety of other disorders such as systemic sclerosis (scleroderma), scleromyxedema, and eosinophilic fasciitis. Distinguishing between these disorders is discussed separately, but a history of advanced renal failure temporally-associated with gadolinium exposure is strongly suggestive of NSF.",
"   </p>",
"   <p>",
"    In addition, the following findings are helpful in the differential diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The absence of Raynaud's phenomenon argues strongly against systemic sclerosis. In addition, the absence of antinuclear antibodies and either anticentromere or anti-DNA topoisomerase I (Scl-70) antibodies argues against both the limited and diffuse forms of systemic sclerosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43095?source=see_link\">",
"       \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The skin lesions and histopathologic findings in NSF resemble those in scleromyxedema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/70\">",
"       70",
"      </a>",
"      ]. Distinguishing clinical features are sparing of the head in NSF and the association of most scleromyxedema cases with a monoclonal gammopathy, usually with an IgG lambda paraprotein [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10,62\">",
"       10,62",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link&amp;anchor=H31#H31\">",
"       \"Cutaneous manifestations of internal malignancy\", section on 'Scleromyxedema and scleredema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical manifestations in NSF resemble eosinophilic fasciitis but are distinguished by frequent involvement of the hands and feet, which are typically spared in eosinophilic fasciitis, and the absence of eosinophilia and eosinophilic tissue infiltration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/10/8360?source=see_link\">",
"       \"Eosinophilic fasciitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Calciphylaxis, which can occur in patients with chronic kidney disease, may be mistaken for early NSF. Tissue biopsy and the clinical presentation can usually distinguish between these disorders, but evidence of both has been described in a case report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15017?source=see_link\">",
"     \"Calciphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Extraosseous calcification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSF has a chronic and unremitting course in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10,11,13,24,57,71,72\">",
"     10,11,13,24,57,71,72",
"    </a>",
"    ]. In a review of the published literature, 28 percent of patients had no improvement, 20 percent had modest improvement, and 28 percent of patients died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10\">",
"     10",
"    </a>",
"    ]. More severe and rapid progression of the skin disease is associated with a poor prognosis and death.",
"   </p>",
"   <p>",
"    A fulminant form of NSF, with development of flexion contractures and loss of mobility, has been described in 5 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/24\">",
"     24",
"    </a>",
"    ]. Such patients may become wheelchair bound within weeks. It is possible that some of these patients had received repeated administrations of gadolinium.",
"   </p>",
"   <p>",
"    Improvement in or remission of NSF has been described, primarily in patients who recovered renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10,11,24,25\">",
"     10,11,24,25",
"    </a>",
"    ]. In such patients, the improvement in renal function seems to slow or stop disease progression and, in many patients, results in gradual reversal of the disease. In the review above, less than 40 percent of patients underwent complete remission following the cessation of dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major preventive measure for nephrogenic systemic fibrosis that can be currently recommended to patients with advanced kidney failure is the avoidance of gadolinium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Avoidance of gadolinium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the apparent association between NSF and gadolinium in the great majority of cases (more than 95 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/13,36,39,73\">",
"     13,36,39,73",
"    </a>",
"    ], the United States Food and Drug Administration (FDA) recommends in patients with estimated GFR&lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2, receiving dialysis, or with acute kidney injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gadolinium-containing contrast agents should be used only if clearly necessary. Gadolinium should be avoided in patients with a diagnosis or clinical suspicion of NSF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/41/39573?source=see_link\">",
"       Gadodiamide",
"      </a>",
"      (Omniscan),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/55/25461?source=see_link\">",
"       gadoversetamide",
"      </a>",
"      (OptiMARK), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24277?source=see_link\">",
"       gadopentetate dimeglumine",
"      </a>",
"      (Magnevist) should be avoided.",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although there are no data that support the following approach, it may be prudent to institute prompt hemodialysis after the imaging study is completed if gadolinium is given. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'If gadolinium must be given'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The American College of Radiology has released similar recommendations to those of the FDA but extend these to individuals with an estimated GFR of 30 to 44",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m",
"      <sup>",
"       2",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients at risk, the best current estimate is that 2.5 to 5 percent will develop NSF after a gadolinium imaging study. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The GFR can be estimated from the serum creatinine concentration ONLY in patients who have a stable value. This is an important issue in patients with acute renal failure in whom the serum creatinine is not stable. Failure to take this into account can lead to marked overestimation of the GFR, falsely suggesting that the patient is not at risk for NSF. As an example, suppose an 80 kg, 60 year-old man has acute renal failure (eg, acute kidney injury) for 18 hours and has a serum creatinine that is now 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    The estimation equations will yield a GFR of approximately 40",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    which would suggest low risk for NSF. However, the real GFR is much lower, as would become apparent by a much higher serum creatinine the next day. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary alternative to gadolinium-based MR imaging is imaging with conventional iodinated radiocontrast media or the use of noncontrast imaging studies. MR imaging has frequently been used in patients at increased risk for contrast nephropathy, (such patients with a reduced estimated GFR from any cause). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In dialysis patients or those with estimated GFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m",
"    <sup>",
"     2",
"    </sup>",
"    , we prefer the risk of radiocontrast nephropathy with iodinated contrast media, using all of the preventive measures that are available (including the use of low doses for mapping hemodialysis access), to the risk of the much more severe complication of NSF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of NSF after gadolinium administration has not been defined in patients who have an estimated GFR between 30 and 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m",
"    <sup>",
"     2",
"    </sup>",
"    . As previously mentioned, almost all cases of NSF after gadolinium exposure have been reported in patients on dialysis or with advanced renal failure (estimated GFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m",
"    <sup>",
"     2",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/74\">",
"     74",
"    </a>",
"    ]. At least two patients have been reported to have developed NSF with an estimated GFR between 30 and 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m",
"    <sup>",
"     2",
"    </sup>",
"    , although the accuracy of these estimates have been called into question as they were performed in the setting of acute kidney injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/17,39\">",
"     17,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to administer gadolinium among patients with an estimated GFR between 30 and 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m",
"    <sup>",
"     2",
"    </sup>",
"    requires consideration of multiple factors including patient preference, the unknown risk of NSF with gadolinium exposure in a single individual, and the risk of arterial puncture if conventional arteriography were performed. Nephropathy due to iodinated contrast is also a concern, but at this level of baseline, renal function is rarely associated with irreversible injury.",
"   </p>",
"   <p>",
"    There is no consensus among the authors and reviewers of this topic. Some would use gadolinium-based contrast if indicated, while others would try to avoid its use if possible. In general it seems advisable to limit exposure of any patient with marginal renal function to the three gadolinium based contrast agents deemed the highest risk. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     If gadolinium must be given",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with estimated GFR &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2, who it is felt must receive a gadolinium contrast study, we suggest the following approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient should be informed of the benefits, risks, and alternatives.",
"     </li>",
"     <li>",
"      Avoid linear chelates such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/41/39573?source=see_link\">",
"       gadodiamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/55/25461?source=see_link\">",
"       gadoversetamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24277?source=see_link\">",
"       gadopentetate dimeglumine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/13,36\">",
"       13,36",
"      </a>",
"      ]. We agree with the 2012 KDIGO guidelines that suggest that among such patients, macrocyclic chelate preparations (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/15/4341?source=see_link\">",
"       gadoteridol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39141?source=see_link\">",
"       gadobutrol",
"      </a>",
"      , or gadoterate) be used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/75\">",
"       75",
"      </a>",
"      ]. Gadolinium should be given in the lowest dose deemed necessary to provide the desired diagnostic information (preferably no more than one-half the standard dose). Attaining nonenhanced sequences may be helpful.",
"     </li>",
"     <li>",
"      Hemodialysis immediately after gadolinium exposure results in significant removal of the contrast agent. As an example, in a review of 70 hemodialysis patients who underwent gadolinium contrast MR imaging, the average rates of gadolinium removal were 78, 96, and 99 percent in the first, second, and third every-other-day dialysis sessions, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/76\">",
"       76",
"      </a>",
"      ]. In a second study of 13 anuric patients, the average elimination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/41/39573?source=see_link\">",
"       gadodiamide",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mmol/kg)",
"      </span>",
"      with hemodialysis initiated at 1 to 4.5 hours after exposure was 73, 93, and 99 percent with one, two, and three treatments, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/31\">",
"       31",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although there is no evidence that hemodialysis immediately after exposure lowers the risk or severity of NSF, we recommend the following approach since NSF is such a severe disease:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among patients who are on maintenance hemodialysis, we try to schedule the study just before the patient's next scheduled dialysis session. When gadolinium administration cannot be timed just before the next scheduled dialysis, we suggest an additional treatment session just after the imaging study. In either case, the dialysis session should optimally be performed as soon as possible after gadolinium administration (within hours not days).",
"     </li>",
"     <li>",
"      A second dialysis session at 24 hours should be considered if clinically safe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gadolinium is cleared much more slowly with continuous ambulatory peritoneal dialysis (69 percent after 22 days in one report) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/29\">",
"       29",
"      </a>",
"      ]. Thus, among patients on maintenance peritoneal dialysis (PD), we recommend hemodialysis after the procedure according to the above regimen in patients. Placement of a temporary hemodialysis catheter (internal jugular or femoral vein) should be performed in PD patients without a functioning arteriovenous vascular access. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of central catheters for acute and chronic hemodialysis access\", section on 'Dialysis catheter complications'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If hemodialysis cannot be performed, we suggest more frequent peritoneal dialysis cycles for at least 48 hours after exposure, with no periods with a dry abdomen. In a case report in a single anuric chronic PD patient, 90 percent of 0.1",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/41/39573?source=see_link\">",
"       gadodiamide",
"      </a>",
"      was removed from the circulation in two days with a regimen of 10 to 15 exchanges per day of PD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients not on dialysis who have an estimated GFR less than 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      and a functioning chronic hemodialysis vascular access, we would also perform hemodialysis as soon as possible after gadolinium administration (within hours not days).",
"     </li>",
"     <li>",
"      Among patients not on dialysis who have an estimated GFR less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      and do not have a functioning vascular access, the possible benefits associated with gadolinium removal must be weighed against the possible adverse effects associated with placement of a large vascular catheter and performance of hemodialysis. Despite the risks, we suggest initiating hemodialysis according to the above regimen. An attempt should be made to schedule elective imaging studies at a time at which the patient has a functioning access so that hemodialysis can be performed soon after the gadolinium is administered. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of central catheters for acute and chronic hemodialysis access\", section on 'Dialysis catheter complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The approach to patients with an estimated GFR between 15 and 29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      who do not have a functioning vascular access is unclear. We do not perform hemodialysis in this setting, given the unknown benefit of gadolinium removal in these patients and the risk associated with placement of a temporary hemodialysis catheter. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of central catheters for acute and chronic hemodialysis access\", section on 'Dialysis catheter complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We do not perform hemodialysis after gadolinium exposure in patients with an estimated GFR between 30 and 60",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the indirect evidence in a single study suggesting a possible link between EPO and NSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/50\">",
"     50",
"    </a>",
"    ], we suggest that EPO NOT be discontinued. EPO doses should be given to attain current recommended hemoglobin target levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no proven therapy for NSF other than recovery of renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10\">",
"     10",
"    </a>",
"    ]. Several treatments and combinations of treatments have been evaluated, but none has shown consistent benefit. Because NSF is a new and uncommon disorder, most studies have involved a small number of patients with limited follow-up.",
"   </p>",
"   <p>",
"    In addition to therapies directed toward improving renal function or the disease process, intensive physical therapy is recommended in all patients to prevent or reverse disability related to joint contractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, the hands should be splinted in a functional position to prevent progressive contractures of the finger joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Kidney transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the frequent stabilization of or improvement in NSF in patients who recover renal function as described in the previous section [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10,11,24,25,79\">",
"     10,11,24,25,79",
"    </a>",
"    ], renal transplantation may offer the best hope of benefit in patients who are candidates for this procedure although efficacy is unproven unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NSF does not currently affect the transplant wait time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11240?source=see_link\">",
"     \"The kidney transplant waiting list\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Extracorporeal photopheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal photopheresis (ECP, also called photochemotherapy) involves extracorporeal exposure of peripheral blood mononuclear cells to photoactivated 8-methoxypsoralen, followed by reinfusion of the treated cells. ECP induces monocyte-derived tumor necrosis factor-alpha, which in turn suppresses collagen synthesis and enhances collagenase production.",
"   </p>",
"   <p>",
"    In a series of three patients, ECP resulted in marked resolution of skin lesions and normalization of skin distensibility in two patients who were treated with 8 to 16 cycles at two to four week intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/16\">",
"     16",
"    </a>",
"    ]. The two patients started to show response by the fourth treatment. The third patient showed some response after two treatments. Additional treatments were stopped due to loss of insurance coverage.",
"   </p>",
"   <p>",
"    Although improvement was also noted in another report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/81\">",
"     81",
"    </a>",
"    ], the benefit of ECP in NSF remains unproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Ultraviolet A phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultraviolet A1 (UV-A1) phototherapy is one of the more common therapies tried in NSF based upon its ability to inhibit procollagen synthesis in human skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/82\">",
"     82",
"    </a>",
"    ]. UV-A1 provides the longest segment of the UV spectrum, which is necessary to reach the dermis, with a negligible capacity to cause sunburn.",
"   </p>",
"   <p>",
"    The results with UV-A1 phototherapy have been inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/8,15,63,65,81\">",
"     8,15,63,65,81",
"    </a>",
"    ]. In addition, there is some question whether UV-A1 phototherapy actually penetrates to the depth of the dermis. However, given its safety relative to other treatments and some studies showing benefit, it is often used alone or in combination with other therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marked improvement with plasmapheresis (one to three five-day courses) was noted in three patients with kidney failure who developed moderate to severe NSF 1 month to 10 years after liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/53\">",
"     53",
"    </a>",
"    ]. However, kidney function was already improving in two of the patients at the time NSF was diagnosed. In another series of four patients, plasma exchange was of no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other modalities have been tried in case reports or small series. Possible efficacy has been noted with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/83-85\">",
"     83-85",
"    </a>",
"    ], photodynamic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/15\">",
"     15",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/36\">",
"     36",
"    </a>",
"    ], intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/86,87\">",
"     86,87",
"    </a>",
"    ], and high dose intravenous immune globulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/88\">",
"     88",
"    </a>",
"    ]. Topical, intralesional, or oral glucocorticoid therapy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    have generally shown no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     REPORTING OF CASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since NSF is a rare disease, multicenter collaborative studies are necessary to further clarify risk factors and to formulate successful preventive and therapeutic strategies. Health care providers are encouraged to report cases, including information about prior exposures, and experience with treatment success or failures to the International NSF registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/22/31082/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, the FDA urges health care providers and patients in the United States to report adverse event information to the FDA via the MedWatch program by phone (1-800-FDA-1088), fax (1-800-FDA-0178), or the Internet at",
"    <a class=\"external\" href=\"file://www.fda.gov/Safety/MedWatch/default.htm\">",
"     www.fda.gov/Safety/MedWatch/default.htm",
"    </a>",
"    . Affected patients outside the United States should be reported to the appropriate regulatory agency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nephrogenic systemic fibrosis (NSF) is a recently identified fibrosing disorder seen only in patients with moderate to severe kidney failure, particularly patients on dialysis. As of January 2013, nearly 400 cases of NSF had been reported to the International NSF Registry at Yale University. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Terminology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increasing evidence has implicated gadolinium-containing contrast agents, which are excreted exclusively by the kidney, as the cause of NSF. More than 95 percent of patients have had recent exposure to gadolinium and the best estimate of risk of NSF after gadolinium exposure is approximately 2.5 to 5 percent among patients with severely impaired renal function. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine light microscopy of a skin biopsy will reveal a subtle proliferation of dermal fibrocytes in early lesions or marked thickening of the dermis with severe disease. Special testing may show gadolinium, which, in itself, does not establish a diagnosis of NSF. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The inciting event is most likely the tissue deposition of gadolinium. This may result in exaggerated local tissue fibrosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the direct stimulation of bone marrow to produce CD34+ circulating fibrocytes. The latter cells subsequently accumulate in the affected tissue and produce collagen. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin involvement occurs in all patients, while only some have systemic manifestations. The latent period between exposure to gadolinium and disease onset is usually two to four weeks. The skin disease presents with plaques, papules,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nodules, with the affected skin becoming thickened and firm and possibly assuming a peau d' orange (orange peel-like) appearance. Manifestations of systemic involvement may include muscle induration, joint contracture, and fibrosis of the lungs, pleura, diaphragm, myocardium, pericardium, and dura mater. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is based upon histopathologic examination of a biopsy of an involved site. Although thickening and hardening of the skin overlying the extremities and trunk can simulate a variety of other disorders such as scleroderma, scleromyxedema, and eosinophilic fasciitis, a history of a temporally-associated gadolinium exposure in the setting of advanced kidney failure is strongly suggestive of NSF. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with an estimated glomerular filtration rate (GFR) of less than 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      or those on dialysis, we recommend NOT administering gadolinium-containing contrast agents (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), unless clinical conditions make gadolinium-based imaging absolutely necessary. In general, among patients with this degree of renal dysfunction, we prefer the risk of radiocontrast nephropathy with iodinated contrast media (using all of the preventive measures that are available) to the risk of the much more severe complication of NSF. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Avoidance of gadolinium'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=see_link\">",
"       \"Prevention of contrast-induced nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is no consensus among the authors and reviewers of this topic as to whether or not gadolinium-based contrast agents should be administered to patients with an estimated GFR of 30 to 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m",
"      <sup>",
"       2",
"      </sup>",
"      . In general it seems advisable to limit exposure of any patient with marginal renal function to the three gadolinium based contrast agents deemed the highest risk. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The GFR can be estimated from the serum creatinine concentration, but ONLY in patients who have a stable value. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"       \"Assessment of kidney function\", section on 'Estimation equations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gadolinium should be avoided in patients with a diagnosis or clinical suspicion of NSF.",
"     </li>",
"     <li>",
"      If it is felt that the patient must receive a gadolinium contrast study, issues that must be addressed include the relative degree of kidney dysfunction, the presence or absence of a functioning vascular access for hemodialysis, and the timing of a hemodialysis session. In this setting, we suggest the following approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The patient should be informed of the benefits, risks, and alternatives.",
"      <br/>",
"      <br/>",
"      Given that the great majority of cases of NSF have followed imaging with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/41/39573?source=see_link\">",
"       gadodiamide",
"      </a>",
"      (Omniscan),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/55/25461?source=see_link\">",
"       gadoversetamide",
"      </a>",
"      (OptiMARK), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24277?source=see_link\">",
"       gadopentetate dimeglumine",
"      </a>",
"      (Magnevist), we suggest giving one of the other commercially available gadolinium preparations (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/15/4341?source=see_link\">",
"       gadoteridol",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The lowest dose that is deemed necessary should be given.",
"     </li>",
"     <li>",
"      Among patients undergoing chronic or acute dialysis (both hemodialysis and peritoneal dialysis) and patients not on dialysis who have an estimated GFR less than 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      and a functioning chronic hemodialysis vascular access, we recommend initiating a hemodialysis session as soon as possible (within hours not days) after gadolinium administration (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Placement of a temporary hemodialysis catheter should be performed in PD patients without a functioning vascular access.",
"      <br/>",
"      <br/>",
"      Given the time required to place a hemodialysis catheter and perform hemodialysis, an attempt should be made to schedule elective imaging studies at a time at which the patient has a functioning access so that hemodialysis can be performed just after the gadolinium is administered. A second hemodialysis session at 24 hours may be performed if clinically safe.",
"     </li>",
"     <li>",
"      Among patients with chronic or acute kidney failure who have an estimated GFR less than 15",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      are not on dialysis, and do not have a functioning vascular access, we suggest initiating a hemodialysis session as soon as possible after gadolinium administration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/1\">",
"      Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006; 18:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/2\">",
"      Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007; 242:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/3\">",
"      Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. Semin Arthritis Rheum 2006; 35:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/4\">",
"      Jim&eacute;nez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004; 50:2660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/5\">",
"      Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004; 30:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). Fibrosing skin condition among patients with renal disease--United States and Europe, 1997-2002. MMWR Morb Mortal Wkly Rep 2002; 51:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/7\">",
"      Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/8\">",
"      Hubbard V, Davenport A, Jarmulowicz M, Rustin M. Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol 2003; 148:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/9\">",
"      LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003; 139:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/10\">",
"      Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/11\">",
"      Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003; 114:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/12\">",
"      Cassis TB, Jackson JM, Sonnier GB, Callen JP. Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis. Int J Dermatol 2006; 45:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/13\">",
"      Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/14\">",
"      Dundov&aacute; I, Treska V, Simanek V, Michal M. Nephrogenic fibrosing dermopathy: a case study. Transplant Proc 2005; 37:4187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/15\">",
"      Schmook T, Budde K, Ulrich C, et al. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant 2005; 20:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/16\">",
"      Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005; 152:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/17\">",
"      Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/18\">",
"      Igreja AC, Mesquita Kde C, Cowper SE, Costa IM. Nephrogenic systemic fibrosis: concepts and perspectives. An Bras Dermatol 2012; 87:597.",
"     </a>",
"    </li>",
"    <li>",
"     The International Center for Nephrogenic Fibrosing Dermopathy Research. file://www.icnfdr.org (Accessed October, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/20\">",
"      Auron A, Shao L, Warady BA. Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 2006; 21:1307.",
"     </a>",
"    </li>",
"    <li>",
"     Krefting, Ira, FDA, 2012, personal communication. Presented at: 5th Annual Scientific Symposium on Nephrogenic Systemic Fibrosis and Allied Fibrotic Disorders. May 20, 2011 at  the Yale University School of Medicine, New Haven, CT.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/22\">",
"      Moschella SL, Kay J, Mackool BT, Liu V. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 2004; 351:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/23\">",
"      Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005; 46:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/24\">",
"      Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003; 15:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/25\">",
"      Cowper SE, Bucala R, LeBoit PE. Case 35-2004: nephrogenic fibrosing dermopathy. N Engl J Med 2005; 352:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/26\">",
"      Neprogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. MMWR 2007; 56:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/27\">",
"      Perazella, MA, Rodby, RA. Gadolinium use in patients with kidney disease: A cause for concern. Semin Dial 2007; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/28\">",
"      Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008; 3:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/29\">",
"      Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/30\">",
"      Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991; 26:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/31\">",
"      Saitoh T, Hayasaka K, Tanaka Y, et al. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 2006; 24:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/32\">",
"      High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/33\">",
"      Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/34\">",
"      High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/35\">",
"      Schroeder JA, Weingart C, Coras B, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008; 3:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/36\">",
"      Grobner T. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222.htm (Accessed January, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/38\">",
"      Elmholdt TR, Pedersen M, J&oslash;rgensen B, et al. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark. Br J Dermatol 2011; 165:828.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/drug/infoSheets/HCP/gcca_200705.htm (Accessed October, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/40\">",
"      Perazella MA. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease? Clin J Am Soc Nephrol 2008; 3:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/41\">",
"      Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2:264.",
"     </a>",
"    </li>",
"    <li>",
"     Stenver DI. Investigation of the safety of MRI contrast medium Omniscan. Danish Medicines Agency, 29 May 2006. file://www.dkma.dk/1024/visUKLSArtikel.asp?artikelID=8931. (Accessed March, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/43\">",
"      Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 2008; 190:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/44\">",
"      Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007; 188:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/45\">",
"      Penfield JG, Reilly RF. Gadolinium and nephrogenic systemic fibrosis: have we overreacted? Semin Dial 2011; 24:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/46\">",
"      Perez-Rodriguez J, Lai S, Ehst BD, et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. Radiology 2009; 250:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/47\">",
"      Wang Y, Alkasab TK, Narin O, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011; 260:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/48\">",
"      H&auml;gele J, Simon M. [Nephrogenic systemic fibrosis (NSF): Effects of stricter guidelines on the use of contrast media containing gadolinium]. Radiologe 2011; 51:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/49\">",
"      Hope TA, High WA, Leboit PE, et al. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology 2009; 253:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/50\">",
"      Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006; 145:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/51\">",
"      Golding LP, Provenzale JM. Nephrogenic systemic fibrosis: possible association with a predisposing infection. AJR Am J Roentgenol 2008; 190:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/52\">",
"      Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006; 6:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/53\">",
"      Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003; 25:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/54\">",
"      Chow DS, Bahrami S, Raman SS, et al. Risk of nephrogenic systemic fibrosis in liver transplantation patients. AJR Am J Roentgenol 2011; 197:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/55\">",
"      Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? Arch Dermatol 2004; 140:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/56\">",
"      Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007; 7:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/57\">",
"      Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/58\">",
"      Wermuth PJ, Del Galdo F, Jim&eacute;nez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009; 60:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/59\">",
"      Swaminathan S, Horn TD, Pellowski D, et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 2007; 357:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/60\">",
"      Bellin MF. MR contrast agents, the old and the new. Eur J Radiol 2006; 60:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/61\">",
"      Edsall LC, English JC 3rd, Teague MW, Patterson JW. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 2004; 31:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/62\">",
"      Evenepoel P, Zeegers M, Segaert S, et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant 2004; 19:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/63\">",
"      Kafi R, Fisher GJ, Quan T, et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 2004; 140:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/64\">",
"      Bangsgaard N, Marckmann P, Rossen K, Skov L. Nephrogenic systemic fibrosis: late skin manifestations. Arch Dermatol 2009; 145:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/65\">",
"      Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/66\">",
"      Kucher C, Steere J, Elenitsas R, et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 2006; 54:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/67\">",
"      Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006; 130:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/68\">",
"      Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 2003; 48:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/69\">",
"      Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011; 65:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/70\">",
"      Kucher C, Xu X, Pasha T, Elenitsas R. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol 2005; 32:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/71\">",
"      Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003; 25:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/72\">",
"      Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007; 56:3433.",
"     </a>",
"    </li>",
"    <li>",
"     The International Center for Nephrogenic Fibrosing Dermopathy Research. file://www.icnfdr.org.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/74\">",
"      Chrysochou C, Power A, Shurrab AE, et al. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol 2010; 5:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/75\">",
"      KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/76\">",
"      Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 2001; 42:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/77\">",
"      Murashima M, Drott HR, Carlow D, et al. Removal of gadolinium by peritoneal dialysis. Clin Nephrol 2008; 69:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/78\">",
"      Taylor RA, Levine JM, Jimenez SA. Case 35-2004: nephrogenic fibrosing dermopathy. N Engl J Med 2005; 352:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/79\">",
"      Cuffy MC, Singh M, Formica R, et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant 2011; 26:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/80\">",
"      Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005; 46:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/81\">",
"      L&auml;uchli S, Zortea-Caflisch C, Nestle FO, et al. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 2004; 208:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/82\">",
"      Fisher GJ, Datta S, Wang Z, et al. c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest 2000; 106:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/83\">",
"      Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/84\">",
"      Chandran S, Petersen J, Jacobs C, et al. Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 2009; 53:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/85\">",
"      Robinson MR, Routhouska SB, Paspulati RM, Korman NJ. Alefacept therapy for nephrogenic systemic fibrosis: a case series. J Drugs Dermatol 2011; 10:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/86\">",
"      Yerram P, Saab G, Karuparthi PR, et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007; 2:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/87\">",
"      Kadiyala D, Roer DA, Perazella MA. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. Am J Kidney Dis 2009; 53:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/22/31082/abstract/88\">",
"      Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 2004; 150:596.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1955 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31082=[""].join("\n");
var outline_f30_22_31082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gadolinium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Erythropoietin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other possible associations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TGF-beta-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Increased circulating fibrocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Proinflammatory/profibrotic cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Role of free gadolinium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Skin involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Systemic involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266305852\">",
"      Consensus scoring system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Avoidance of gadolinium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - If gadolinium must be given",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Extracorporeal photopheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Ultraviolet A phototherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      REPORTING OF CASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1955\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1955|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/6/27757\" title=\"figure 1\">",
"      Cases of NSF reported to the USFDA AERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/51/17214\" title=\"figure 2\">",
"      Diagnosis and reporting grid for NSF scoring system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1955|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/51/2869\" title=\"picture 1A\">",
"      Skin biopsy NSF Light I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/47/5877\" title=\"picture 1B\">",
"      Skin biopsy NSF Light II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/47/6898\" title=\"picture 2A\">",
"      Skin biopsy NSF CD34 cells I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/18/24871\" title=\"picture 2B\">",
"      Skin biopsy NSF CD34 cells II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/61/6111\" title=\"picture 3\">",
"      Peau d orange pattern in NS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/24/23937\" title=\"picture 4A\">",
"      Frozen fingers in NSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/44/28352\" title=\"picture 4B\">",
"      Frozen knees in NSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/63/29680\" title=\"picture 5\">",
"      Scleral plaques in NSF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1955|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/46/38635\" title=\"table 1\">",
"      Clinicopathological criteria for NSF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15017?source=related_link\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/29/5594?source=related_link\">",
"      Definition and staging of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43095?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/10/8360?source=related_link\">",
"      Eosinophilic fasciitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11240?source=related_link\">",
"      The kidney transplant waiting list",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_22_31083="Clinical circumstances for ICD evaluation";
var content_f30_22_31083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical circumstances suggesting the need for implantable cardioverter-defibrillator evaluation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical Situation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Considerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent shocks, therapies",
"       </td>",
"       <td>",
"        Lead failure, inappropriate therapies for atrial arrhythmias, recurrent or refractory ventricular arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New antiarrhythmic drugs (affect defibrillation threshold or ventricular tachycardia rate, or both)",
"       </td>",
"       <td>",
"        Antiarrhythmic drugs can alter ventricular tachycardia rate, requiring reprogramming; can also affect defibrillation threshold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant change in clinical status: myocardial infarction, deteriorating cardiac function",
"       </td>",
"       <td>",
"        Can affect sensing (if infarction involves tissue near",
"sensing lead); require new medications, rarely, affect defibrillation",
"threshold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reprogramming to a lower sensitivity (eg, for T wave oversensing)",
"       </td>",
"       <td>",
"        Might result in underdetection of ventricular fibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other events: such as pneumonectomy or patch crinkle",
"       </td>",
"       <td>",
"        Can affect defibrillation threshold",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Hayes, DL, Friedman, PA. In: Cardiac Pacing and Difibrillation, Hayes, DL, Lloyd, MA, Friedman, PA (Eds), Futura Publishing Company, Inc. Armonk, NY 2000. pp.541-587. Copyright &copy; 2001 Futura Publishing Company, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31083=[""].join("\n");
var outline_f30_22_31083=null;
var title_f30_22_31084="Percutaneous mitral valvotomy";
var content_f30_22_31084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Percutaneous mitral balloon valvotomy (PMBV) in mitral stenosis (MS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that PMBV is effective in the following settings in patients with MS who have favorable valve morphology in the absence of left atrial thrombus or moderate to severe mitral regurgitation:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Symptomatic patients with moderate or severe MS (mitral valve area &le;1.5 cm2).*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Asymptomatic patients with moderate or severe MS who have pulmonary hypertension (defined as pulmonary artery systolic pressure &gt;50 mmHg at rest or &gt;60 mmHg with exercise).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of PMBV in the following setting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients with moderate or severe MS* who have a nonpliable, calcified mitral valve, have moderate to severe symptoms of heart failure (New York Heart Association [NYHA] class III to IV), and are not candidates for or at high risk from surgery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of PMBV in the following settings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients with asymptomatic moderate to severe MS* who have favorable valve morphology and new onset of atrial fibrillation in the absence of left atrial thrombus or moderate to severe mitral regurgitation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients with symptoms of heart failure (NYHA class II to IV) who have a mitral valve area &gt;1.5 cm2 and evidence of hemodynamically significant MS as evidenced by a pulmonary artery systolic pressure &ge;60 mmHg, a pulmonary artery wedge pressure &ge;25 mmHg, or a mean mitral valve gradient &ge;15 mmHg during exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; As an alternative to surgery for patients with moderate to severe MS* who have a nonpliable, calcified mitral valve and moderate to severe symptoms of heart failure (NYHA class III to IV).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that PMBV is not useful in in the following settings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients with mild MS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients with MS who also have moderate to severe mitral regurgitation or left atrial thrombus.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * There may be variability in the measurement of mitral valve area; as a result, the mean transmitral gradient, pulmonary artery wedge pressure, and pulmonary artery pressure at rest or during exercise should also be taken into consideration.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31084=[""].join("\n");
var outline_f30_22_31084=null;
var title_f30_22_31085="Perfusion scan chest pain ER";
var content_f30_22_31085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    A positive rest perfusion scan predicts outcome in patients with chest pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 245px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 532 patients with chest pain seen in the emergency room, those with a positive rest perfusion scan had a higher incidence of myocardial infarction (MI); MI or need for revascularization (R); and MI, revascularization, and a diagnosis of significant coronary disease (S) when compared to patients with a normal perfusion scan (P&lt;0.0001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Kontos ML, Jesse ML, Schmidt KL, et al. J Am Coll Cardiol 1997; 30:976.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31085=[""].join("\n");
var outline_f30_22_31085=null;
var title_f30_22_31086="Chondrosarcoma CT";
var content_f30_22_31086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chondrosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone window of a coronal CT scan shows a chondrosarcoma of the right clivus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Silloo B Kapadia, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31086=[""].join("\n");
var outline_f30_22_31086=null;
var title_f30_22_31087="Avulsed incisors";
var content_f30_22_31087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Avulsed incisors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Avulsed permanent teeth should be handled by the crown (arrows) to prevent damage to the periodontal ligament.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dennis J McTigue, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_22_31087=[""].join("\n");
var outline_f30_22_31087=null;
